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 Gene therapy is promising because nearly all inheritable diseases and cancer has 
an underlying genetic component. However, the development of a gene vector capable of 
delivering nucleic acids efficiently while remaining safe has been a challenge. Generally 
speaking, viral vectors are highly adept at delivering nucleic acids intracellularly. Viral 
vectors, however, have been known to be associated with insertional mutagenesis and 
immunogenicity and in severe cases, death. Furthermore, viral vectors are difficult to 
chemically modify for optimization and to mass produce. 
To date, despite that there have been more than 2000 gene therapy clinical trials 
worldwide, the U.S. FDA has yet to approve a gene therapy application. The lack of gene 
therapy approval by regulatory bodies delineates the need for safer and more effective 
vectors. A safer alternative to viral-based vectors are cationic, amine-containing 
polymeric vectors. Cationic polymers are capable of ionically complexing nucleic acid 
and forming nanoparticles on the order of 100-250 nm. This particle diameter is capable 
of extravasating through mal-formed tumor vasculature. The polymers can be engineered 
to have a buffering ability that allows the nucleic acid cargo to escape the lysosomal 
degradation pathway post-endocytosis. Ester-containing backbone polymers are capable 
of hydrolytic degradation, which helps mitigate toxicity. However, much is unknown 
regarding how polymer structure affects gene delivery. To date, the polymer vectors 
which work well have been discovered through empirical methods. Understanding how 
polymer structure affects gene delivery function would allow for a more rational 
approach to designing new vectors for gene delivery. 
iii 
 
          The objective of this work has been two-fold: the first objective has been to 
elucidate non-viral gene delivery barriers – in particular investigating polymer structure-
function relationships for polymeric vectors; the second objective has been to develop a 
polymeric/inorganic hybrid, theranostic-enabling nanoparticle platform technology 
capable of co-delivering DNA and siRNA and modulating temporal release. 
 More specifically, this work details how polymer structure of poly(β-amino 
ester)s (PBAEs) affects polymer-DNA binding and how binding affects transfection 
levels, viability, and nanoparticle physical properties (zeta potential and diameter). We 
found transfection levels are biphasic with respect to binding in two human cancer cell 
lines and that binding constants in the range of (1-6)x104 M-1 were necessary but not 
sufficient for optimal transfection. We also investigated the comparative binding 
strengths of branched and linear polyethyleneimine, poly(L-lysine) and PBAEs with 
plasmid DNA and found PBAEs have the weakest binding. 
This work also details new bioassays including a more high throughput method 
for assessing cellular and nuclear uptake rates using flow cytometry. This method may be 
used for elucidating structure-function relationships in various cell types. An auto-fitting, 
first order mass-action kinetic model was developed in MatLab to quantify the 
intracellular delivery rate constants for comparing delivery bottlenecks of various 
polymer structures in various cell lines. This model was used to assess rate differences 
between polymers which do not transfect well, tansfect mediocre, and transfect well in 
primary human glioblastoma in vitro. The model recapitulated the experimental data with 
good agreement without needing to extrapolate data from literature. 
Principal component analysis is a method to look at large data sets with unknown 
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variable correlations and to quantify how each variable is correlated with another, as well 
as which and to what degree each variable may drive another. Principal component 
analysis was utilized to look at 27 physico-chemical properties and cell gene delivery 
outcomes (i.e., uptake, transfection levels, and viability). We found that certain key 
parameters, such as hydrophobicity, drove uptake and transfection. 
The development of a theranostic-enabling platform technology involved gold 
nanoparticles and a layer-by-layer coating process to create polymer-inorganic hybrids. 
Gold nanoparticles are relatively biocompatible, are monodisperse, have interesting 
optical properties, have photothermal capabilities, and are easily chemically modified via 
thiol bonds. Gold nanoparticles can be synthesized to absorb a desired wavelength of 
electromagnetic radiation and can be imaged through various modalities such as 
photoacoustics or X-rays for diagnostic purposes.   
 The theranostic-enabling technology was capable of co-delivering DNA and 
siRNA as well as delivering two layers of DNA with two different expression time 
profiles. Co-delivering DNA and siRNA could allow for the knockdown of a 
dysfunctional aberrant protein while replacing it with a functional protein. The ability to 
express proteins with different time profiles could have multiple applications such as 
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1 Chapter 1: Introduction to the thesis 
1.1 Objectives 
 As inheritable diseases and cancer can result from inactive genes2,3, delivering 
DNA and shRNA to encode and generate a functional copy or to inhibit mRNA 
expression of a non-functioning protein can potentially treat and cure many genetic 
diseases. Despite being generally less effective than viruses, degradable cationic 
polymers are attractive as they are generally safer, are easier to manufacture and have 
more functional capabilities.4 Varying a polymer’s structure and functional groups allow 
optimization of delivery properties via high-throughput analyses of vast combinatorial 
libraries, but rational design of structure to control function would be more efficient.5-7 I 
am interested in evaluating polymer structure-function relationships to further our 
mechanistic understanding of, and to improve polymeric materials for non-viral gene 
delivery. PBAEs are promising due to their ability to condense DNA into nanoparticles 
and thereby protect the DNA in the extracellular space, facilitate cellular uptake8, mediate 
endosomal escape and subsequently release the DNA effectively within the cell.9-12 
Designing such systems require proper understanding of the binding between DNA and 
polycations.13,14 One challenge in the field in evaluating and optimizing polymer structure 
is that synthetic polymers can be polydisperse, with variable extents of reaction and 
molecular weight heterogeneity.15-17 Isolating precise polymer structures and uniform 
molecular weight are key to being able to evaluate polymer structure-function 
relationships and has been a confounding factor. I will quantify how poly(beta-amino 
ester) (PBAE) structural properties affect polmer/DNA binding thermodynamics and 
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gene delivery in Aim 1. 
Aim 2. Improved nanobiotechnologies which enable multi-functional imaging 
and intracellular delivery of difficult to deliver biologics such as DNA and siRNA are 
needed. Gold nanoparticles (AuNPs) are easy to synthesize, monodisperse, relatively 
biocompatible, have optical properties useful for colorimetric sensor applications, and 
can be diversely functionalized with chemical moieties. AuNPs have been used as 
biosensors, imaging agents18-20, and as therapeutic vectors (i.e., conjugation or ionic 
complexation to small molecules21, or various nucleic acids, such as DNA22, short hairpin 
RNA23 or short interfering RNA (siRNA)24 for promoting or inhibiting protein 
expression) for theranostic applications; the nanoscale size and the ability to functionalize 
with tumor/cancer-specific small molecules or antibodies allows passive and active 
targeting, respectively.25-27 AuNPs may be tuned for photothermal therapy at wavelengths 
transparent to biological tissue on the order of centimeters.28 Photothermal therapy takes 
advantage of tumors’ decreased ability to self-thermoregulate.29 Layer-by-layer (LbL) 
approaches coat a surface or a core with multiple layers of charge-alternating 
polyelectrolytes.22,30-34 Nanoparticle LbL approaches are ideal for complexing ionically 
charged macromolecules into relevant particle sizes for systemic administration. LbL 
approaches can be accomplished using aqueous solvents, are versatile regarding 
molecular structure as natural and synthetic polyelectrolytes are able to be used, and are 
easily tuned by varying the number and order of the layers.31,35 I will demonstrate a 
degradable hybrid gold/polymeric nanoparticle theranostic platform technology capable 
of delivering nucleic acid via a modifiable LbL approach in Aim 2. 
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In designing new biomaterials for gene delivery, a thorough understanding of the 
intracellular barriers is critical. Although there are a number of intracellular barriers for 
successful expression4, cellular and nuclear entry are key. I will quantify the rates of 
cellular and nuclear uptake in Aim 3 which will help further elucidate the bottlenecks of 
non-viral gene delivery.36 In addition, there is currently a need to methodically 
understand how polymeric structure affects rates of cellular and nuclear uptake which I 
undertake using PBAEs to better understand structure-function relationships which will 
help in designing new non-viral biomaterial vectors. I develop a new method to quantify 
the number of plasmids within the cells and nuclei based on flow cytometry, which can 
be more efficient than using Polyermase Chain Reaction (PCR) which requires isolation 
and purification of the plasmid and genomic DNA for all samples. In the new method, 
after PCR is used to establish the degradation kinetics within each cell type, flow 
cytometry can then be used for multiple types of polymers within the cell type of interest.  
The gene delivery field has observed certain general polymer properties that result 
in increased or decreased transfection levels. For example, generally speaking, it was 
previously known that as hydrophobicity of polymers increase, transfection levels 
increase; or that there is an optimal molecular weight which results in optimal 
transfection levels. However, there has not been a methodical mathematical approach 
applied to a large biomaterial library set used for non-viral gene delivery to date which 
quantifies correlative relationships between variables of interest. In Aim 3, I use Principal 
Component Analysis to methodically quantify which and to what degree physicochemical 




Aim 1. To quantify how poly(beta-amino ester) (PBAE) structural properties affect 
polymer/DNA binding thermodynamics and gene delivery. I hypothesize that there is an 
optimal binding constant that will maximize exogenous gene expression. 
 
a. Synthesize a library of PBAE polymers which vary only in the following: 
molecular weight; the number of carbons in the backbone which varies the amine 
density and hydrophobicity; the number of carbons in the sidechain which varies 
the distance of a hydroxyl group from the backbone and its hydrophobicity; and 
the endcap type (primary, secondary, tertiary amines and no endcap or diacrylate 
terminated). 
 
b. Assess the binding affinity between the various polymers mentioned in Specific 
Aim 1a and DNA and how the binding affinity impacts DNA delivery 
functionality, namely transfection and cytotoxicity in human breast and brain 
cancer in vitro, as well as the physical properties of the polyplexes. In addition, 
the binding affinity between poly(L-lysine), and linear and branched PEI and 
DNA will be quantified. 
 
 
Aim 2. Develop a hybrid gold/polymeric nanoparticle theranostic platform technology 
capable of delivering nucleic acid via a modifiable Layer-by-Layer (LbL) approach. I 
hypothesize that nanoparticles beginning with a gold nanoparticle (AuNP) core and 
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layered in multiple types of nucleic acids and polymers with differing degradable 
mechanisms are capable of resulting in effective transfection with tunable release.  
 
a. Develop an siRNA and DNA-co-delivering formulation using a gold nanoparticle 
core via an LbL approach using cationic polymers which degrade mechanistically 
differently, via hydrolysis and reduction, and assess physicochemical properties. 
 
b.  Assess simultaneous knockdown and expression in human brain cancer 
 
c. Tune multilayers to be able to control the timing of protein expression from two 
independent layers of plasmid DNA 
 
Aim 3. Quantify transport as a major non-viral gene delivery barrier, namely the rates of 
cellular and nuclear uptake of DNA carried by polymeric nanoparticles; also to assess 
which and to what degree polymer physicochemical properties drive transfection and 
uptake. I hypothesize that nuclear uptake is the major barrier to polymeric gene delivery 
and rates will vary as a function of polymer structure.  
 
a. Develop an assay to quantify kinetics of cellular uptake and nuclear uptake in a 
more high-throughput fashion 
 
b. Via the assay from Specific Aim 3a, determine how polymer structure affects 




c. Via principal component analysis, determine which and to what degree polymer 
physicochemical properties drive cellular transfection levels, uptake, and viability 
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2 Chapter 2: State of the Art 
 
2.1 1Biomolecule Delivery to Engineer the Cellular 
Microenvironment 
Regenerative medicine has the potential to repair many cells and tissues to 
dramatically improve the quality of life of patients suffering from a myriad of diseases. In 
cases where a patient’s own cells and tissues are used, rather than allogenic cells 
transplanted from another source, the complications of tissue rejection are prevented. The 
ability to regenerate tissue would also afford patients healthcare independent from a 
limited supply of allogenic cells or tissue. Although promising, regenerative medicine is 
still a nascent field requiring further refinement of bioengineered materials, cells, and 
biological microenvironmental cues, which are all necessary for integrative solutions to 
be found.  
Tissue regeneration is not a new concept as it has been discussed for organisms 
such as the hydra, anurous batrachians and the midwife toad since at least 1744, 1769, 
and 1898, respectively.1-3 Furthermore, in humans it is known that an embryo’s wound 
healing process is faster than that of adult tissue and that it is better able to re-gain full 
functionality with reduced scar formation.4 Understanding how such biological systems 
                                                     
Chapter 2.1 is published as “Bishop CJ, Kim J, Green, JJ. Biomolecule delivery to engineer the cellular 
microenvironment for regenerative medicine. Ann. Biomed. Eng. 2014;42(7):1557-72” and chapter 2.1.1 is 
published in “Sunshine JC, Bishop CJ, Green, JJ. Advances in polymeric and inorganic vectors for nonviral 




are capable of self-regeneration has been of great interest in the scientific community due 
to its translational potential.  
To engineer a tissue to be a particular type and have a desired function, the 
microenvironment of the cells within the tissue must be controlled. Key controlling 
elements of cellular microenvironments or niches can be subdivided into four signaling 
categories which control the critical actions of cells including their cellular proliferation 
and death, migration, and differentiation. These signaling categories are: 1) Outside-in 
soluble biological factors that direct internal cell signaling; 2) Outside-in insoluble 
factors of the extracellular matrix (ECM) that direct cell-ECM signaling and  3) Cell-cell 
interactions and 4) Endogenous and exogenous genetic instructions within the cell 
functioning from the inside-out (Figure 1A).5,6 In this review, we describe the current 
state of the art in engineering microenvironments (i.e., stem cell niches) through 
biomolecule delivery, highlighting biomolecule presentation to cells in soluble (i.e., 
autocrine/paracrine) or insoluble form, through cell-cell or cell-ECM interactions, as well 
as intracellular delivery of nucleic acids for regenerative medicine (Figure 1B).7 
Although mechanical cues, such as substrate elasticity and topography, are also important 
and an interesting avenue of research to control cellular responses, this is outside the 
scope of the current review; we refer interested readers to other reviews or articles on this 
topic such as Higuchi or Khetan, et al.8,9  
Biomolecules delivered to cells can affect cells’ interactions with each other and 
their microenvironment, and as a result promote the repair of defective tissues. 
Exogenous biomolecules can be presented to the cell microenvironment through various 
methods including: 1) loading in microparticles, nanoparticles, or controlled release 
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devices, 2) adsorbing or conjugating to a scaffold that may present the signal in a 
particular orientation, and 3) freely dissolving in a solution that is injectable and that may 
also contain other components such as injectable scaffolds. The box labeled “Exogenous 
Delivery: Outside-In” in Figure 1A provides a schematic diagram of three methods of 
exogenous delivery of biomolecules. When successfully delivered, these biomolecules 
can trigger intracellular signaling, promote cell-cell interactions, and control cell-ECM 
interactions. Such events can induce healing through mechanisms of ECM remodeling or 
specific differentiation of stem cells towards a tissue of interest.  
 
2.1.1 Biomolecule Delivery and Release of Soluble Signals 
Natural ECM regulates the biological activities in a tissue through soluble, 
bioactive effectors such as growth factors and morphogens.10 The ECM locally binds, 
stores, and releases these biomolecules to meet the needs of cells for tissue repair or 
remodeling. Such interactions between soluble biomolecules and the ECM provide 
increased concentration of signaling molecules, localized morphogenetic activity, and 
protection against degradation.11 There is a need to engineer the delivery of biomolecules 
so that the needed factor is provided to the right cells at the right time and place to 
properly control cell and tissue function. Approaches to engineer biomolecule delivery 
systems for regenerative medicine applications have focused on mimicking the biological 
release dynamics of the ECM by incorporating the biomolecules into scaffolds or 
controlled release devices.  
Several strategies have been designed to incorporate growth factors within 
scaffolds: through diffusion into porous scaffold, direct incorporation into a hydrogel for 
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controlled release, or encapsulation in particulate delivery vehicles that are localized 
within a scaffold.12,13 The simplest method of generating scaffolds that contain soluble 
biomolecules is by allowing the biomolecules to diffuse in and/or adsorb onto the 
scaffold. In order to create transplantable tissues, porous scaffolds seeded with cells ex 
vivo are incubated in bioreactors that contain flowing media with growth factors that 
spread through the scaffolds by convection and diffusion. For example, Davis, et al. 
showed that a mineralized, apatite-coated polymeric scaffold containing human 
mesenchymal stem cells (hMSCs) adsorbed bone morphogenetic protein-2 (BMP-2) from 
a BMP-2 solution and that the adsorbed BMP-2 induced osteogenic differentiation of 
hMSCs.14 In another study, new mature cartilage tissue was formed in vivo from a 
chondrocyte-collagen composite, into which basic fibroblast growth factor (bFGF) had 
diffused prior to implantation.15 
An alternative approach is to incorporate soluble signals into hydrogels. A 
hydrogel system is composed of hydrophilic polymer(s) in a solution that solidifies into a 
gel upon different cues, such as a change in temperature, pH, biomolecular interactions, 
or UV light.13 Hydrogels in solutions with biomolecules can be gelled ex vivo and 
implanted or injected for subsequent cross-linking in vivo. For example, a UV-
crosslinked chitosan hydrogel was able to release entrapped fibroblast growth factor-2 
(FGF-2) upon in vivo biodegradation of the hydrogel and thereby accelerate the wound 
healing process.16 In another example, Hea Kyung, et al. used a pH / temperature-
sensitive hydrogel based on a synthetic polymer. The polymer was injected into mice as a 
solution mixed with recombinant human bone morphogenetic protein-2 (rhBMP-2) and 
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hMSCs, and then cross-linked in situ to form the hydrogel, which subsequently induced 
osteogenesis successfully.17  
In an effort to better mimic physiologically relevant environments, growth factors 
have been incorporated into degradable matrices as well by means of cleavable covalent 
and separable non-covalent interactions.18 Chemical conjugation or enzymatic cross-
linking techniques are used to covalently bind growth factors to the backbone polymers 
of matrices. Lorentz et al. demonstrated that fibrin matrix cross-linked with α2-plasmin 
inhibitor-fused insulin-like growth factor-1 at bladder lesion sites in vivo induced 
significant increase in smooth muscle cell proliferation.19 Non-covalent binding occurs 
via growth factors’ specific interactions with ECM components. For example, bone 
morphogenetic protein-2 with high heparin-binding affinity added to collagen/heparin 
matrix significantly improved bone formation in vivo.20 Also, in many situations, 
physiological “on-demand release” is mimicked via proteolytic degradation by proteases, 
a key step during tissue remodeling. Natural and synthetic hydrogels with specific 
protease cleavage domains can release their cross-linked growth factors upon 
physiological demand in situ. Lutolf et al. showed that poly(ethylene-glycol) hydrogel 
with matrix metalloproteinase as linkers efficiently delivered human bone morphogenetic 
protein-2, recruited primary human fibroblasts, and remodeled bony tissue in rat crania in 
situ.21  
An often-used delivery strategy is to utilize a particulate delivery system for 
controlled release. Micro- and nanoparticles are constructed from biomaterials, such as 
polymers, and incorporate therapeutic agents either throughout the particle or 
concentrated at the core. The particles can protect sensitive biological cargo from quick 
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degradation and clearance by the body, thereby significantly extending activity of the 
biomolecule.22 The particles may be further surface-modified to render them hydrophilic 
and/or neutral in charge in order to evade non-specific protein adsorption, minimize 
immune response and clearance, and prolong circulation time. Some of the conventional 
methods include coating particles with polyethylene glycol, polyacrylamide, 
polysaccharides such as dextran, albumin, and transferrin.23-27  Another primary 
advantage of using a particulate delivery system is the ability for controlled release of the 
encapsulated biomolecules. Particle-based release can enable constant release of a desired 
drug or biological factor to maintain a gradient or an effective concentration at a target 
site over time. Particulate delivery systems can be combined to enable programmed 
temporal release of multiple factors simultaneously or sequentially such as the release of 
BMP-2 and BMP-7 from particles to promote MSC differentiation and osteogenic 
activity.28 Polymeric particle release kinetics can be controlled and modeled by the 
design of a material’s physicochemical characteristics such as chemical bond degradation 
rate and diffusivity of water through the polymer as well as the length scale of the 
particle.29,30  
Microparticles and nanoparticles can be either injected alone or incorporated into 
a scaffold. Seshadri, et al. demonstrated that the direct injection of superoxide dismutase 
encapsulated in polyketal microparticles in the myocardium following myocardial 
infarction significantly reduced myocyte apoptosis and improved cardiac function.31 In an 
application related to bone tissue engineering, Park, at el. showed that rabbit bone 
marrow mesenchymal stem cells encapsulated in an oligo(poly(ethylene glycol) 
fumarate) hydrogel were able to differentiate into a chondrogenic lineage upon exposure 
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to transforming growth factor-β1 (TGF) released from co-encapsulated gelatin 
microparticles.32 The authors of this study demonstrated that only the hydrogel containing 
TGF-β1 loaded microparticles induced stem cells to express chondrocyte-specific type II 
collagen and aggrecan in a dose-dependent manner. Particles can also be combined into 
hydrogels to facilitate sequential delivery of multiple growth factors, such as a system 
composed of alginate hydrogels and poly(lactic-co-glycolic acid) (PLGA) microparticles 
for sequential release of vascular endothelial growth factor (VEGF) and platelet-derived 
growth factor (PDGF) to promote angiogenesis.33  
As multiple soluble factors can have synergistic function for regenerative 
medicine and this activity is often dependent on kinetics, the temporally controlled 
sequential delivery of multiple biomolecules can be critical.34 A single delivery system 
may be used to achieve multiple stages of release by incorporating drugs at the core and 
the surface.35 On the other hand, combining more than one system may also provide 
temporal control of the release of multiple biomolecules. In one study to engineer a 
vascularized bone tissue, Kempen, et al. formulated a composite with PLGA 
microparticles encapsulating BMP-2 embedded within a poly(propylene) scaffold which 
was in turn surrounded by a gelatin hydrogel loaded with VEGF.36 Figure 2 shows 
enhanced vasculature and bone formation in the scaffold loaded with both BMP-2 and 
VEGF after 8 weeks of subcutaneous implantation.36  
2.1.2 Insoluble Biomolecule Delivery Affecting Cell-Cell and Cell-Extracellular 
Microenvironment Interactions 
Soluble factors in the previous section act by triggering cells’ intracellular 
signaling to affect cell fate and promote tissue regeneration. However, cells in native 
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tissue are surrounded by neighboring cells as well as ECM that also influence the 
decisions that cells make through insoluble signals. Much research has focused on 
delivering exogenous biomolecules that support desired cell-cell and cell-ECM 
interactions. 
Cells are in close proximity with homotypic or heterotypic cells in a living tissue. 
These cells need to communicate with each other through gap, adherens, and tight 
junctions as part of their cell-cell interactions in order to support tissue function and 
structure.37 Due to the important roles that cell-cell interaction plays in tissue function, 
research in tissue engineering has aimed to mimic such architecture within an engineered 
construct.38 A widely employed technique in this area of research is the patterned 
coculture of cells by utilizing a three-dimensional microfluidic system39, a molded 
hydrogel40, or thermally responsive cell sheets using poly(N-isopropylacrylamide) 
(PIPAAm).41 Also, a layer-by-layer deposition method can be used to coculture cells 
together, such as fibroblasts and hepatocytes. This method involves sequential coating of 
different biomolecules to a substrate, utilizing ionic adsorption of charged 
polyelectrolytes such as hyaluronic acid (HA) and poly-L-lysine.42 The function of 
hepatocytes can be modulated by the degree of heterotypic interaction with fibroblasts 
and by the extent of homotypic interaction between two fibroblasts. Such artificial tissue 
constructs have potential applications in not only the regeneration of the liver, but also 
other tissues with specific architecture for cell-cell interaction.  
The ECM is a three-dimensional support for cells that provides biomolecular as 
well as mechanical cues and guides tissue formation and regeneration processes. Because 
of the similar viscoelastic and diffusive properties between natural ECM and hydrogels, 
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many types of artificial scaffolds used in tissue engineering are synthetic hydrogels.11 
Other types of hydrogels composed of more hydrophobic constituents are aimed at 
providing stronger mechanical architecture.13 Scaffold designs often integrate 
biologically important molecules which mimic structural and functional aspects of 
natural, tissue-specific microenvironments. In this manner key insoluble biomolecules 
can be delivered and presented in a biomimetic manner. Examples include presentation of 
receptor-binding ligands for cell adhesion as well as proteolytic degradability for cell 
migration and ECM remodeling.43,44  
Various ligands of small oligopeptide sequence promoting cell adhesion have 
been identified and are incorporated into tissue scaffolds.44 One of the most commonly 
used motifs is the Arginine-Glycine-Aspartate (RGD) sequence that specifically 
recognizes and binds to integrin receptors. Many studies have tested the effectiveness of 
RGD peptide coated scaffolds for cell adhesion and their influence on cell behavior with 
respect to tissue engineering.45 For example, Yang, et al. studied the growth and 
differentiation of human osteoprogenitor cells with RGD containing scaffolds.46 Human 
bone marrow cells were able to adhere, grow, migrate and undergo osteogenesis on a 
three-dimensional PLGA scaffold modified with GRGDS peptides. In a more recent 
study, Wang, et al. showed that differential RGD nanospacing on a poly(ethylene glycol) 
(PEG) hydrogel directed preferential lineage commitment of mesenchymal stem cells 
(MSCs).47 Adipogenic/osteogenic co-induction of MSCs on large RGD nanospacings 
resulted in a more robust differentiation into osteoblasts. These studies reinforce that 
defined and controlled presentation of insoluble cell-adhesion ligands on scaffolds is a 
critical parameter for engineering cells and tissues.  
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Other biomolecules are used to promote scaffold interaction with cell surface 
glycosaminoglycans (GAGs). Peptide sequences in this category are mostly derived from 
extracellular matrix proteins, such as laminin, fibronectin and vitronectin. For example, a 
vitronectin-derived GAG-binding peptide GKKQRFRHRNRKG was linked to a 
polyacrylamide hydrogel, into which human pluripotent stem cells were seeded. This 
hydrogel, which was unable to adhere nor self-renew stem cells prior to modification, 
was able to control self-renewal and maintain pluripotency in its peptide modified form.48 
Silva, et al. investigated cell-ECM interactions in inducing specific differentiation of 
neural progenitor cells (NPC) into neurons but not astrocytes.49 They showed that NPCs 
increased expression of β–tubulin (neuronal marker) when cultured in a three-
dimensional nanofiber matrix in the presence of bioactive epitope IKVAV of laminin, 
which is known to promote adhesion of neurons, further demonstrating how delivery and 
presentation of insoluble factors is key to control cell fate.  
Cell migration through natural extracellular matrices is one of the key processes 
in tissue development, maintenance and regeneration.11 Cells in synthetic three-
dimensional scaffolds can migrate in two different ways. In the first case, cells can 
migrate in matrices with macroscopic pores of size larger than the cell diameter.50 
Secondly, cells can actively pave their migration path by utilizing proteases, such as 
matrix metalloproteinases (MMP), collagenase, serine proteases, and hyaluronidases that 
degrade extracellular proteins and proteoglycans.51,52 In one example, smooth muscle 
cells (SMC) were able to migrate through PEG hydrogels functionalized with an RGD 
sequence and a polyalanine peptide sequence by secreting elastase which degraded the  
polyalanine peptide sequences.53,54 The degradation, migration and formation of void 
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space in a scaffold can allow the natural process of tissue formation by allowing cellular 
synthesis and deposition of biomolecules such as collagen.  
2.1.3  Intracellular Nucleic Acid Delivery for Engineering the Cellular 
Microenvironment 
In contrast to engineering cells from the outside-in via soluble or insoluble 
factors, nucleic acid delivery approaches allow the engineering of the cell from the 
inside-out through promoting or inhibiting protein expression as a result of delivering 
nucleic acid.  Intracellular nucleic acid delivery to the cytoplasm or nucleus is more 
challenging than delivery to the extracellular space, but can enable novel regeneration 
modalities by turning on and off exogenous and endogenous genes. Figure 3, taken from 
Sunshine, et al.,55 depicts barriers of gene delivery which must be overcome for 
successful gene modulation that include: 1) Complexation or condensation of the nucleic 
acids, nanoparticle formation, and protection against nucleases; 2) Cellular uptake (i.e., 
via endocytosis); 3) Endosomal escape of the particle to the cytosol; 4) Release of the 
cargo from the gene carrier into the cytosol, which is the target location of short 
interfering RNA (siRNA); 5) Degradation of the gene carrier to minimize cytotoxicity; 6) 
Nuclear import for the case of DNA and short hairpin RNA (shRNA) plasmids.55  
Nucleic acids are delivered using either viral or non-viral vectors. Viral methods 
can be effective, but the efficacy can diminish with repeated administration due to an 
adaptive immune response against the viral vector. Furthermore, viral vectors can have 
delivery limitations such as small cargo capacity and safety limitations such as insertional 
mutagenesis. Despite these complications, viral vectors are the most commonly used 
modality for gene transfer in clinical trials. Non-viral methods, albeit typically less 
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effective in comparison to viral vectors, have a higher cargo capacity, can be more easily 
functionalized for tissue targeting, more easily manufactured, are less immunogenic, and 
can be engineered to be relatively non-toxic.  
However, both viral and non-viral gene delivery vectors have difficulty delivering 
their cargo intracellularly in vivo. To bypass in vivo nucleic acid delivery challenges, 
researchers often genetically manipulate autologous or allogenic cells ex vivo then deliver 
the modified cells for the specific regenerative medicine application. Caution is still 
warranted however as transplanting cells can be potentially associated with graft versus 
host disease, immunosuppression requirements, tumor formation, and unregulated protein 
synthesis.56 
 
2.1.4 Viral Vectors for Ex Vivo Cell Engineering 
Many researchers have utilized viruses to ex vivo engineer cells that are 
subsequently injected into animal models. In one example to aid cardiac regeneration 
after an ischemic heart attack, Haider, et al. supplied a source of myoblasts as well as 
growth factors to promote angiogenesis.57  Haider, et al. created VEGF165 expressing 
human skeletal myoblasts which were transduced by adenoviral vectors carrying human 
VEGF (hVEGF165) and a lac-z reporter gene. 3x10
8 transduced cells were injected at 20 
different intramyocardial sites in Yorkshire swine, which were used as a model for 
chronic infarction.  The authors found this angiomyogenesis regeneration method safe 
and able to result in improved perfusion, myocardial contractility and overall 
performance. 
To promote vascularization in a rat myocardial infarct model, human embryonic 
stem cells (hESC) were transduced by an adenovirus to express VEGF165 to enhance the 
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stem cells’ differentiation down the endothelial cell line.58 The obtained endothelial 
progenitor cells were then transplanted intramyocardially into the infarcted and peri-
infarcted regions in the rat model; the progenitor cells were able to survive in the infarct 
model and aided infarcted myocardium regeneration (size and mature blood vessel 
density).  
For osteogenic applications, Blum, et al. transfected and transduced rat marrow 
stromal cells to overexpress human bone morphogenetic protein 2 (hBMP-2) via 
Lipofectamine® Plus™ and an adenovirus or retrovirus and found that the adenovirus 
was the only vector capable of expressing detectable hBMP-2.59 The authors were able to 
significantly increase endogenous alkaline phosphatase activity which indicates 
successful osteogenic differentiation. 4x105 stromal cells were then seeded onto Ti-mesh 
scaffolds for in vivo osteogenic application assessment in an orthotopic, critically-sized, 
rat cranium. The authors found there was a small, statistically significant improvement in 
osteogenesis when using the adenoviral vector.59 
To repair large nonunion bone defects, Wojtowicz, et al. retrovirally transduced 
bone marrow stromal cells (BMSC) to overexpress Runx2, a transcription factor 
regulating osteoblast differentiation.60 These modified BMSCs were delivered in rats, 
which had a critical-sized femur defect, on polycaprolactone scaffolds with type I 
collagen mesh. The authors observed accelerated healing in the large bone defects 
compared to unmodified BMSCs.60  
Cerebral vascular diseases of an occlusive nature lead to brain ischemia, causing 
neuropathological complications. Zhao, et al, endeavored to induce marrow stromal cells 
to express hepatocyte growth factor (HGF) using a herpes simplex virus type-1 vector.61 
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Marrow stromal cells themselves are capable of releasing cytokines and growth factors 
and are able to migrate towards damaged areas, improving functional recovery after 
cerebrovascular accidents. HGF has been associated with anti-apoptosis, angiogenesis, 
increased neurite growth, and neuroprotective properties post-ischemia and Zhao, et al. 
observed a significant neurological recovery when they intracerebrally transplanted 
transduced stromal cells into a rat occluded artery model.61  
 
2.1.5  Viral Vectors for In Vivo Applications 
 
While in vivo gene therapy is more challenging than ex vivo gene therapy, several studies 
suggest that may be a promising avenue for regenerative medicine. As there is limited 
osseointegration for allografts used in critical bone defects, Yazici, et al. endeavored to 
coat allografts in 1010 self-complementary adeno-associated virus (AAV) serotype 2.5 
vector, delivering the BMP-2 gene.62 The coated allograft was able to form cortical shells 
that were indistinguishable from those formed by live autografts; furthermore, there was 
reduced bone resorption, which led to increased bone volume than the autograft which 
rendered superior biomechanical properties.62  
Gelse, et al. investigated complementary DNA (cDNA) delivery using adenoviral 
vectors encoding for bone morphogenetic protein or insulin-like growth factor 1 for an 
articular cartilage repair application.63 Hyaline repair cartilage in the defect was produced 
in most partial thickness lesions in the rat model that was used. However, cells that failed 
to be transduced did not fill the defect or were associated with type I collagen.63  
To assess spinal cord injury regeneration, Shea, et al used a rat spinal cord 
hemisection injury model using PLGA multichannel bridges.64 Lentiviruses encoding for 
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brain derived neurotrophic factor and neurotrophin 3 transduced a number of cells 
including, astrocytes, macrophages, fibroblasts, and Schwann cells for at least 4 weeks, 
resulting in a significant induction of myelinated axons into the bridge in comparison to 
bridges with lentiviruses encoding for β-galactosidase. 
In a final example, Bainbridge, et al. used recombinant adeno-associated viral 
vectors carrying a gene encoding for retinal pigment epithelium (RPE65) using the 
RPE65 promoter for three patients suffering from Leber’s congenital amaurosis which is 
associated with infantile-onset rod-cone dystrophy.65 There were no adverse events due to 
the subretinal vector delivery, nor changes in visual acuity, peripheral visual fields, and 
retinal responses to electroretinography, indicating the vision was stabilized.65 Thus, in 




2.1.6  Non-viral Vectors for Ex Vivo Cell Engineering 
Numerous non-viral approaches for ex vivo gene transfer for regenerative medicine have 
been described. Autologous bone grafts from the iliac crest are commonly used for spinal 
arthrodeses for stabilizing adjacent disks and minimizing back pain. However, to avoid 
donor site morbidity complications Sheyn, et al. non-virally nucleofected primary porcine 
adipose tissue-derived stem cells to over express recombinant hBMP-6 which is capable 
of osteogenesis induction.66 Post-transfection, 5x106 cells were injected into the lumbar 
paravertebral muscle of mice. The authors found this gene transfer method to be safe and 
the mice exhibited temporary overexpression of BMP-6. Enough bone was formed in the 
lumbar region to fuse two to four vertebrae of the spine.66 
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Post-myocardial ischemia, overexpression of VEGF may result in the formation 
of angioma.  Lei, et al. complexed a hypoxia-regulated VEGF plasmid with the cationic 
polymer, polyethyleneimine (PEI), to form particles and delivered them to rabbit skeletal 
myoblasts and then transplanted the transfected myoblasts to an acute myocardial 
infarcted rabbit model.67 1x107 transfected cells were intramyocardially injected into the 
infarcted and peri-infarcted areas. The authors found that the ability to repair the infarcted 
tissue, as well as the global left ventricular function was improved. 
With the purpose of increasing neovascularization for myocardial ischemia and 
peripheral vascular disease, human umbilical cord blood-derived progenitor cells were 
used in conjunction with polyethersulfone (PES) electrospun nanofibers by Das, et al.68 
The purpose of the nanofibers were to expand the stem/progenitor cells many fold 
without differentiation in an ex vivo environment; the progenitor cells were able to retain 
their phenotype prior to in vivo delivery. The progenitor cells were transfected using 
Nucleofector® technology to overexpress the VEGF-A164 and PDGF-BB growth factors. 
5x105 cells were delivered per immunodeficient NOD/SCID mouse, in a hind limb 
vascular injury animal model. The growth factor-overexpressing cells were able to 
promote angiogenesis more effectively compared to non-expressing progenitor cells.68  
 
2.1.7  Non-viral Vectors for In Vivo Applications 
Large bone implant osseointegration presents healing challenges even while using 
autologous bone grafts. Park, et al. investigated whether liposomal vectors delivering 
BMP-2 cDNA mixed with crushed bone and delivered onto the implant surface as well as 
the peri-implant defect could transfect trabecular-lined cells and induce bone—graft 
osseointegration in pig calvariae.69 The authors found that the liposomal vector was able 
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to induce abundant BMP-2 protein production throughout the defect, enhance bone 
formation and caused the particulate bone to become trabecular, in contrast to the control 
groups.69  
 As there are still no optimal solutions for nonunion bone defects, Kimelman-
Bleich, et al. endeavored to recruit host progenitor cells to nonunion radius bone defect 
sites in mice using a collagen sponge.70 A plasmid encoding BMP-9 was injected into the 
radial defects and electroporation was accomplished 10 days after the defect was created. 
The authors found that the gene expression was localized to the site of the defect and that 
bone formation bridged the nonunion gap; whereas the gaps remained in the control 
groups.70  
Trentin, et al. demonstrated that they were able to achieve upregulation of VEGF-
A165 in full-thickness dermal wounds in a mouse model with vessel maturity by 
delivering a mutated hypoxia-inducible factor (HIF)-1α gene lacking the oxygen sensor 
so that the gene was constitutively on.71 The gene was delivered using an intracellularly 
reducible disulfide-containing, cysteine-flanked lysine peptide in a fibrin matrix.71  
Shea, et al. investigated the efficacy of delivering of FGF-2-encoding plasmids 
using a porous PLGA scaffold formed via a gas foaming method in the intraperitoneal fat 
of C57BL/6 male mice.72 They found the expression peaked after the first couple of days 
and subsided over the following week or two and that the vascular volume fraction 
increased 40% in comparison to the controls at week two.  
Park, et al. demonstrated the ability to significantly increase vascular endothelial 
growth factor and stromal cell-derived factor-1α chemokine in mice with full-thickness 
dermal wounds by intradermally delivering the sonic hedgehog gene using poly(β-amino 
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ester) polymers.73 By varying the type of small molecule endcap, they were able to 
optimize toxicity and achieve higher transfection of the morphogen than commercially 
available reagents such as Lipofectamine® 2000 in vitro.73  Thus, emerging non-viral 
approaches are able to achieve efficacy in vivo for regenerative medicine challenges, 
while also reducing potential safety concerns as compared to viruses. 
 
2.1.8 Combination Biomolecule and Cell Therapy Application 
There have been several biomolecule and cell-based combination therapies used for 
regenerative medicine. One of particular interest involves the treatment of Duchenne 
muscular dystrophy (DMD).  Filareto, et al. investigated an autologous cell-based 
combination therapy in a DMD mouse model which involved the following procedures: 
the extraction of fibroblasts and their induction of pluripotency; gene delivery to correct 
for the missing micro-utrophin gene in the fibroblasts; the promotion of myogenic 
progenitor cells using Pax3; and the eventual re-implantation of the corrected myogenic 
progenitor cells into a DMD mouse model.74  
More specifically, Filareto, et al. retrovirally transduced dystrophin/utrophin-
double knockout (dKO) tail-tip fibroblast cells with Oct4, Sox2, and Klf4 to obtain the 
dystrophic induced pluripotent stem cells (iPSC), which were then expanded (Figure 
4).74 The dystrophic iPSCs were corrected by delivering the micro-utrophin gene via the 
Sleeping Beauty transposon system to allow for precise excision and relocation of a DNA 
segment. Pax3 was then used to promote skeletal muscle stem/progenitors cells. Flk-1 
and PDGFα receptor expression were shown to establish pluripotency using 
differentiated embryoid bodies. The micro-utrophin-corrected myogenic precursors were 
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then autologously re-implanted back into the same dKO mice. The muscles of such mice 
had improved contractility and muscle regeneration in vivo.74  
 
2.1.9 Current Limitations 
The development of thick complex tissues requires multiple cell types and 
involves microenvironments that may overlap, greatly increasing complexity. Although 
many of the techniques discussed in this article can be used for temporal and spatial 
control of delivery in a broad sense, they generally do not control in vivo delivery with 
the cellular and subcellular spatial resolution and second-scale temporal resolution that 
may be in many ways ideal. Coupled with this engineering limitation is the basic science 
limitation of not having precise knowledge about these precise spatial and temporal 
requirements. Despite the use of various computer-controlled 3D cell printing techniques, 
spatiotemporally controlling multiple microenvironments within close regions remains a 
challenge. Newer techniques involving computational topology design and solid free-
form fabrication help alleviate some disadvantages, yet the remaining challenges include 
but are not limited to vascularization, host integration, resolution and porosity, and the 
seeding and co-culturing of multiple cell types.75,76 Furthermore, the mechanisms by 
which complex tissues are orchestrated to develop and heal are largely unknown.77 
Therefore, there are opportunities in the field for the invention of higher resolution in 
vivo biosensing technologies, extracellular and intracellular drug delivery technologies 
with increased spatial and temporal control, and cell delivery and scaffold technologies 
with increased spatial control and organization of diverse cell types.         
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2.1.10 Clinical Trials 
As of June 2010, according to the Journal of Gene Medicine website1, there have 
been a total of 1,644 gene therapy clinical trials approved worldwide. The leading 
diseases being treated in the gene therapy clinical trials are cancer (64.5%), 
cardiovascular diseases (8.7%), and monogenic diseases (8.2%). The majority (60.5%) of 
the clinical trials are in phase I. The most common gene types used have been antigens 
(19.8%), cytokines (18.4%), tumor suppressors (10.5%), and growth factors (7.7%). 
Table 1 is a summary of non-viral gene therapy clinical trials detailing the type, the 
current or last clinical phase, the nucleic acid being delivered, and the disease target.  
This data highlights that the majority of clinical trial thus far have been with viral vectors 
(~75%), and the leading non-viral approaches in clinical trials are “naked” free DNA 
(18%) followed by Lipofection (7%). Polymeric and inorganic vectors for gene delivery, 
although promising for the future, are for the most part still in preclinical stages of 
development. However, one recent approach in polymeric gene delivery to reach clinical 
trials is Mark Davis and Calando Pharmaceuticals work with cyclodextrin-based 
polymers 78,79. In this work it has been demonstrated that biocompatible polymeric 
nanoparticles can reach solid tumors following systemic administration in humans and 




A key element important to consider for bioengineered delivery is that the needed 
factor be provided to the right cells at the right time and place to properly control cell and 
tissue function. Engineering a cell from the outside-in via delivery of soluble and 
insoluble factors to the outside of the cell was compared to engineering a cell from the 
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inside-out via gene transfer using both viral and non-viral methods. Combinations of 
delivery of biomolecules, scaffolds, and cells were demonstrated as approaches that are 





Figure 1 (A) Key controlling signals regulating cellular responses (B) A depiction of 
niche factors which control microenvironments: soluble growth factors which could be 
either autocrine or paracrine acting, cellular receptors involved in binding other cells or 
the ECM, as well as growth factor receptors; from Discher, et al. Growth factors, 
matrices, and forces combine and control stem cells. Science 324:1673-1677, 2009.7 





Figure 2. A depiction of enhanced vasculature and bone formation in the scaffold loaded 
with both BMP-2 and VEGF after 8 weeks of subcutaneous implantation. Reprinted from 
Biomaterials, Vol. 30, Kempen, et al., Effect of local sequential VEGF and BMP-2 
delivery on ectopic and orthotopic bone regeneration, pages 2816-2825, Copyright 





Figure 3. Barriers of nucleic acid delivery for gene modulation.55  Reprinted from 
Therapeutic Delivery, Vol. 2, Sunshine, et al., Advances in polymeric and inorganic 
vectors for nonviral nucleic acid delivery, pages 493-521, Copyright (2011), with 




Figure 4. Ex vivo gene therapy approach to treat muscular dystrophy.74 Reprinted by 




Figure 5. A depiction of applicable avenues of gene and cell therapies using stem cells.80 
Reproduced by permission from Macmillan Publishers Ltd: Clinical Pharmacology and 
























Table 1. Summary of clinical trials (some of which are ongoing) 
*Acronyms: AMD = Age-related macular degeneration; CNV = choroidal 
neovascularization; DC-Chol = 3B[N-(iV’,W-dimethylaminoet hane)-
carbamoyllcholesterol; FGF = fibroblast growth factor; GMC-SF = Granulocyte-
macrophage colony stimulating factor; heNOS = human endothelial nitric oxide synthase; 
HGF = hepatocyte growth factor; IL = interleukin; PAOD = peripheral artery occlusive 
disease; RSV = Respiratory syncytial virus;  
Type Clinical 
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II IL*-2 Renal cell cancer 
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II E1A  Ovarian Cancer 
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2.2 2Non-viral Gene Delivery Barriers 
Nucleic acid therapies have enormous potential in the clinic, from treatment of 
specific genetic diseases such as cystic fibrosis 1, Leber hereditary optic neuropathy 2, 
hemoglobinopathies 3,4 and hemophilia 5, to the treatment of cancer 6,7 and cardiovascular 
                                                     
Chapter 2.2 is published as “Sunshine JC, Bishop CJ, Green, JJ. Advances in polymeric and inorganic 
vectors for nonviral nucleic acid delivery. Ther. Deliv. 2011;2(4):493-521”. 
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disease 8 and the use of genetic vaccines 9.  Additionally, nucleic acid delivery plays a 
crucial role in cellular engineering and basic biomedical research through the ability to 
knock in and knock down genes and proteins in the lab, as well as in the creation of 
induced-pluripotent stem-cells (iPSCs) via viral methods 10,11 and investigations into the 
induction of iPSCs via non-viral 12 methods.  
The central challenge for effective therapy using nucleic acids is finding a safe 
and effective delivery system 13. With regards to gene therapy, since viral gene therapy 
can have serious safety concerns 14,  recent efforts have focused on non-viral methods. 
These non-viral methods can be used to deliver various nucleic acids (Table 1), 
including DNA 15, small interfering RNA (siRNA) 16,17, immunostimulatory RNA 18, 
short hairpin RNA (shRNA) 19, anti-gene RNA (agRNA), and small-activating RNA 
(saRNA) 20. The choice of nucleic acid to deliver may influence where the nanocarrier 
needs to deliver its cargo (Fig 1). For example, to target Toll-like receptors (TLRs) such 
as TLR3, TLR7, and TLR8, isRNA should be targeted to the endosome itself 18. siRNA 
needs to get into the cytoplasm, so vectors that carry these cargoes, if they are trafficked 
through the endosome, need some method to escape it. Finally, DNA, shRNA-encoding 
plasmids, agRNA, and saRNA all need to be further transported from the cytoplasm into 
the nucleus to be expressed, to interfere with, or to promote gene expression. 
There are several barriers to cellular entry and delivery of the nucleic acid cargo 
that challenge the development of an effective delivery vehicle (Fig. 1). The vehicle 
needs to form a stable complex with its nucleic acid cargo, protect it from degradation 
extracellularly, arrive at the cell of interest, get internalized (typically via either receptor-
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mediated endocytosis and or non-specific endocytic pathways), escape endo-lysosomal 
degradation, release its cargo, and harmlessly degrade or otherwise be eliminated.  
After escaping the endosomal compartment and making it into the cytoplasm, 
nucleic acids such as DNA and agRNA, need to make it to the nucleus. This is among the 
largest challenges remaining for non-viral gene delivery. Simply getting the plasmid into 
the cytoplasm of the cell is not sufficient; in order to achieve the same level of 
transfection, delivery of 30 to 100-fold more DNA to the cytoplasm is required compared 
to direct delivery of DNA to the nucleus 21. Dividing cells are more easily transfected due 
to the breakdown of the nuclear membrane that occurs during mitosis 22. While this 
breakdown can enhance localization of plasmids to the nucleus and transfection 
efficiency, cell division is not a requirement for successful transfection 22. Plasmids can 
also enter the nucleus through nuclear pore complexes (NPCs) when they are coupled to 
nuclear localization signals, but this process is not as efficient 22.  
 Here we will review the current progress in non-viral nucleic acid delivery, 
especially highlighting the progress in the use of cationic polymers and inorganic 
nanoparticles (as well as their hybrids). Lipid-based materials for nucleic acid delivery 
are outside the scope of this review and are well-described elsewhere for siRNA delivery 
23 and gene delivery 24. In this review general properties and biomedical applications of 
polymeric and inorganic materials are described first.  This is followed by further 
discussion of new approaches to solving the barriers to non-viral delivery. Subsequently, 
an overview of past and present gene therapy clinical trials will be discussed in terms of 
the type of delivery system, its current clinical phase, the gene of interest being delivered, 
and the targeted disease. 
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When designing gene therapy vectors it is important to note that physical 
properties such as size, aspect ratio, molecular weight, surface area, shape, 
polydispersity, zeta potential, and others, can have an impact on cytotoxicity and delivery 
25. To meet certain barrier requirements for gene delivery, surface modifications can be 
used to modify the physical properties of the delivery system to improve circulation time 
and solubility (i.e., PEGylation) 26, localization (i.e., folic acid, RGD) 27, biostability (i.e., 
zeta potential: amine or carboxylic groups) 26,  cytotoxicity (addition of carboxyl or 
hydroxyl groups) 28,29, internalization, and inhibition of reticuloendothelial system 
clearance 30,31 
 
2.2.1 Shape/Surface Morphology  
Recently, manipulation of particle shape has come into focus as a new method for 
modulating drug delivery 32. Local shape of the particle where it makes contact with the 
cell and not necessarily the overall shape dictate whether or not the particle is internalized 
by macrophages 33. Elongated particles have been shown to circulate longer and avoid 
phagocytosis more effectively than spherical particles 34, however, spherical particles are 
much more efficiently internalized into target tissues as compared to elongated particles 
35. Seeking to take advantage of this property, Yoo et al. has recently constructed PLGA-
based shape shifting particles (one way, from ellipsoid to spherical) in response to 
temperature, pH, or a chemical signal and demonstrated efficient uptake of the spheres as 
compared to the ellipsoids 36 (Fig 2). It is also possible to complex anisotropic faces of 
AuNPs with DNA oligonucleotides to form sticky patches which allows for complicated 
self assembly 37.   
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Other nanoparticle morphologies may prove worthwhile to investigate to tune 
cytotoxicity and nucleic acid delivery of potential vectors. Spherical silver nanoparticles 
can be induced via light to transform into triangular prisms with efficiency nearing 100%. 
This is accomplished by irradiating a solution of silver nanoparticles with a halogen lamp 
at 150 watts for 5 hours (bandpass filter at 550 nm) 38. DeSimone and coworkers have 
elegantly used soft lithography using polydimethylsiloxane and perfluoropolyether to 
make molds enabling nanoparticle replication in a non-wetting template. Using this, 
nanoparticles with diverse shapes are able to be fabricated (i.e., 200 nm trapezoidal 
particles, 200 x 800 nm bar particles, 3 μm arrow particles, and 2.5 x 1 μm2 hexnut 
particles with 1 μm holes) 39.  
Tuning surface morphology has recently been shown to be another important aspect of 
controlling nanoparticle delivery 40. Verma et al. showed that gold nanoparticles with 
surface “ribbon-like” domains of alternating hydrophobic/hydrophilic composition were 
able to enter the cell without the membrane disruption associated with cationic 
nanoparticle systems; control particles with random surface organization were unable to 
penentrate cells at all 41. Cell penetrating peptides appear to have similar functionality 
41,42. This property should reduce the toxicity usually associated with membrane 
disruption 41. 
 
2.2.2 Size  
Polymer nanoparticles have been developed with a wide variety of sizes for 
different purposes. Nanoparticles of approximately 100 nm show prolonged blood 
circulation and a relatively low rate of mononuclear-phagocyte system uptake. 43 Particles 
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with a 1-5 μm diameter are likely to be trapped in the liver and phagocytosed by Kupffer 
cells 36. Larger than 5 μm particles are likely to be trapped in the capillary beds 36. When 
NPs are greater than 200 nm they are likely to be filtered in the spleen, whereas the NPs 
less than 100 nm are likely to leave the blood vessels through fenestrations in the 
endothelial lining 36. NPs that are ~50-200 nm have been known to accumulate in tumors 
by the enhanced permeability and retention (EPR) effect (as a result of leaky vasculature 
and the absence of a draining lymphatic system) 44,45. It has been suggested that particles 
must not exceed 300 nm to take advantage of the EPR effect 46. Nanoparticles smaller 
than 50 nm are more likely to enter most cells, and those with sizes smaller than 20 nm 
can get out of the blood stream and into tissues 45,47. The glomerular apparatus’ capillary 
wall has fenestrations ~4-5 nm and it has been reported that nanoparticles >8 nm cannot 
be filtered through the glomerular filtration system 25 as a result would increase 
circulation half-life 48.  
 
2.2.3 Charge  
To best avoid nonspecific interaction and escape the reticuloendothelial system, 
nanoparticles should be designed to have neutral or slightly negative zeta potentials 49. 
On the other hand, a positive zeta potential enhances nanoparticle-cell contact and 
promotes uptake and internalization through stronger affinity for anionic proteoglycans 
on the cell surface 50.  For example, the zeta potentials of lysine-, arginine-, and histidine 
modified nanoemulsions were reported to be 50 mV, 43 mV, and 7 mV, with transfection 
efficiency decreasing with neutralization of the zeta potential 51. Some nanoparticles may 
be more or less cytotoxic depending on their charge (i.e., AuNPs are less cytotoxic when 
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anionic) 52. It is important to consider zeta potentials when complexing nucleic acids via 
ionic interactions. The interaction must be strong enough to condense the nucleic acid to 
protect against restriction enzymes. It is important to note that zeta potentials of 
nanoparticles can switch signs when in the presence of serum and this should be 
considered in the design and testing process 53,54.  
 
2.2.4 Biocompatibility  
Biocompatibility is crucial for maintaining an appropriate host response during 
gene therapy. In depth assessments and characterizations are required to elucidate the 
physicochemical differences responsible for low cytotoxicity and acceptable viability. 
PEI lacks degradable linkages and is too toxic for therapeutic applications, 
inducing both apopotosis and necrosis in an endothelial cell model 55.  As a result, a 
number of investigators have synthesized an array of degradable PEIs consisting of LMW 
PEIs and degradable cross-linkers, in the hopes of achieving higher efficacy with the 
reduced cytotoxicity of low molecular weight PEIs 56,57. 
Other groups have focused on developing new, biodegradable polymers for non-
viral gene delivery, which we will review here by method of degradation. Biodegradable 
polymers should be able to both reduce the cytotoxicity associated with the transfection 
reagent as well and potentially improve dissociation of the vector from its cargo to allow 
the cargo to be utilized intracellularly. 
Multiple strategies have been formulated using ester bonds to allow hydrolytic 
cleavage of the polymer. Amine containing hydrolyzable polymers have been utilized 
which are effective gene delivery agents with significantly decreased cytotoxicity as 
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compared to non-degradable polymers such as poly(ethylenimine) (PEI) 58 and 
poly(lysine) (PLL) 59. These structures include poly(lactide-co-glycolide) (PLGA) 60, 
hyperbranched poly(amino ester)s 61, poly(lactic acid) (PLA) 62, and linear poly(β-amino 
ester)s (PBAE) 63, among others.   
Libraries of PBAEs have been developed for gene vector screening 64,65. Studies 
have shown that amine-terminated PBAEs are more effective at pDNA transfection than 
acrylate-terminated versions. Modification of the polymer ends with different amines can 
lead to virus-like efficacy in human primary cells in vitro 66 (Fig. 3).  Tuning of polymer 
end group leads to significant differences in transfection efficacy, and the optimal end-
group for each cell type appears to be different 67,68.  PBAEs also have been shown to be 
non-toxic to human primary cells in vitro 69 and in mice in vivo 70,71. 
 
2.2.5 Stealth Properties  
The binding of serum proteins to nanoparticle surfaces after intravenous injection 
allows the nanoparticles to be recognized and internalized by macrophages, resulting in 
removal of nanoparticles from circulation 72. Addition of hydrophilic moieties, like 
poly(ethylene glycol) (PEG), poly(N-(2-hydroxypropyl-methacrylamide) (pHPMA), and 
various oligosaccharides, have been shown to increase solubility, prolong circulation 
time, neutralize zeta potential, and reduce interactions with the environment within the 
bloodstream due to a higher tolerance against incubation with serum proteins 73,74. One 
disadvantage of this approach is that while it may stabilize the polyplex in serum and 
reduce cytotoxicity, it may also interfere with complexation and reduce transfection 
efficiencies depending on the extent of addition 75. Modification of the surface of 
50 
 
preformed particles with PEG/pHPMA that can bind to exposed surface amino groups 
has been shown to alleviate this problem 73,76. Recently, Yuan et al. showed that adding 
PEG to PAMAM dendrimers via bis-aryl hydrazone bond linkages into the vector 
significantly enhanced the buffering capacity of the vector even with a high degree of 
PEGylation 77. PEG can be added to a variety of nanoparticles and can be further 
modified to provide targeting 78-81, or can be attached by degradable bonds (such as 
matrix metaloproteinases (MMP)) that can be cleaved to expose underlying 
functionalities 82-86.  Electrostatic coatings can also be used to improve the delivery 
properties of a charged particle without significantly altering the core particle 87,88. 
 
2.2.6 Nucleic Acid Complexation  
Many polymers for nucleic acid delivery rely on electrostatic interaction between 
a cationic polymer and the anionic phosphate backbone of nucleic acid substrate. For 
polymer-DNA complexes, requirements include condensation of the plasmid to an 
appropriate scale for internalization, neutralization of the negatively charged phosphate 
backbone of the DNA, and protection of DNA from degradation both intra- and 
extracellularly 89,90. Sufficient cationic charge is crucial to condense DNA, but it is also 
correlated with increased cytotoxicity, and higher DNA binding affinity may lead to 
decreased DNA release and reduced transport through the cytoplasm 91. Gold 
nanoparticles can use electrostatic methods for complexation with nucleic acids as well. 
AuNP rods conjugated with cationic cetyltrimethylammonium bromide were 
electrostatically complexed with siRNA (anti-DARPP-32 gene in dopaminergic neuronal 
cells) with 98% cell viability and 67% expression knockdown at 120 hr post-transfection 
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49. Alternatively, hydrolytically degradable nanoparticles can be formed through 
encapsulation of DNA by non-cationic polymers such as PLGA.  These particles degrade 
to release their nucleic acid cargo and the size of the particle can be controlled in the 
nanometer to micrometer range, depending on the method of particle formation used. 
Methods have been developed to protect the cargo from destruction during these 
processes 60 but are still limited by low encapsulation efficiency and potential DNA 
degradation in the hydrolyzing polymer core 92. 
Chitosan can form nanoparticles through a process called ionotropic gelation with 
polyanions such as sodium tripolyphosphate 93. Chitosan has been optimized to allow for 
the encapsulation of both hydrophilic and hydrophobic drugs and has been utilized in 
nucleic acid delivery 94,95, most successfully as hybrid co-polymers with various 
polycations 96-99.  
Inorganic nanoparticles can be complexed with nucleic acids via ionic 
complexation or covalent bond. For example, AuNPs (4.1 nm) can be covalently attached 
to cationic N-dodecyl polyethylenimine (2 kDa) and complexed with β-gal pDNA. When 
this conjugated complex was delivered to COS-7 cells, there was 67% cell viability and 
50% transfection efficacy which compared favorably to regular PEI and PEI25 which had 
4 and 8% transfection, respectively (~93% cell viability) 100. 
Another nucleic acid complexation technique involved 11-mercaptoundecanoic 
acid which was deposited on Au to bind oppositely charged polyelectrolyte solutions. 
The deposited Au combined with PEI (23kDa MW) and double-stranded 21-mer anti-
EGFP siRNA and was then coated again in a PEI layer. This complex was delivered to 
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CHO-K1 cells resulting in ~95% cell viability and ~72% knockdown of EGFP 
expression101. 
 
2.2.7 Cellular Targeting  
By utilizing a targeting moiety, smaller dosages can elicit comparable therapeutic 
responses while minimizing side effects and reducing the cost of therapy 102. There are 
two types of targeting; passive and active. Passive targeting utilizes natural processes 
such as the enhanced permeability and retention effect (EPR), in which the leaky tumor 
vasculature and lack of efficient lymphatic drainage in a solid tumor leads to passive 
accumulation of drugs or particles at the tumor site, given sufficient circulation time 103. 
Active targeting consists of an additional ligand to assist in localization or internalization 
such as antibodies or their fragments (i.e., J591 against prostate-specific membrane 
antigens 104, anti-HER2 (Trastuzumab) 105, etc) 106, folic acid(107),  sugars (i.e., galactose, 
mannose, and lactose) 108, peptides (RGD) 109,110, transferrin 111,  and nucleic acid 
aptamers 112.  Large targeting moieties, however, may hamper internalization and gene 
unpacking and having triggered removal of the target moiety at the cell surface may be 
worthwhile 102. Targeting moieties are typically attached chemically but can be physically 
adsorbed to the delivery system as well 88. Interestingly, it has been shown that 
biodistribution of cargo at the accumulation site can be independent of the presence of 
targeting ligands 45. The reason for improved functionality when targeting ligands are 
used appears to be due to an increase in cell internalization and specificity of the 
nanoparticles rather than tissue localization. Passively targeted nanoparticles have a 
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propensity to end up in the extracellular space of tumors and in tumor-associated 
macrophages 45. 
Cationic polymers have been modified with targeting ligands for various 
applications. For example, the addition of lung surfactant to ternary nanoparticles for 
aerosol-based gene therapy enhances gene delivery to the lung, resulting in 12-fold 
higher transfection compared to pure nanoparticles and 30-fold higher compared to 
polyethylenimine 113. Insulin adsorption significantly increased gene expression of PEI-
pDNA nanoparticles up to 16-fold on alveolar epithelial cells but not on bronchial 
epithelial cells 114. 
AuNPs can be complexed with PEG-NH2 and folic acid via non-covalent 
interactions and can be taken up by cancer cells (OV167, OV202, OVCAR-5) 
proportional to the degree of folic acid receptors expressed on them. However, 
unintended delivery to the liver and kidneys can also occur due to over-expression of 
folic acid receptors there as well 115,116. 
AuNPs and the monoclonal antibody CD11b have been targeted to RAW264.7 
macrophages and resulted in 81% cell death post 30 J/cm2 exposure as opposed to 0.9% 
cell death with non-labeled cells 31. 
 
2.2.8 Enhancing Internalization  
AuNP can be internalized to a greater degree via electroporation which causes 
membranes to become permeabilized by pulsed electric fields (several kV/cm amplitude 
and submicrosecond duration). Membrane pores occur momentarily as a result, allowing 
for easier passage of gene therapy systems. However, electroporation can also cause 
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osmotic lysis of the cells. Kawano et al has delivered AuNP-SS-mPEG-pDNA  in vivo in 
combination with electrical pulses to the mouse liver and observed greater stability in 
circulation and a gene expression increase by ten-fold in comparison to naked DNA 117. 
Multi-walled CNTs combined with irradiation of microwaves for 8 seconds can aid gene 
delivery by creating transient nanochannels in the cell while maintaining cell viability at 
100% 118. Hexagonal layered double hydroxide nanoparticles (LDHs) are most likely 
taken up by clathrin-mediated endocytosis and localize to the perinuclear area of the 
cytoplasm (where siRNA/mRNA complexes can degrade).  In contrast,  rod-like LDHs 
concentrate in the nucleus 119. 
Gene-associated magnetic nanoparticles (i.e., SPIONs) can be guided toward a 
particular region of the body via external magnetic fields. Application of external 
magnetic fields to aid traversing membrane barriers and enhancing cell contact is known 
as magnetofection 120. CNTs with ferromagnetic-nickel tips have been known to be able 
to align in an external magnetic field to spear cell membranes. This increases the 
shuttling efficiency of cargo by 107 fold and was shown to increase transfection rates to 
approximately 100% to mammalian cells in vitro 121 Ultrasound is non-invasive and safe 
at a broad range of frequencies and intensities and can be used to enhance gene delivery. 
The main mechanism responsible for increased gene delivery is cavitation, where 
reversible nanopores are formed (up to 100 nm with a half life of a few seconds) by 
microbubble expansion and collapse.  122. Stride et al. endeavored to combine ultrasound-
mediated gene delivery and magnetofection and showed significantly improved 
transfection over magnetofection and ultrasound alone 123. 
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Gene guns are biological ballistic hand held delivery systems which physically 
propel nucleic acid-complexed nanoparticles (i.e., AuNP) into cell cytoplasm and nuclei 
with a low pressured propellant (i.e., helium).  Chitosan and poly-g-glutamic acid (150-
250 nm) nanoparticles have been used to encapsulate reporter genes and transfect liver 
cells via the gene gun method which increases delivery by 2 log orders of magnitude in 
terms of luciferase RLU/mg protein compared to naked DNA 124.   
 
2.2.9 Endosomal Escape 
In early experiments with non-viral gene delivery, non-degradable polycations, 
including poly(l-lysine) (PLL) and polyethylenimine (PEI) were used. Compared to PLL, 
a major advantage of PEI is the “proton sponge” effect due to PEI’s extensive buffering 
capacity. When PEI:DNA complexes gain entry to the endosome, the secondary and 
tertiary amines in PEI function to buffer acidification of the endosome.  This causes an 
influx of negatively charged chloride ions into the endosome to maintain electroneutrality 
as protons are continually pumped into the endosome.  Eventually, this leads to osmotic 
swelling and rupture of the endosomes and release of the vector and cargo into the 
cytoplasm 125. This mechanism has been widely explored for gene and siRNA delivery 
58,126. This concept has also been extended and heavily used in the design of next-
generation biodegradable vectors which also contain this buffering capacity. 
A widely used buffering moiety is the imidazole ring of histidine. It is a weak 
base with a (pKa ~ 6) capable of buffering the endosome. For example, a 
poly(phosphazene) based polymer has been histidylated, and the resulting polymer 
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showed improved transfection and reduced cytotoxicity when compared to the histidine-
free polymer and branched PEI 127. 
Newer methods for endosomal escape involve functionalizing a polymer with 
peptides that enhance endosomal release. Melittin enhances endosomal escape and 
nuclear transport via cationic C-terminal lysine-arginine-lysine-arginine cluster 128. 
Modifying melittin either by reversible acetylation of a lysine residue in melittin 129 or 
replacement of two glutamines with glutamic acids which get neutralized at acidic pH 130 
takes advantage of the acidification of the endosome to induce membrane lysis only in 
the endosomal compartment and reduces the cytotoxicity associated with use. 
Functionalizing polylysine with polyethylene glycol and a pH-responsive melittin peptide 
was shown to be an efficient siRNA delivery agent 131.  
Protonation of glutamate residues (pKa 5-5.5) within “anionic fusogenic peptides” 
within the endosome triggers disruption of the endosomal membrane via the formation of 
an alpha-helical structure in the peptide 132-134. Adding these peptides to polymeric 
vehicles was shown to enhance the endosomal escape rate constant by two orders of 
magnitude 135.  
 
2.2.10 Release of Cargo/Degradation  
Nucleic acids must be released from the vector to have an effect. This can be done 
by taking advantage of the redox potential gradient 136, acidic environment of the 
endosome 137, MMPs 138,139, photocatalysis 140, and hydrolytic degradation of the carrier 
63,141,142.  It has been shown that plasmid unpacking can be a limiting step with regards to 





Using bioreducible polymers via incorporation of disulfide linkages takes 
advantage of the relative reducing environment of the intracellular space. Intracellular 
reduction of the disulfide bond occurs via the glutathione (GSH) pathway. GSH is 
regenerated from its oxidized form by glutathione reductase, and is an important 
component in many cellular pathways and plays  a major role in cellular defense against 
oxidative stress. Disulfide bonds are stable extracellularly, preventing particle breakdown 
before the nano-complex reaches the cell surface, whereas the reducing environment of 
the intracellular space allows for enhanced polymer breakdown and nucleic acid release 
144-148.  
Disulfide bonds have been shown to degrade intracellularly within 3 hours 149. 
When cell lines with different intrinsic glutathione levels were compared, increased 
cellular GSH levels were associated with improved transfection of mRNA polyplexes. In 
other experiments, no clear trend was observed for plasmid DNA or siRNA containing 
complexes and GSH levels; rather, the cell line which demonstrated the best DNA 
transfection was the fastest dividing cell line 150. 
Enhancing release of the pDNA cargo can lead to dramatic gains in transfection 
efficiency. Chen et al synthesized a series of reducible hyperbranched poly(amido 
amine)s and found that reducible polymers were able to achieve nearly 200-fold higher 
transfection as compared to control polymers 151.  Combining hydrolyzable and 
bioreducible functional groups as a single polymer might also help further tune the 
release profile 152,153.   
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 Reducible polymers have also been used to deliver siRNA. Histidine containing 
reducible polycations based on CH(6)K(3)H(6)C monomers (His6 RPCs) were examined 
for their utility in delivering siRNA. Co-delivery of EGFP siRNA with EGFP DNA 
reduced reporter gene expression by 85%. Interestingly, while as with most polymer 
systems, larger polymer size correlated with increased DNA transfection efficiency, 
effective delivery of siRNA was only possible with smaller polymers (36-80kDa) 154. 
Low molecular weight PEI has also been crosslinked via disulfide linkages to 
show reduced cytotoxicity and equivalent DNA transfection efficacy to higher MW PEI 
155.  In one study, reducible poly(amido ethylenimine) (SS-PAEI) was synthesized by 
addition copolymerization of triethylenetetramine and cystamine bis-acrylamide 
(poly(TETA/CBA)) and used as a carrier for siRNA. Under normal conditions there was 
significantly higher suppression of VEGF with poly(TETA/CBA) than with linear-
polyethylenimine. The addition of dl-buthionine sulfoxamine, which reduces intracellular 
level of reduced glutathione reduced the RNAi activity level of poly(TETA/CBA) 
formulation to that of L-PEI, showing that reduction of the polymer was crucial to gene 
knockdown 156. 
Jere et al used a reducible polyspermine (RPS) carrier composed of multiple 
spermine units with disulfide linkages and showed improved efficacy in gene delivery 
and in gene knockdown compared to 25K PEI. RPS delivered anti-Akt1 sh/si/ssiRNA 
and altered the cancer cell survival, proliferation and metastasis to different extents 
depending on the nature of siRNA treatment 157. 
 
Acid labile linkages 
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Acid labile linkages would also be useful for endosomal escape and for enhanced 
cargo release into the cytoplasm, as they take advantage of the acidification of the 
endosome to allow for release of the cargo. Acid labile acetal and ketal bond bearing 
polycations were recently developed for this purpose. Oligoethylenimines linked by 
either acid-degradable ketal or acetal linkers in a copolymer with 5 kDa PEG formed 
complexes with half-lives of 3 min at pH 5.0, and 5 h (OEI-MK) or 3.5 h (OEI-BAA) at 
physiological pH 7.4 84. Using acylhydrazides or pyridylhydrazines to link a PEG shield 
to the polymer backbone enhanced transfection by two (in vitro) or one (in vivo) order(s) 
of magnitude compared to complexes whose PEG shield was not acid-hydrolyzable 82. 
 
Irradiation-released  
An Nd:YAG laser was used to release DNA from a 44 nm spherical AuNP 
complex conjugated to PEG-orthopyridyl-disulfide. The Nd:YAG laser irradiation was 
applied at 80 mJ/pulse (~10 ns, 6 mm diameter). DNA was released without any 
degradation seen 140.  
When EGFP DNA-SS-AuNR was delivered to HeLa cells and was controlled 
remotely using femtosecond near-infra red (NIR), a shape change from rod to sphere was 
observed. It was proposed that this transformation induces DNA release from its 
conjugate 158. Also using NIR, AuNR-EGFP-DNA conjugates were delivered to HeLA 
cells and there was expression detected at the irradiated spots of NIR exposure (79 
uJ/pulse for 1 min). There was 80% cell viability observed and the NIR irradiation 
induced plasmid release without structural degradation 159. 
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AuNRs of different aspect ratios can be melted selectively at their unique 
longitudinal plasmon resonance by morphing to a sphere to release DNA 
oligonucleotides. Aspect ratios at 4.0 and 5.4 will have a longitudinal plasmon resonance 
at 800 and 1100 nm, respectively. By irradiating a combined sample of the aspect ratios 
at one wavelength 50-60% of the intended oligonucleotides can be released and are still 
functional whereas the unintended oligonucleotides from the other aspect ratio released 
<10% of its cargo 160. 
 
2.2.11 Nuclear Translocation  
Diffusion of DNA longer than 250 base pairs in length is significantly reduced in 
the cytoplasm compared with water due to the involvement of the cytoskeleton 161. The 
nuclear pore complex (NPC) forms a selective permeability barrier, allowing free 
diffusion of molecules (e.g. ions, small proteins, and metabolites) with a mass/size less 
than about 40 kDa/10 nm proteins 162. Macromolecules greater than 40 kDa are 
transported actively across the nuclear envelope through the nuclear pore complexes 
(NPCs) using soluble transport factors or carrier molecules (β-karyopherins) that cycle 
between the cytoplasm and nucleus 163. In the classical case, nuclear localization signals 
(NLS) are recognized by importin-α, which then binds to importin-β, and this complex is 
allowed through the NPC. Once inside the nucleus, the importin-β binding domain is 
released by binding to RanGTP and the cargo is released 163 (Fig. 4). By utilizing electron 
microscopy and gold nanoparticles complexed to NLSs, Panté and Kann were able to 
show that the largest rigid particle to achieve nuclear entry through NPCs was ~39 nm in 
diameter including NLSs 164.  
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Strategies for obtaining access to the nucleus have relied primarily on diffusion 
through the cytoplasm and presentation of NLS to allow pDNA access to the nucleus 22. 
Numerous groups have tried to complex synthetic or naturally occurring NLS peptides 
with the delivered DNA, with variable efficacy 22, and transfection enhancement may be 
due to NLS peptides inducing improved nanoparticle complexation and not increased 
nuclear import 22.  A single NLS has been shown to be sufficient to carry the DNA 
through the NLS 22, but the addition of hundreds of NLS sequences to a plasmid lead to 
no nuclear localization of the plasmids 22, Multiple NLS sites might lead to cellular 
machinery attempting to pull a single plasmid in multiple directions at the same time, as 






Figure 1: Barriers to intracellular nucleic acid delivery. (1) Nucleic acid must be 
complexed to the nanocarrier and protected from degradation as it makes its way to the 
target cell. (2) The nanocarrier and cargo must be internalized successfully. (A) TLR7 is 
localized to the endosome; for isRNA activity, endosomal escape is not required. For 
other nucleic acid, (3) endosomal escape is required. (4) For cytoplasmic activity (B), 
nucleic acid must be released intracellularly. (5) Nanocarrier degradation is not required, 
but is useful for reduced toxicity. (6) For DNA, shRNA-encoding plasmids, and agRNA, 





Figure 2: Time-lapse video microscopy clips of shape-dependent phagocytosis by 
macrophage. (A) Shape-switching PLGA-ester elliptical disk (ED) allows macrophage 
internalization. (B) PLGA-ester elliptical disk (ED) which does not switch shape prevents 

















Figure 3. Gene expression of PBAE vs. adenovirus. A) Gene expression histogram 
comparing adenovirus (blue), PBAE (green), and negative control. B) Comparison of 
various PBAE formulations with adenovirus with respect to % positive cells and 
normalized expression. 
Images of GFP+ cells 24 hrs post transfection with C) PEI, D) C32-103, and E) 500 MOI 


























Table 1: Summary of results of various polymeric and inorganic vectors for delivering 
genes. It is important to note that direct comparisons are difficult as the experimental 




used & size 
Cargo 
(DNA) 
Target Cell viability Transfection 
efficacy 
165 Folate PLL, 
chloroquine 
Luc KB cells Not reported in 
detail 
6x higher than 





Luc HepG2 No cytotox. 4-
24 incubation 
hours 
~ 5 log orders of 
higher RLU than 
PLL @ 48 hpt 
167 Galactosylated 
PLL (Gal13-






Not reported in 
detail 
~850 mU/mg @ 
48 hpt 
58 800 kDa PEI 
(nitrogen to 
DNA base = 9)  




4 log orders more 
efficient than PLL 
(light units/mg  
protein) 
168 Low molecular 
weight PEI at 
11.9 kDa; High 
molecular 
weight PEI at 
1620 kDa 
Luc ECV304 MTT assay: 
LMW, none up 
to 1 mg/mL; 
HMW, IC50 = 
35 μg/mL 
LMW PEI (N/P = 
66.66) RLU was 
100-fold higher 
than HMW PEI 


























PEI25 in vitro; 
115x-higher 
expression vs. 
PEI25 seen by 
deAc-PEI87 in 
vitro; 10 N/P 
deAc-PEI25 
showed 5 log 
orders of higher 
RLU and 1500-
fold enhancement 
in lung specificity 
vs. PEI25 in vivo 
170 PBAE (C32); 
71 nm; 1.2:1 
amine/acrylate 
ratio 








117); <200 nm 
Luc HUVEC 2 orders of 
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lower than 25 
kDa PEI 
~adenovirus and 
lentivirus; 2 log 
orders greater 
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used & size 
Cargo 
(siRNA) 










as a counter 
ion to the 














In vitro no 
observed 
decreased cell 
viability up to 











by >40-fold; in 




















HEK293T >80% over 3 
day period; 
IC50: 0.125 mg 
mL-1 
RLU for NP 
alone and w/ 
siRNA: ~1.1 a.u. 
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detail 
61.7% 72 hpt 
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2.3 3Polymer and Inorganic Vectors for Nucleic Acid 
Delivery 
2.3.1 Cationic Polymers  
Various cationic polymer systems have been utilized for nucleic acid delivery. A 
wide range of structures have been explored, including linear and branched non-
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degradable polycations as well as biodegradable and bioreducible polycations and 
oligosacharides. Some of the most commonly used polymer structures are shown in Fig. 
1. All of the cationic polymers have primary amine groups which are protonated at 
neutral pH, which enables electrostatic interaction with the anionic nucleic acid. 
Poly-L-lysine (PLL) was one of the first polymeric gene transfection agents 
developed, and was shown to condense DNA into small complexes with rod (25-50 nm) 
or toroidal (40 to 80 nm) structure 1. PLL can be synthesized by several-step 
polymerization of ε,N-benzyloxycarbonyl-α,N-carboxy-L-lysine anhydride2. PLL is 
especially limited for intracellular delivery by its lack of an endosomal escape 
mechanism and endosomolytic groups like histidine 3 have been used to improve 
delivery. To reduce serum interaction and increase cell uptake, a variety of other 
molecules such as poly(ethylene glycol) (PEG)4, and targeting ligands such as 
asialoorosomucoid 5, transferrin 6, galactose 7,8, lactose 9, and folate 10  have been 
conjugated to PLL. Poly(ethylenimine) (PEI) was the second polymeric transfection 
agent developed 11. Branched PEI (b-PEI) can be synthesized from aziridine monomers 
under acidic conditions, and linear PEI (l-PEI) can be synthesized by the hydrolysis of 
poly(2-proplyl-2-oxazoline)12, or by polymerization of aziridine monomers at lower 
temperatures 13. Compared to later generation nucleic acid delivery agents, PEI is 
cytotoxic, leading to necrosis and apoptosis 14. The high proportion of nitrogen atoms 
provides for a strong buffering effect (“the proton sponge effect”) which is advantageous 
for endosomal escape, as described below. 25 kDa b-PEI has been shown to be an 
efficient transfection reagent with reduced toxicity as compared to higher molecular 
weight b-PEI 15. For delivery of shorter nucleic acids (e.g. mRNA) low molecular weight 
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PEI (2 kDa or less) leads to enhanced biological effect, as complexes with higher 
molecular weight PEI are more stable and do not release the nucleic acid as efficiently 
into the cytoplasm 16.  Standard PEI has also been modified by deacylation to boost 
delivery of DNA and siRNA by orders of magnitude in vitro and in vivo 17.  
Poly(lactide-co-glycolide) (PLGA) microspheres have been used in nucleic acid 
delivery in part for their relative biocompatibility and biodegradability. PLGA is 
synthesized by co-polymerization of cyclic dimers of glycolic acid and lactic acid with 
various catalysts.  Microparticles can be formed from pre-made polymer by emulsion 
evaporation, emulsion diffusion, solvent displacement and salting out techniques, and 
particle size depends on the formulation conditions and molecular weight of the starting 
material 18. Both the polymer and its degradation products are well tolerated in animal 
studies 19,20.  PLGA has recently been used to delivery siRNA in vivo and achieved 
sustained gene silencing when delivered to the vaginal mucosa 21. 
Poly(β-amino ester)s (PBAE) are synthesized by Michael addition of either 
primary or bis(secondary) aliphatic amines to diacrylate compounds 22, and their simple 
chemistry leads them naturally to a combinatorial approach to synthesis and screening of 
polymer libraries 23-27. They are hydrolytically degradable at the backbone ester linkages 
which allow for release of nucleic acid cargoes and reduced cytotoxicity.  
As opposed to mostly linear, cross-linked, or other branched systems, dendrimers 
such as poly(amido amine) (PAMAM) dendrimers are synthesized iteratively to produce 
nanoscale structures characterized by dendritic connectivity and radial symmetry. 
Advantages of dendrimeric systems include precise, nanoscale, structural control, dense 
and tunable surface chemistry (for addition of targeting ligands, modification of surface 
78 
 
charge, etc.), and high charge density for complexation and buffering. PAMAM 
dendrimers were first synthesized in the mid 1980s 28. Typically, ethyenediamine or 
ammonia are used as cores and allowed to undergo repeating two-step reactions whereby 
methyl acrylate is added by Michael addition to all the primary amines, and then the ester 
groups are amidated by a large excess of ethylenediamine to produce primary amine 
termini. They have been extensively studied for gene delivery 29,30 as well as 
oligonucleotide delivery 31-34. Interestingly, thermal degradation of the dendrimers was 
shown to increase transfection efficacy 35.  Dendrons, rather than full dendrimers, have 
also been used for successful gene delivery 36. Mannose-PEG-PAMAM linear-dendritic 
hybrid polymers successfully delivered the luciferase gene to P388D1 murine 
macrophages bearing the mannose-receptor, and showed 1.6 to 1.8-fold more efficient 
transfection of these cells than PEI with no serum and 4-fold more efficient transfection 




Sugars are crucial in a wide variety of biological applications. They are 
hydrophilic molecules composed predominantly of carbon, hydrogen and oxygen, and 
exist both in ring form as well as in extended conformations. Every extracellular protein 
in the human body is glycosylated (addition of oligosaccharides to proteins). The ABO 
blood group antigens are oligosaccharides, and oligosaccharides play a crucial role in 
tethering and rolling via the interaction of selectins to sialyl-lewis X 37. Glycosylation is a 
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crucial consideration in the production of monoclonal antibodies (mAb) for therapeutics 
in terms of optimization of biological activity 38 and improved pharmacological profile 39.  
Due to the hydrophilic nature of oligosaccharides and the fact that sugars are 
relatively well tolerated by the body, cationic polysaccharides have been explored for 
gene and nucleic acid delivery. Cyclodextrins (CD) are produced by the degradation of 
starch by the enzyme glucosyltransferase. This generates natural cyclic oligosaccharides 
composed of 6, 7, or 8 D(+)-glucose units known as alpha, beta and gamma 
cyclodextrins. Cyclodextrins are of particular interest because in addition to showing low 
toxicity, good biocompatibility, they can form inclusion complexes with small, 
hydrophobic compounds. This ability allows for modification of the surface of the 
cyclodextrin-based particles without interfering with polycation/nucleic acid interactions 
and particle morphology 40. Polycationic cyclodextrins have been shown to transfect cells 
in serum in a comparable level to 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) 
41. Grafting of cyclodextrins onto a PEI polymer lead to reduced transfection efficacy 
depending on the extent of modification (increased modification lead to further decreases 
in transfection efficacy) but significantly reduced toxicity 40. Interestingly, however, 
grafting of cyclodextrins onto PAMAM dendrimers increased their transfection efficacy 
(100x that of the dendrimer alone and comparable to Lipofectin and TransFast); the 
optimal formulation used α-cyclodextrin 42. 
One excellent recent example of utilizing cyclodextrins for nucleic acid delivery 
currently in clinical trials is CALAA-01. CALAA-01 is a cyclodextrin-containing 
polymer (CDP) for siRNA delivery which is sterically stabilized by PEGylation and 
modified to contain human transferrin (Tf) for targeting 43,44. The CDPs are synthesized 
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by condensing two difunctionalized comonomers. In addition, imidazole end group 
modifications were added to enhance endosomal escape 45. Interestingly, separate in vivo 
studies using earlier constructs for for DNA and DNAzyme delivery showed that 
nanoparticle localization to the tumors was independent of the targeting ligand but 
addition of the targeting ligand increased tumor cell uptake 46,47. CALAA was later 
formulated for siRNA delivery, and after animal studies was used to treat the first patient 
in a phase I clinical trial in May 2008 45; this trial was able to provide evidence of 
inducing an RNAi mechanism of action in a human from the delivered siRNA for the 
first time 44. 
Another sugar used significantly in drug and nucleic acid delivery is chitosan. Chitosan is 
formed by the deacetylation of chitin. It is mucoadhesive and biodegradable, with a 
reasonable toxicity profile, and has been specifically useful in transmucosal drug delivery 
48. Oral administration of chitosan and Arah2 (a peanut allergy gene) was shown to 
significantly decrease IgE levels in response to anaphylaxis induction 49. N-alkylated 
chitosan was investigated for gene delivery, and lengthening the side chains to 8-carbons 
was found to improve gene delivery 50. The optimal trimethyl chitosan-cysteine conjugate 
showed 1.5-fold higher in-vitro and 4.1-fold higher in-vivo transgene expression when 
compared to Lipofectamine 2000 51. Imidazole-modified chitosan siRNA delivery 
showed good gene knockdown in the lungs and the liver 52. Chitosan 
hydroxybenzotriazole showed ~60% knockdown of the control enhanced green 




2.3.3 Inorganic Materials 
Many types of inorganic nanoparticles are in use today for gene therapy and have 
properties that can be exploited for multifunctional use (i.e., theranostics – therapy and 
diagnostics). A large portion of these are gold nanoparticles (AuNP) 54-70 (Fig. 2A-C), 
carbon nanotubes (CNTs) 71-76] (Fig. 2D,E),   silica 71,77-81 (Fig. 2F),  quantum dots (QD) 
82-89 (Fig. 2G),  superparamagnetic iron oxide nanoparticles (SPION) (Fig. 2H) 88,90-93,  
layered double hydroxide nanoparticles (LDH) 94 (Fig. 2I).  
 
2.3.4 Gold Nanoparticles 
AuNPs’ structures can be solid spheres (Fig. 2A), rods (Fig. 2B), or shells (Fig. 
2D). Many investigators synthesize AuNP spheres by dissolving tetrachloroauric acid 
(HAuCl4) in purified water and then adding a reducing agent (i.e., sodium borohydride, 
sodium citrate) converting Au(III) to its neutral form 54,57-59,95. To make gold nanorods 
(AuNR), a seed solution and a growth solution can be prepared separately and mixed. A 
possible seed solution uses CTAB, HAuCl4, and NaBH4 and a possible growth solution 
uses CTAB, AgNO3, HAuCl4, and ascorbic acid 
60. When AuNP shells are synthesized, a 
shell forms around a core. Investigators have used the reverse micelle method 61 or the 
Stöber method 62 to synthesize AuNP shells.  AuNP shells have encapsulated SiO2 
63, Fe 
61,64, Pt 56 and other materials. Other ways to synthesize AuNPs are citrate reduction or 
the Brust-Schiffrin method as reported by Daniel et al. 65 . The timing and the relative 
amounts of reagents used can be varied to tune the size of the AuNPs 65.AuNPs are 
known to have low cytotoxicity, can be synthesized with decent monodispersity, and can 
be conjugated at high densities with a wide range of organic molecules 66,67. AuNPs can 
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be functionalized with antibodies for the detection of molecules. The detection is made 
possible because AuNPs have surface plasmon resonance effects which scatter light at 
various intensities and absorb light at different wavelengths dependent on their size and 
degree of aggregation 68. For example, the high expression of a surface receptor (i.e., 
folic acid receptor [107], EGFR 68, HER2 62) due to the presence of a cancer can cause an 
increase in AuNP-antibody local concentration which causes a shift in optical properties 
and detection. In addition, AuNPs do not undergo photobleaching 68.  
Furthermore, AuNPs can be used to localize photothermal cancer therapy. 
Spatially localizing the thermal therapy minimizes collateral damage. The AuNPs can be 
excited at near-infrared wavelengths to produce heat in an aspect-ratio dependent manner 
55,62,69. The near-infrared light can be applied externally as biological tissue does not 




Fullerenes are carbon-only nanostructures (i.e., spherical, cylindrical, ellipsoidal). 
The two most common nanostructures applied to nanomedicine are carbon nanotubes 
(CNT) and spherical fullerenes (C-60 buckyballs) as discussed below. 
 
2.3.6 Carbon Nanotubes 
CNTs are highly ordered and hollow 70. They are single atom thick cylinders of 
sp2- bonded carbon atoms 70. CNTs can be synthesized by a variety of methods including 
laser ablation, arc discharge, thermal chemical deposition, and plasma-enhanced chemical 
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vapor deposition 72 (Refer to cited literature for an in depth discussion of methods (i.e., 
73). Post synthesis, CNTs can be sonicated to a desired length with some size restraints 74.  
Single-walled and multi-walled CNT diameters can be 1-2 nm and 2 to 25 nm, 
respectively 74 (Fig. 2D,E). Spherical, hydrophobic carbon-nanostructures can be 
cationically functionalized via amine groups to become soluble and to enable ionic 
complexation with nucleic acids 75 for gene delivery applications. Carbon nanostructures 
can be conjugated to antibodies to increase specificity 96. The single-walled CNTs have 
Raman signal to improve cancer detection and near-infrared absorption for photothermal 
applications 96 similar to AuNPs. CNTs have unprecedented high tensile strength 72 and 
CNTs’ electrical and thermal conductivities make them useful for biosensor applications 
72. CNTs also have high surface area for dense loading of cargo 23,97. Its needle-like shape 
can also enable the penetration of cell membranes with greater ease  97, however, its 
structural similarity to asbestos warrants further research 98. Nanotoxicology of these 
materials and other nanomedicines is important to consider prior to any clinical 
experimentation89. 
CNTs are cytotoxic as there is lipid membrane peroxidation due to residual metal 
catalysts. Due to this toxicity CNTs are known to down-regulate adhesive proteins and 
increase cell death (aspect ratio dependent), but can be non-toxic to primary immune cells 
when functionalized appropriately 99. Poly(amido amine) dendrimers can be used to coat 
multi-walled CNTs to improve biocompatibility and cellular uptake 99. Glycodendrimers 
can be used to coat single-walled CNTs to lower cytoxicity as well 100. DNA-CNT 
complexes have been demonstrated to be non-toxic and non-mitogenic to activated or 
non-activated lymphocytes 101. Larger carbon nanomaterials (i.e., fibers, flakes) are less 
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toxic than single-walled or multi-walled CNTs, possibly due to their different interaction 
with the cellular membrane 102. Aggregation of CNTs can influence their toxicity due to 
the alteration of their physical properties 103. Fullerenes can be stabilized via functional 
groups to decrease cell death. For example, functionalization using SWNT in 1% 
Pluronic F108 at 2 μg/ml, di-carboxylation with a carbon to functional group ratio of 23 
at 2 mg/mL, SO3H with a carbon to functional group ratio of 80, 41, and 18 at 2 mg/mL 
resulted in ~65, 50, 40, 15, and nearly 0% cell death, respectively 104,105. 
 
2.3.7 Spherical Fullerenes 
Carbon-60 Spherical fullerenes (buckyballs) are around 1 nm in diameter. They 
have a propensity to aggregate, and are hydrophobic but can be made to be hydrophilic 
by the addition of functional groups (i.e., amine, carboxyl), particularly by the Hirsch-
Bingel reaction 106. Hydrophilic buckyballs mainly localize in the liver and have slow 
metabolism 106. Buckyballs can function as an anti-oxidant for neuroprotective 
applications76, an anti-viral agent such as HIV, a gene delivery carrier (particularly 
amine-derivatized fullerenes), and as a photosensitizer for photodynamic therapy 
applications  106. Buckyballs can carry an unstable atom (i.e., Gd3+, 99mTc -- which mainly 
localizes in macrophages of the bone marrow, liver, and spleen) which is not released 
into the biological system and can then be used as an MRI contrast agent, X-ray imaging 




2.3.8 Silica Nanoparticles 
Mesoporous silica nanoparticles (Fig. 2F) used for gene therapy are commonly 
synthesized using tetraethyl orthosilicate and cetyltrimethyl ammonium bromide (CTAB) 
under basic conditions using sodium hydroxide 78,79 or aqueous ammonia 107 at ~80oC. By 
varying the amount of CTAB added the nanoparticles’ size can be modified 107. 
Mesoporous silica nanoparticles are used in gene delivery because they have relatively 
large surface areas for dense conjugation, tunable pore sizes for cargo encapsulation, and 
are surface modifiable 78.  
A few non-exhaustive applications of silica nanoparticles include the delivery of 
nucleic acids (siRNA) by functionalization of PEI for ionic complexation 78, the delivery 
of GFP to osteoblasts by ionic complexation of conjugated Ca-silica 81, and the delivery 
of genes (luciferase) to the Achilles tendon 70.  
Silica nanoparticles can activate macrophages and produce pro-inflammatory 
cytokines and reactive oxygen species 108. Positively charged silica nanotubes are 
significantly more toxic than their bare counterparts. Toxicity was also significantly 
greater for positively  charged silica nanotubes that were 200 nm versus 500 nm for a 
given mass in both HUVEC and MDA-MB-231 cell lines 109. It was reported that the 
smaller particles have a greater extent of interaction with cells and therefore increased 
cytotoxicity 109.   
 
2.3.9 Quantum Dots 
 Quantum dots (QD) are composed in pairs of semiconductor elements (i.e., ZnS, 
CdS, CdSe, InP, CdTe, PbS, PbTe). For example, CdSe QDs can be synthesized by 
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adding cadmium oxide to tetradecylphosphonic acid and trioctylphosphine oxide at 
300oC under Ar flow to dissolve the Cd. At 270oC, a Se solution of tri-n-octylphosphine 
is injected. The QDs can be grown at 250oC for different lengths of time to control size. 
This solution can then be injected into chloroform and the CdSe will then precipitate out 
of solution 82. 
For biological applications QDs are sometimes synthesized in a core-shell 
fashion. The shell is chosen such that the band gap is winder than the core. This improves 
fluorescence properties, passivates the core, and prevents leaching (i.e., of toxic Cd ions) 
83. Heavy metal ions (i.e., Cd2+) are toxic at low concentrations (0.65 μM); however, 
when using silica shells and silane-PEGylation 
(methoxy(polyethyleneoxy)propyltrimethoxysilane (Gelest P/N SIM6492.7) (MW=450-
600)), there was no toxicity observed at quantum dot concentrations up to 30 μM 110.  
 QDs’ photoluminescence spectra are resistant to photobleaching 84 and emission 
is narrow, symmetrical, and tunable as a function of core size 83. Figure 2G shows the 
color dependence of different radii of CdSe core QDs with emission 77. The intensity of 
the fluorescence typically has a half-life of 27 hours which is many fold greater than 
other fluorescence agents (i.e., Alexaflour, R-phycoerythrin, and FITC) 83. 
QDs can be carboxylated to conjugate peptidyl amine residues or aminated by 2-
aminoethane thiol hydrochloride for maleimide derivatization. Thiolated and 
polyhistidine-conjugated biologicals can also directly interact and self-assemble on the 
surface of QDs, respectively 83. 
QDs have been encapsulated in chitosan nanoparticles to track and monitor 
siRNA delivery and transfection of SKBR3 breast cancer cells 87. QDs have been used to 
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quantify and monitor changes in transgene expression of two similar prostate cancer cell 
lines (PC3 and PC3-PSMA) due to changes in microtubule dynamics 86. QDs have been 
used for multiplex fluorescence imaging, tumor cell extravasation tracking, and real-time 
in vivo imaging 84. 
 
2.3.10 Superparamagnetic Iron Oxide Nanoparticles 
Superparamagnetism relates to the stochastic magnetization changes of 
nanoparticles. In the absence of a magnetic field, the nanoparticles have an average 
magnetic state of zero. However, under an external magnetic field, magnetism is induced 
and their magnetic susceptibility is stronger to that of paramagnets 111. 
Superparamagnetic Iron Oxide Nanoparticles (SPION) are typically comprised of a 
crystalline iron-oxide core coated with a biomaterial (i.e., dextran, starch) 90 and  
synthesized by co-precipitation in water 91. In one example, SPIONs can be synthesized 
by precipitation in a reverse water-in-oil microemulsion system of water/SDS and 1-
butanol/cyclohexane 92. SPIONs can also be synthesized in an aqueous solution by co-
precipitation of ferric and ferrous chlorides in alkaline medium 88. 
SPIONs constitute a hydrophobic crystalline iron-oxide core which can be coated 
with relatively hydrophilic and or biocompatible materials (i.e., dextran, starch, polyol 
derivatives, phospholipids, silica, or amphiliphilic polymers) 89. SPIONs can be 
conjugated with targeting moieties and gene delivery carriers. Figure 2H shows 
doxorubicin-loaded SPIONs.  
SPIONS are rapidly cleared by the reticuloendothelial system (also known as the 
mononuclear phagocyte system). SPIONs (namely Ferumoxides and Ferumoxtran-10, 
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magnetic resonance contrast agents) are mainly cleared in the liver by Kupffer cells in a 
nanoparticle size-dependent manner 112. Another SPION formulation (AMI-25) resulted 
in 80% uptake of the initial dose by Kupffer cells and its half life was 10 minutes 113.  
SPIONs  can be used for delivery systems via magnetofection, contrast enhancers 
for magnetic resonance imaging for T2 and T2* weighted imaging 89,114, tissue repair, 
immunoassays, detoxification, and anticancer magnetic hyperthermia 92,93. Iron oxide 
nanoparticles that are associated with Metafectene and dioleoylphosphatidyl-
ethanolamine delivering anti-eGFP and firefly luciferase have been known to accomplish  
at least 90% knockdown at 48 hours post transfection with reasonable cell viability using 
the HeLa cell line 115. 
SPIONs are metabolized in the hepato-renal system and are capable of entering 
the endogenous iron reserves by means of hematopoiesis 116. 
 
2.3.11 Layered Double Hydroxide Nanoparticles 
Layered double hydroxide nanoparticles (LDHNP) are anionic clay materials 
which can be generally written as [MIInM
III(OH)2+2n]
+(Am-)1/m x H20 (n=2-4) (M
II/III = 
di/trivalent metal cation, Am- = anion) 94. LDHNPs can be synthesized by dissolving 3 
mmol of Mg(NO3)2 and 1 mmol of Al(NO3)3 in 10 mL of deionized water and quickly 
added to 40 mL of 6 mmol NaOH 94. The mixture is then stirred for 10 min. The slurry 
can be purified and heated at 100oC for 16 hours 94 to obtain the inorganic crystals. 
LDHNPs can be synthesized in controlled sizes.   
LDHNPs can be used in cellular drug and gene delivery, are relatively 
biocompatible, have large cargo capacities, and can be tailored to have pH-controlled 
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release of their cargo. LDHNPs can complex with siRNA which helps protect the nucleic 
acids and can efficiently deliver the siRNA in vitro 94.   
LDH was found to have negligible effects on cell viability and proliferation at 
0.050 mg/mL. Furthermore, there was a significant decrease in HEK293T protein which 
was targeted using siRNA. LDHNP’s IC50 is 0.125 mg/mL. Greater than 94% viability 
was maintained at concentrations less than 0.050 mg/mL of LDH 94.  
 
2.3.12 Co-precipitating Mineral Solutions 
Macromolecules such as DNA is thought  to be capable of co-depositing with inorganic 
minerals (biomineralization) and form bioactive nanocomposites in close proximity to 
cells to promote DNA uptake with controllable surface-mediated release 117. An inorganic 
mineral solution constituting (i.e., CaCl2, KH2PO4, NaCl, KCl, MgSO4, MgCl2, NaHCO3) 
was used to co-precipitate β-galactosidase DNA (Fig. 2) 117. 
 
2.3.13 Multifunctional Nucleic Acid Carriers 
Multifunctionalized constructs are typically a hybrid of materials which are 
intended to accomplish different objectives simultaneously such as gene therapy and 
diagnostics (i.e., imaging), commonly referred to as theranostics. Multifunctional hybrid 
vectors could also incorporate components to overcome multiple entry barriers discussed 
above: nucleic acid complexation, physical requirements (i.e., charge, biocompatibility), 





Hybrid Gold Nanoparticle/siRNA/PBAE System 
Thiol-modified siRNA can be combined with PBAEs and complexed with thiol-
modified gold nanoparticles by disulfide linkages for multiple functionality (AuNP for 
sensing, siRNA for silencing, and reduction-triggered release of cargo) (Fig. 3). PEG was 
used as a spacer between the disulfide bond and the AuNP surface as the Au can induce 
release of the cargo. This system has high stability and low aggregation of the ~100 nm 
particles. There was no significant cytotoxicity reported and the system resulted in ~95% 
gene knockdown of luciferase expression in HeLa cells 66. 
 
Multifunctional QDs 
ZnO QDs have been reported to have dual functionality (pDNA delivery and cell 
labeling) when capped with poly(2-(dimethylamino)ethyl methacrylate). This system was 
capable of condensing pDNA into nanoplexes and delivering DNA to COS-7 cells with 
real-time imaging of gene transfection under UV 118. 
 
Mesoporous Silicon 
Mesoporous silica nanoparticles have been tri-functionalized (imaging, targeting, 
therapy). To enable traceable imaging an optical agent ATTO 647N was used. cRGDyK 
peptides were used as the targeting moiety which binds specifically to αvβ3 integrin. αvβ3  
integrins are overexpressed in tumor metastatic and endothelial cells. An oxygen sensing 
porphyrin-based photosensitizer was used to enhance the photo-induced cytotoxicity for 
photodynamic therapy.  In vitro experiments using MCF-7 human breast cancer cells and 
U87-MG human glioblastoma cells demonstrated that there was excellent specificity, 
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minimal collateral damage, and potent photodynamic effects 119.  Mesoporous silica can 
also be used in other ways for combination/theranostic use 120. 
 
2.3.14 Conclusion 
Polymeric and inorganic based-vectors for nucleic acid delivery need to overcome 
many crucial barriers in the delivery process, and a variety of novel approaches have 
been investigated to overcome these challenges. A wide array of materials have been 
investigated for their potential in this area, including degradable and non-degradable 
cationic polymers, oligo- and polysaccharides, fullerenes, carbon nanotubes, quantum 
dots, and gold, silver, silica, layered-double hydroxide, and iron-oxide nanoparticles. 
Each has unique properties and potential advantages. 
For effective delivery, the vector first must be stably complexed to the nucleic 
acid cargo and needs to stay compacted until cellular entry. The size, shape, surface 
charge, and surface functionality of the gene delivery particles are critical to efficient 
delivery, increased circulation time, and specific cellular entry. Size is a crucial 
parameter in determining the passive biodistribution of a nanoparticle delivery system 
and charge shielding / PEGylation has been shown to improve circulation time and 
increase accumulation at tumor sites as a result of the EPR effect. Particles can be 
fabricated in a variety of different shapes and shape-shifting particles whose shape-
change can be triggered by pH, heat, and light are also possible.  
A majority of delivery systems achieve cellular entry via endocytosis. The desired 
delivery compartment within the cell is dependent on the type of nucleic acid being 
delivered. For delivery of isRNA, interaction with TLR7 in the endosome is the end-goal, 
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so particles should be designed to target and then remain in the endosome. For siRNA 
and all DNA based systems, there needs to be a mechanism for endosomal escape. 
Mechanisms employed by non-viral vectors for endosomal escape include the proton-
sponge effect, endosomolytic peptide-based lysis, and acid-triggered hydrophobic residue 
exposure. Hydrolysis, bioreduction, and photolysis have been utilized to reduce toxicity 
and promote unpacking of nucleic acid cargo intracellularly. Finally, for cargo such as 
DNA that needs to localize to the nucleus, particles and nucleic acids can make use of 













Figure 2. A: TEM of AuNP spheres adapted from 54; B: TEM of Au nanoparticle rods 
adapted from 55; C: AFM topography of AuNP shells coating platinum adapted from 56; 
D: Multi-walled CNT adapted from 121. E: Representative TEM of carbon samples 
produced by catalysis - adapted from 71; F: Mesoporous silica nanoparticles adapted from 
107; G: Quantum dots – top and bottom row are illuminated under visible and UV, 
respectively - adapted from 77; H: Doxorubicin-loaded SPIONs with a diameter of 8 +/- 2 
nm - adapted from 88; I: TEM of pristine layered double hydroxide NPs of 
Mg2Al(OH)6NO3 - inset NPs are associated with siRNA - adapted from 
94.  Figures 















Figure 3: TEM images of HeLa cells. A: PBAE-siRNA-AuNPs; B: siRNA-AuNPs 
without PBAE; C: unmodified AuNPs; D: No nanoparticles (control). Adapted with 
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3 Chapter 3: The Effect and Role of Carbon Atoms in 
Poly(β-amino ester)s for DNA Binding and Gene 
Delivery 4 
3.1 Introduction 
Inheritable diseases and cancer can result from inactive genes (i.e., CFTR in 
cystic fibrosis or P53 as a tumor suppressor).1,2 Delivering DNA and shRNA to encode 
and generate a functional copy or to inhibit mRNA expression of a non-functioning 
protein can potentially treat and cure many genetic diseases. Viruses have been used as 
delivery vectors as they are highly efficient in nucleic acid delivery, but they can cause 
insertional mutagenesis, immunogenic responses, and toxicity.3 The safety and efficacy 
of the viral vectors depend on the viral vector type, route of administration and 
therapeutic target. To date there have been only two gene therapy formulations approved; 
one by the SFDA in China (2003) and one in Europe (2012) by the European Medicines 
Agency; there are still no FDA-approved gene therapies.4 Degradable cationic polymers 
are an attractive alternative to viruses, as they are generally safer, are easier to 
manufacture and mass produce, and have more functional capabilities than viruses.5 
Varying a polymer’s structure and functional groups allows one to optimize nucleic acid 
delivery properties while minimizing toxicity levels.6 High-throughput analyses of 
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combinatorial biomaterial libraries can allow a vast number of polymers to be screened, 
but rational design of structure to control function would be more efficient.7,8  
We are interested in evaluating polymer structure-function relationships to further 
our mechanistic understanding of, and to improve polymeric materials for non-viral gene 
delivery (Scheme 1).  We have previously investigated poly(beta-amino esters) (PBAEs) 
as biodegradable cationic polymers capable of promoting gene delivery to various types 
of cells.9-11 These polymers are promising due to their ability to condense DNA into 
nanoparticles containing many plasmids per particle,12 facilitate cellular uptake,13 and 
mediate endosomal escape.14,15  Certain PBAE nanoparticles have been shown effective 
for in vivo gene delivery in the eye16 and to tumors.17  Despite this progress, gene 
delivery efficiency using polymers remains lower than with viral delivery. One challenge 
in evaluating and optimizing polymer structure is that synthetic polymers can be 
polydisperse, with variable extents of reaction and molecular weight heterogeneity.18-20 
Isolating precise polymer structures and uniform molecular weight are key to being able 
to evaluate polymer structure.    
The interactions between a cationic polymer and DNA are critical to facilitate 
DNA protection, nanoparticle formation, cellular uptake, and subsequent DNA 
release.21,22 Anionic phosphate groups on the DNA associate with and bind to positively 
charged amine groups on cationic polymers to cause nucleic acid condensation and 
protection. This is important because the degradation half-life of naked DNA in the 
presence of serum is on the order of minutes.23 Upon binding with a cationic carrier (i.e., 
polymer), the nucleic acid half-life can increase substantially.24,25 An optimal DNA 
carrier system should bind, condense, and protect DNA in the extracellular space, but 
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release DNA effectively within the cells. Designing such systems require proper 
understanding of the binding between DNA and polycations.26,27  
In this manuscript, we use time-resolved fluorescence spectroscopy,28,29 a new approach 
to quantitatively probe polymer-DNA interactions and binding. We report our findings of 
systematically investigating binding properties of DNA and monodisperse, size-
fractionated poly(beta-amino ester)s with differential structures. In particular, we 
investigated series of polymers which varied the following: molecular weight; the 
number of carbons in the backbone which varied the amine density and hydrophobicity; 
the number of carbons in the sidechain which varied the distance of a hydroxyl group 
from the backbone and its hydrophobicity; and the endcap type (primary, secondary, 
tertiary amines and no endcap or diacrylate terminated). The effects of these small 
changes in the polymeric structures were characterized by fluorescence spectroscopy and 
gene delivery efficacy in human brain cancer and human breast cancer cells in vitro.30 
The experimental procedures, including materials and methods, can be found in the 
Supporting Information. 
 
3.2 Materials and Methods 
3.2.1 Materials (Reagents, Assays, Cells and Instruments) 
The polymers were synthesized from commercially available monomers: 1,3-
propanediol diacrylate (B3) (Monomer-Polymer and Dajac Laboratories Inc.), 1,4-
butanediol diacrylate (B4) (Alfa Aesar), 1,5-pentanediol diacrylate (B5) (Monomer-
Polymer and Dajac Laboratories Inc.), 1,6-hexanediol diacrylate (B6) (Alfa Aesar), 3-
amino-1-propanol (S3), 4-amino-1-butanol (S4) (Alfa Aesar), 5-amino-1-pentanol (S5) 
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(Alfa Aesar), 6-amino-1-hexanol (S6) (Sigma Aldrich), 2,2-dimethyl-1,3-propanediamine 
(E2) (Sigma Aldrich), 2-methyl-1,5-diaminopentane (E4) (TCI America), 2-(3-
aminopropylamino)ethanol (E6) (Sigma Aldrich), 1-(3-aminopropyl)-4-methylpiperazine 
(E7) (Alfa Aesar). Other reagents include the following and were used as received: 
peptide (KK)2KGGC (Biomatik), tetrahydrofuran (THF) (Sigma Aldrich), dimethyl 
sulfoxide (DMSO), (Sigma Aldrich), ethidium bromide (ETB; Sigma Aldrich), 
Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA), OptiMEM I (Invitrogen), plasmid 
enhanced green fluorescent protein (pEGFP-N1) DNA (Clontech), amplified and purified 
by Aldevron (Fargo, ND). The breast cancer cell line (MDA-MB-231; ATCC) is of 
human origin and was cultured using DMEM high glucose 1x media and supplemented 
with 10% heat inactivated fetal bovine serum (FBS) and 100 U/mL of penicillin and 100 
g/mL of streptomycin (Invitrogen). The glioblastoma multiforme (GBM) cell line 
(GBM319) was derived from brain tumor stem cells from a 79-year old patient, was 
cultured as previously described in DMEM:Ham’s F12 (1:1) (Invitrogen) supplemented 
with 10% heat inactivated FBS and 1x Antibiotic-Antimycotic (Invitrogen).11 All cells 
were cultured in a humid 37oC and 5% CO2 atmosphere. Propidium iodide (PI) 
(Invitrogen), 25 mM sodium acetate buffer (NaAc, pH=5.2) (Sigma Aldrich), CellTiter® 
Aqueous One Solution Cell Proliferation Assay (Promega), Gel Permeation 
Chromatography (GPC) (Waters®, Breeze 2 software), a Bruker nuclear magnetic 
resonance (NMR) spectrometer, UV-Vis Spectrometer (Synergy2, BioTek®, Gen5 
software), and a BD Accuri™ C6 flow cytometer equipped with HyperCyt® (Intellicyt 
Corp.) for high-throughput were used following manufacturer instructions. A Visi-
Blue™ Transilluminator was used for imaging agarose gels. The single photon counting 
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instrumentation consisted of a PicoQuant GmBH, PicoHarp 300 controller and a PDL 
800-B driver.  
 
3.2.2 Polymer Synthesis and Fractionation 
Diacrylate monomers that form the polymer backbones (B3, B4, B5, B6) and 
amine monomers that form the polymer side chains (S3, S4, S5, S6) were mixed neat 
using 1.05:1, 1.2:1, or 1.4:1 mole ratios and endcapped as previously described with 
slight modification (E2, E4, E6, E7) (Scheme 2).6 Briefly, the base polymer (diacrylate 
and side chain) reactions were carried out for 24 hours at 90oC, solvated in THF and 
endcapped for 1 hr using a 0.5 M amine monomer solution. Subsequently, the polymers 
were purified in anhydrous diethyl ether and vacuum dried for at least 24 hours and then 
fractionated by gel permeation chromatography (Waters Corp., Milford MA) using THF 
Styragel columns (3 7.8 x 300 mm in series). Two minute time fractions were collected at 
a 1 mL/min flow rate and again ether purified and vacuum dried for 48 hours. The 
polymers were then solvated in anhydrous DMSO to 100 mg/mL and stored at -20oC in 
small aliquots to minimize freeze-thaw cycles. GPC was used to assess molecular weight 
of the fractionated polymers. Synthetic PBAE polymers are referred to by the order of 
their constituent monomers: backbone acrylate monomer, side chain amine monomer, 
and end group amine monomer.  For example, B4-S4-E7 is 447 as an abbreviation 




3.2.3 Nuclear Magnetic Resonance 
Representative acrylate-terminated base polymers and amine-terminated end-
capped polymers were analyzed via 1H NMR. Polymers designated as "ether-purified" 
were synthesized in THF (or, in the case of 44 base polymer, dissolved in THF without 
reaction) and then precipitated into diethyl ether as described. After 48 hr drying under 
vacuum, polymers were dissolved in deuterated chloroform (CDCl3) with 0.03% v/v 
tetramethylsilane (TMS) at 10-20 mg/mL Other 44 base polymers were not purified after 
neat synthesis and were similarly dissolved in CDCl3 with TMS. All spectra were 
obtained with Bruker instruments (400 MHz, Topspin 2.0 or 2.1 software) and analyzed 
with NMR Processor v.12 (ACD Labs, Toronto, Canada).6 
 
3.2.4 Fluorescence Measurements/Time-Correlated Single Photon Counting 
Plasmid DNA encoding enhanced green fluorescent protein (pEGFP) at 0.0975 
mg/mL (300 μM of phosphate concentration) was added to ETB  (20 μM) in a 15:1 mole 
ratio in 250 μL of 25 mM sodium acetate (NaAc, pH 5.2). The resulting intercalated 
DNA-ETB complex was a homogeneous pink color. Subsequently, 250 μL of each 
polymer was added to the resulting solution in polymer weight to DNA weight ratio 
(w/w) ranging from 1.2 to 47 w/w (N/P ratios ranging from 1 to 40) and was immediately 
mixed thoroughly. The polyplexes were allowed to stabilize for 10 minutes before 
beginning fluorescence measurements. The time-resolved fluorescence was measured by 
a time-correlated single photon counting (TCSPC) system (PicoQuant GmBH) consisting 
of a PicoHarp 300 controller and a PDL 800-B driver. The samples were excited with the 
pulsed diode laser head LDH-P-C-485 at 483 nm with 130 ps time resolution. The signals 
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were detected with a microchannel plate photomultiplier tube (Hamamatsu R2809U). To 
diminish the influence of the scattered excitation, a cut-off filter was used in front of the 
monitoring monochromator. To study the decay associated spectra (DAS), the decays 
were collected with a constant accumulation time in the 560–670 nm wavelength range 
with 10 nm increments. The decays were simultaneously fitted to the sum of two 
exponents in the equation (1): 
𝐼(𝑡, 𝜆) = 𝑎1(𝜆)𝑒
−𝑡 𝜏1⁄ + 𝑎2(𝜆)𝑒
−𝑡 𝜏2⁄  (1) 
where τi is the global lifetime and ai(λ) is the local amplitude at a particular wavelength. 
The factors ai(λ) represent the DAS (Figure S2), which in the case of a mixture of 
different non-interacting fluorescing species corresponds to the individual spectra of the 
species (ETB bound to DNA and ETB free in solution). The photomultiplier tube 
becomes increasingly less sensitive at higher wavelengths which was taken into account. 
The spectral areas (Ai) of the components can be calculated by integrating the pre-
exponential factors over the measured wavelength range as indicated in the following 
equation: 
𝐴𝑖 = ∫ 𝑎𝑖(𝜆)𝑑𝜆 (2) 
The short-living component, corresponding to free ETB in the bulk solution, has a lower 
fluorescence quantum yield than the long-living component corresponding to ETB bound 
to DNA. The relative fluorescence quantum yield of the short-living component, 𝜙rel = 
0.112 (equation 3), was calculated from the steady state absorption (UV-VIS 
spectrophotometer Shimadzu UV-3600) and fluorescence (Fluorolog Yobin Yvon-SPEX, 










where 𝜙ETB is the quantum yield of ETB free in solution, 𝜙DNA-ETB is the quantum yield of 
the DNA-ETB complex, 𝐼𝑖 is the area of the fluorescence spectra with an excitation 
wavelength of 483 nm and  𝐴𝑖 is the absorbance at wavelength of 483 nm. The corrected 
spectral area (A1
c) for the short living component is obtained by dividing A1 by 𝜙rel. As 
polymer (P) is added to the DNA-ETB complex, the polymer binds DNA and the ETB is 
freed into solution as follows: 
DNA-ETB + P ⇌ DNA-P + ETB (4) 
The proportion of the short-living decay component of the total area of the DAS spectra, 
B, is the proportion or ratio of free ETB and is directly proportional to the amount of 
formed polyplexes (or the fraction of DNA bound to polymer). Thus, the bound fraction 
of DNA, B, can be assessed by monitoring the ratio of free ETB and can be calculated 







The bound fraction of DNA as a function of amine concentration was assessed and the 
maximum was determined. All data points up to the maximum bound fraction were used 
to determine the binding constants. Of note, the initial concentration of ETB in the 
system is chosen such that without polymer there is no free ETB. 
 
3.2.5 Cooperative Binding Constant Calculations 
The Hill plot equation for multivalent ligands binding to multi-subunit substrates 








= 𝛼ln [𝑃] + 𝛼ln 𝐾 (6) 
Kα is the overall binding constant for the reaction DNA + nP ⇌ DNA-Pn, K is the binding 
constant for the binding of one functional amine group according to the reaction DNA-Px-
1 + P ⇌ DNA-Px the experimental 
Hill´s coefficient (α = 1 for non-cooperative systems,  α < 1 for negative cooperativity 
and α > 1 for positive cooperativity). The error in K is calculated from the standard error 
of the y-value in the linearly fitted Hill plots.  
 
3.2.6 Particle Diameter and Zeta Potential 
Particle diameter was determined by nanoparticle tracking analysis (NTA) using a 
NanoSight NS500 (Amesbury, UK, 532 nm laser), and zeta potential was determined 
using a Malvern Zetasizer Nano ZS (Malvern Instruments, UK, detection angle 173°, 633 
nm laser) in triplicate. Polymer/DNA nanoparticles were made at a 60 w/w ratio in 25 
mM sodium acetate buffer (pH = 5.2) at a DNA concentration of 0.005 mg/ml and diluted 
into 1x PBS, pH 7.4. Particles were diluted 100-fold into PBS before NTA measurement. 
Particles were diluted 5-fold into PBS when using the Zetasizer; average electrophoretic 
mobilities were measured at 25C, and zeta potentials (ZP) were analyzed using the 
Smoluchowski model. Additional experiments of representative polyplexes were 
conducted at concentrations comparable to delivery conditions at various pHs (5 and 7.4) 





3.2.7 Transfection and Cytotoxicity (Relative Metabolic Activity) 
MDA-MB-231 and GBM319 cells were seeded in 96-well plates at 15,000 cells 
per well and allowed to adhere overnight at 37oC and 5% CO2. Polymers and DNA were 
diluted in 25 mM NaAc and mixed in a 1:1 v/v ratio at 30, 60, and 90 w/w. Particles were 
allowed to self-assemble for 10 minutes prior to in vitro delivery. Subsequently, 20 μL of 
particle solution was delivered to each well already containing 100 μL of media (10% or 
70% serum) for a DNA dosage of 600 ng/well (5 μg/mL) in quadruplicate. Naked DNA 
at the same final concentration in 25 mM sodium acetate and an untreated group were 
used as negative controls. Lipofectamine 2000 was used as a positive control to deliver 
100 and 200 ng of DNA per well using a 2.5:1 v/w ratio (Lipofectamine reagent:DNA) in 
quadruplicates (following manufacturer recommendations). After 4 hours of incubation, 
the wells were aspirated and replenished with fresh media. To assess relative metabolic 
activity as an indication of toxicity at 24 hours post-delivery, each of the wells were 
aspirated and incubated with 110 μL of a 10:1 mixture of culture media to CellTiter 96® 
Aqueous One Solution in quadruplicate according to the manufacturer’s instructions. The 
absorbance at 490 nm was measured using the Synergy2 UV-Vis spectrometer. 
 
3.2.8 Flow Cytometry 
The transfection efficacy was assessed using flow cytometry at 48 hours post-
delivery. The 96-well plates were aspirated, washed with PBS, and trypsinized. After 
quenching with 2% FBS (in PBS) with propidium iodide (PI) at 1:200 v/v, the contents 
were transferred to a round-bottom 96-well plate and centrifuged at 800 RPM for 5 
minutes. After centrifuging, all but 30 L of buffer was removed, and each cell pellet was 
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triturated before loading on the Hypercyt high-throughput reader.  FlowJo (v. 7.6) was 
used for gating and further analysis. Singlets were identified using FSC-H vs SSC-H; 
dying cells were identified with PI (a DNA intercalator which fluoresces with a 
compromised cell membrane) using FSC-H vs FL3-H; FL1-H vs FL3-H was used to 
identify the GFP-positive population. 
Geometric and arithmetic fluorescence means of the flow cytometer’s FL1-A 
channel can be an indicator of the relative amount of EGFP present on a per cell basis. 
Normalized fluorescence means of the FL1-A channel were calculated by dividing the 
viable singlet population’s FL1-A mean fluorescence by the untreated conditions’ mean 
fluorescence.  
 
3.2.9 Heparin Competition Release Assay 
 Gel electrophoresis was accomplished using 1% agarose gels containing 1 μg/mL 
of ETB in a 1x TAE buffer. The gels were loaded with 15 μL of polyplexes at 60 w/w 
(pEGFP-N1 of 0.01 mg/mL). The polyplexes were allowed to stabilize for 10 minutes. 
Just prior to the loading the polyplexes were added to glycerol (30% v/v). The gels were 
run for 1 hour using 100 volts and imaged using a Visi-Blue™ Transilluminator. Four 
representative polymers ranging from the weakest to the strongest binding constants were 
used for the release assay (44, 447 Low Mw, 446, 447 High Mw). 
3.2.10 Statistics 
All binding constants are reported as previously described; transfection and toxicity 
plots show the mean and standard error of the mean. All other physical characterizations 
and data plotted show the mean and standard deviation. One-way ANOVA tests were 
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used with Tukey post-hoc analyses to assess significance between multiple groups. 
Differences were considered significant with p-values < 0.05 (* < 0.05, ** < 0.01, *** < 
0.001). 
 
3.3 Results and Discussion 
3.3.1 Polymer Synthesis and Fractionation 
The 447 polymer series varying molecular weight ranged from 10.3 to 91.6 kDa 
(weight average molecular weight (Mw)). The polydispersity indices (PDI) increased as 
the Mw increased (PDIs: 1.3, 1.4, 2.9).  The average Mw of the groups varying the 
backbone, sidechain and endcaps were 10 ± 1 kDa, 13 ± 2 kDa, and 10.9 ± 0.7 kDa, 
respectively. The PDIs of the groups varying backbone, sidechain and endcaps were 1.3 ± 
0.1, 1.3 ± 0.1, and 1.34 ± 0.09, respectively (Table S1). The differences in the 447 
molecular weight series and the similarities of the molecular weights in the groups which 
differ with respect to their backbone, sidechain and endcap groups are depicted in the 
normalized GPC curves per the refractive index detector (Figure 1). The similarity of the 
Mw and narrow PDIs of the comparable polymers with small differences in the backbone, 
sidechain and endcap allow comparisons between the groups and ensure differences are 
due to the monomer type as opposed to Mw or size heterogeneity. 
Representative 1H NMR spectra of polymers 44, 442, 444, 446 and 447 can be 




Some of the spectra above include the following sharp peaks corresponding to the solvent 
in which the polymer was synthesized (tetrahydrofuran, THF) or diethyl ether, used to 
precipitate the polymer: 
THF: 1.85 ppm 
Diethyl ether: 3.45-3.55 ppm (q, CH3CH2OCH2CH3) 
Diethyl ether: 3.15-3.25 ppm (t, CH3CH2OCH2CH3) 
 
Solvent peaks were not considered during analysis. Shown in the spectra below: 
 
44 (B4-S4) (all molecular weights) 
1.45-1.6 (m, NCH2CH2CH2CH2OH and NCH2CH2CH2CH2OH) 
1.6-1.75 (t, COOCH2CH2CH2CH2OOC) 
2.35-2.6 (t, COOCH2CH2NCH2CH2OOC and t, NCH2CH2CH2CH2OH) 
2.7-2.85 (t, COOCH2CH2NCH2CH2OOC) 
3.55-3.7 (t, NCH2CH2CH2CH2OH) 
4.0-4.2 (t, COOCH2CH2CH2CH2OOC) 
5.8-5.9 (d, CH2OOCCH=CHH) 
6.1-6.2 (dd, CH2OOCCH=CHH) 
6.35-6.5 (d, CH2OOCCH=CHH) 
 
442 (B4-S4-E2) 
0.9-0.95 (s, NHCH2C(CH3)2CH2NH2) 
1.45-1.6 (m, NCH2CH2CH2CH2OH and NCH2CH2CH2CH2OH) 
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1.6-1.75 (t, COOCH2CH2CH2CH2OOC) 
2.35-2.6 (t, COOCH2CH2NCH2CH2OOC and t, NCH2CH2CH2CH2OH and  
t, NHCH2C(CH3)2CH2NH2) 
2.7-2.85 (t, COOCH2CH2NCH2CH2OOC) 
3.55-3.7 (t, NCH2CH2CH2CH2OH) 
4.0-4.2 (t, COOCH2CH2CH2CH2OOC) 
 
444 (B4-S4-E4) 
0.9-1.0 (m, NCH2CH2CH2CH(CH3)CH2N) 
1.45-1.6 (m, NCH2CH2CH2CH2OH and NCH2CH2CH2CH2OH and 
NCH2CH2CH2CH(CH3)CH2N) 
1.6-1.75 (t, COOCH2CH2CH2CH2OOC) 
2.35-2.5 (t, COOCH2CH2NCH2CH2OOC and t, NCH2CH2CH2CH2OH and  
m, NCH2CH2CH2CH(CH3)CH2N) 
2.7-2.85 (t, COOCH2CH2NCH2CH2OOC) 
3.55-3.7 (t, NCH2CH2CH2CH2OH) 
4.0-4.2 (t, COOCH2CH2CH2CH2OOC) 
 
446 (B4-S4-E6) 
1.45-1.6 (m, NCH2CH2CH2CH2OH and NCH2CH2CH2CH2OH) 
1.6-1.75 (t, COOCH2CH2CH2CH2OOC and quin, NCH2CH2CH2NHCH2CH2OH) 




2.7-2.85 (t, COOCH2CH2NCH2CH2OOC) 
3.55-3.7 (t, NCH2CH2CH2CH2OH and t, NCH2CH2CH2NHCH2CH2OH) 
4.0-4.2 (t, COOCH2CH2CH2CH2OOC) 
447 (B4-S4-E7) 
1.45-1.6 (m, NCH2CH2CH2CH2OH and NCH2CH2CH2CH2OH and  
t, NCH2CH2CH2N<(CH2CH2)2>NCH3) 
1.6-1.75 (t, COOCH2CH2CH2CH2OOC) 
2.3 (s, NCH2CH2CH2N<(CH2CH2)2>NCH3) 
2.35-2.6 (t, COOCH2CH2NCH2CH2OOC and t, NCH2CH2CH2CH2OH and m, 
NCH2CH2CH2N<(CH2CH2)2>NCH3) 
2.7-2.85 (t, COOCH2CH2NCH2CH2OOC) 
3.55-3.7 (t, NCH2CH2CH2CH2OH) 
4.0-4.2 (t, COOCH2CH2CH2CH2OOC) 
3.3.2 Cooperative Binding Constants for Polyplex Formation 
The polyplex formation can be monitored by plotting the proportion of bound 
DNA, B in equation 5, against the concentration of amine. As an example the plot for 
polymer 442 is shown in Figure 2. The proportion of bound DNA increases with 
increasing polymer concentration until it reaches a saturation limit of approximately 76 % 
at w/w ratios of 24 in this case. Most PBAEs polymers saturated close to 80%. The 
saturation limit of polymer 44 and 346 is 60 and 96%, respectively. Polymers with 
negative cooperativity typically have saturation less than 100%, whereas polymers with 
high positive cooperativity saturate near 100%. 
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The Hill plots for the 447 molecular weight series are shown in Figure 3A. 
Similar linear curves with negative cooperativity (Table S1) were obtained for most of 
the polymers except polymer 646 (Figure 3B-D). The fact that most polymers’ Hill plots 
entail negative cooperativity and most polymers’ bound fraction saturate close to 80% are 
in agreement. 
While most polymers show a single linear Hill plot, varying the polymer 
backbone structure (646) may enable a biphasic response (Figure 3B). Polymer 646’s 
Hill plot is associated with a negative and a positive cooperativity phase, which may 
account for why polymer 646 saturates at 96%.  
This biphasic nature of binding suggests a change in the binding mechanism with 
increasing the molar amine to phosphate ratio. The analysis and discussion of polymer 
646 will focus on the positive cooperativity slope associated with the higher amine to 
phosphate ratios, as all other experiments (i.e., transfection, toxicity, diameters, etc.) were 
carried out at weight/weights of 30, 60 or 90 (N/P ratios greater than 35). Polymers 346 
and 546 (Figure 3B) have a data point which may either be an outlier or may also be 
associated with a binding mechanism which is biphasic, similar to polymer 646. Too few 
data points in these regions where there may be positive cooperativity for polymers 346 
and 546 restrict further analysis. The multi-phase cooperativity is an interesting aspect for 
future investigation. 
As the molecular weight of 447 increased, the binding constant per amine (K) 
increased (Figure 4A). Thus, larger polymer molecular weight led to increased polymer-
DNA interaction and stronger binding. By utilizing this trend, one could potentially 
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fractionate a polymer with a particular molecular weight corresponding to a desired 
binding constant. 
When evaluating the number of carbons that make up the polymer backbone 
repeat (3, 4, 5, or 6), the binding constants decreased as the number of carbons in the 
backbone monomer increased (Figure 4B). The binding affinity reduced 400-fold when 
the number of carbons in the backbone increased from 3 to 6. The decrease in the binding 
constant is likely due to the decrease in amine density as the number of carbons in the 
backbone increases.   
The binding constants in the sidechain series (437, 447 Med Mw, 457, 467) 
decreased with increasing side chain length (Figure 4C). As the sidechain was altered 
from 3 to 6 carbons, the binding affinity reduced 24-fold. Again, the decrease in the 
binding constant is likely due to the decrease in amine density as the number of carbons 
in the sidechain increases.  
The base polymer (polymer 44) had a lower binding constant than any of the 
endcapped polymers (442, 444, 446, and 447 Low Mw). The binding constant increased 
6.6 ± 0.1, 15.2, and 8.0-fold when the base polymer was endcapped using primary (442 
and 444), secondary (446), and tertiary amines (447 Low Mw), respectively (Figure 4D). 
Considering the pKa values of primary, secondary, and tertiary amines, one would 
suspect that there would be greater binding between primary versus tertiary; however, 
these differences would be diminished as the buffer was at a pH of 5.2. We observed a 
larger than expected value for the 446 K. This higher K value is understandable when the 
molecular weight of the 446 polymer is considered; the molecular weight of the 446 
polymer was 14% higher than the other molecular weights of the endcap polymer series 
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(Table S1) which had 3-5 more amines per polymer strand than the other polymers in the 
group (un-endcapped, primary, secondary, and tertiary amine-type polymers had 40, 39, 
44 and 41 amines per polymer strand, respectively.  
3.3.3 Comparison of Binding Constant Calculation Methodology 
 
The binding constant of a cationic peptide (KK)2KGGC was also evaluated to 
compare our time-resolved fluorescence spectroscopy binding assay to other binding 
assays found in the literature. The proportion of bound DNA, B in equation 5, as a 
function of (KK)2KGGC concentration displayed a saturation level close to 90 %. The 
Hill plot of the peptide presented in Figure S3 shows the presence of two phases, similar 
to polymer 646. The kink point corresponds to the w/w ratio 3.6. The peptide, perhaps 
due to the presence of positive cooperativity (at low w/w) was associated with a higher 
saturation than most of the PBAEs, similar to what was observed with polymer 646. The 
Hill coefficient of the positive and negative cooperativity phases were 2.2 and 0.50, 
respectively, suggesting that further binding is hindered by the already bound amines. 
The overall binding constant, Kα, obtained from the positive cooperativity phase is 1.2 ± 
0.2×107 M-1. Plank et al. obtained a value of 2.09x106 M-1 with this peptide which is ~6 
times smaller than by our method.21  
 
3.3.4 Relationship Between Polyplex Diameter and Binding 
 
The diameter of the polyplexes (nanoparticles) formed due to the binding and self 
assembly of cationic polymer with anionic DNA ranged from a mean diameter of 122 to 
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227 nm (Figure S4 and S5). While a polymer with one of the lowest binding constants 
(646, 1.19 x 103 M-1) formed polyplexes of the largest size (227 nm) and the polymer 
with the largest binding constant (346, 4.8 x 105 M-1) formed polyplexes of the smallest 
size (122 nm), there was not an overall trend between PBAE-DNA binding affinity and 
polyplex size (Figure S4). For the case of polymer backbone length, there was an 
apparent decrease in the diameter as the binding constant increased (or as the backbone 
length decreased (Figure S4B). As the backbone length increases the amine density 
decreases and hydrophobicity increases as well. 
 While an increased binding constant appears to correlate with smaller polyplex 
diameter, the trend is not very strong as a range of polymer binding constants and 
polymer structures can produce polyplexes of similar size (Figure S5A). Our data 
suggests that tighter binding constants may, but do not necessarily result in smaller 
polymer/DNA polyplexes. Complex size is affected by the number of plasmids and 
polymer chains per complex as well as the association of individual complexes in ion 
containing buffer solutions. 
Polyplex/particle diameter does not appear to show any clear trends in 
transfection efficacies in either cell line (Figure S5B and S5C).  This finding suggests 
that the diameter of the polymer/DNA polyplexes is not a key determining factor for this 
class of PBAE particles in these cell lines. As all nanoparticles studied were relatively 
small in diameter they should be able to mediate successful endocytic cellular uptake. 
Polyplexes were successfully formed at both pHs (5.2 and 7.4) and various ionic 
strengths (Figure S6). At these conditions, the diameters of the polyplexes ranged from 




3.3.5 Relationship Between Polyplex Zeta Potential and Binding 
The polyplexes’ zeta potentials (ZP) (Figure S7 and S8) ranged from +5 to +18 
mV. There were no apparent trends between the binding constants and ZP (Figure S7 
and S8A). In contrast to our cationic ZPs, Eltoukhy et al. found their PBAEs were neutral 
in sodium acetate, likely explained by the use of different polymer structures as well as 
20-40 w/w formulations, which use less polymer than what was tested in our experiments 
(60 w/w).18 Our nanoparticles are weakly positively charged, allowing interaction with a 
cell’s anionic surface. Their charge is not excessive and they do not cause high toxicity 
when added to cells. When comparing all ZP measurements against transfection 
efficacies, there are no clear trends in either cell line (Figure S8B and S8C). 
These findings suggests that ZP of the polymer/DNA particles is not a key 
determining factor for transfection for this class of PBAE particles in these cell lines. As 
all nanoparticles studied were relatively weakly positive in ZP, they should be able to 
mediate successful cellular uptake. 
The ZP of the polyplexes at both pHs (5.2 and 7.4) and in various ionic strengths 
ranged from approximately +6 to +25 mV (Figure S9). The ZP appeared to be inversely 
proportional to pH. At a pH of 5.2, the ZP decreased as the salt content increased. At a 
pH of 7.4, the ZP did not appear to increase in all cases as the salt content decreased 




3.3.6 Effect of Binding Constant on Transfection Efficacy 
Two human cancer cell lines (MDA-MB-231 and GBM319) were utilized in these 
experiments to evaluate transfection efficacy. The former is derived from invasive triple 
negative human breast cancer and the latter is from human glioblastoma multiforme. 
Generally speaking, we have found both cell lines to be difficult to transfect, with MDA-
MB-231 (Figure 5A, 5C, 5E, 5G) being more difficult to transfect than GBM319 
(Figure 5B, 5D, 5F, 5H). The relative amount of EGFP per cell according to the 
normalized mean fluorescence linearly correlated with the transfection efficacy as 
measured by percent of cells with EGFP (Figure S10).  
The optimal molecular weight of the 447 polymer that resulted in the highest 
transfection efficacy was polymer 447 Med Mw at 90 w/w in both cell lines (Figure 5A 
and 5B). By flow cytometry the 447 Med Mw polymer achieved 30 ± 4% and 69 ± 1% 
transfection in the MDA-MB-231 cell line and the GBM319 cell line, respectively. In 
MDA-MB-231 cells, the PBAE nanoparticle formulation with the highest transfection 
efficacy achieved 74% of the transfection percentage achieved with Lipofectamine 2000, 
a highly effective positive control widely used in the non-viral gene delivery community; 
positive and negative controls can be found in Figure S11. In GBM319 cells, the leading 
PBAE nanoparticles transfected 240% of the amount achieved with Lipofectamine 2000. 
Naked DNA, which is the same dose of plasmid DNA without added polymer, resulted in 
no transfection in both cell lines.  
When all binding constants are analyzed with transfection efficacy, it is apparent 
that a biphasic trend is observed where the peak transfection occurs at an intermediate 
binding affinity (Figure S12A and S12B). However, the correlation is not 
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straightforward, as similar binding affinities can also lead to dramatically lower 
transfection. This is to be expected as binding constants alone are likely insufficient to 
predict whether a particular polymer will deliver DNA successfully as there are many 
factors affecting gene delivery such as cellular uptake, endosomal escape, DNA release 
and nuclear import (Scheme 1).5  
 
3.3.7 Effect of Mw on Binding Constants/Transfection Efficacy 
In the MDA-MB-231 cells, a comparison of 447 polymers with incremental 
molecular weight (Figure 5A) revealed a biphasic response, with the highest transfection 
efficacy at intermediate polymer molecular weight (447 Med Mw) and intermediate 
binding affinity (58,000 M-1). For the 30 w/w group, there was an increase in transfection 
efficacy as the molecular weight increased in the MDA-MB-231 cell line (Figure 5A) 
whereas there was a decrease in the GMB319 cell line (Figure 5B). 447 Med Mw with a 
binding constant of 58,000 M-1 was the most effective binding constant evaluated in 
terms of transfection efficacy in the GBM319 cells (Figure 5B). This suggests that there 
is an optimal range: too low of a binding constant is unfavorable and too high of a 
binding constant is also unfavorable. Low binding constant polymers may not be able to 
sufficiently condense and protect the DNA and excessively high binding constants are 
likely to not release the DNA as efficiently.22 As the molecular weight increased from 
10.3 to 91.6 kDa, the transfection efficacy decreased from approximately 60% to 30% 




3.3.8 Effect of Single Carbon Differences on Binding Constants/Transfection 
Efficacy 
When holding molecular weight approximately constant and varying the 
backbone and sidechain, the optimal binding constant was near 58,000 M-1 (polymer 447 
Med Mw) for MDA-MB-231 cells (Figure 5C and 5E) and transfection was similarly 
high (~70%) for GBM319 cells in the range of 1-6x104 M-1 (Figures 5D and 5F). In the 
case where the binding constant is smaller than 104   M-1, increasing the binding constant 
correlates with increased transfection efficacy for MDA-MB-231 cells. GBM319 cells 
are better transfected by polymers with weaker binding constants (103-104 M-1) than the 
MDA-MB-231 cells are and this is likely due to intrinsic differences in the gene delivery 
transport steps (Scheme 1) between these two cell types. For both cell types, when 
binding constant increased further (>105 M-1), even with molecular weight constant, 
transfection decreased. 
Although it is common practice to use 10% FBS for in vitro transfection 
experiments, higher media serum content may be more physiologically relevant. 70% 
serum was used to assess transfection efficacy and its correlation with the observed 
binding constants in the GBM319 cell line. The highest transfection achieved in the 
presence of high serum was similar to the highest transfection observed with low serum, 
approximately 70% of human cells positively transfected. A similar biphasic trend was 
also observed as in the 10% serum conditions (Figure S13) and a similar optimal range 




3.3.9 Effect of End Caps on Binding Constants/Transfection Efficacy 
The MDA-MB-231 and GBM319 cell lines had very low transfection for un-
endcapped, acrylate terminated (polymer 44) polymers. Furthermore, primary amine 
polymers (polymer 442 and 444) were not able to effectively transfect MDA-MB-231 
cells; whereas primary, secondary and tertiary amines were able to transfect the GB319 
cells. 
Secondary or tertiary amine endcapped groups, depending on the w/w ratio, were 
required in the MDA-MB-231 cell line for effective transfection with these polymers. 
The GBM319 cell line was able to be transfected via primary amine-endcapped PBAE 
polymers 442 and 444 in addition to the polymers endcapped with secondary or tertiary 
amines. There did not appear to be a strong trend however with the binding constant and 
transfection efficacy in the endcapped series (Figures 5G and 5H). 
 
3.3.10 Effect of Binding Constant, Mw, Single Carbon Differences, and End Caps on 
Cytotoxicity 
In general, cytotoxicity increased with increasing polymer to DNA w/w ratio (Figure 
6). In both cell lines tested it appeared there was low cytotoxicity with polymers that had 
binding constants in the 104-105 M-1 range (Figures S11C and S11D).  
 
I. Effect of Mw 
Particle-induced cytotoxicity increased as the binding constant (and the Mw) 
increased in both cell lines (Figures 6A and 6B). There was relatively less toxicity in the 
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MDA-MB-231 cell line compared to the GB319 cell line, especially for the 447 High Mw 
polymer. 
 
II. Effect of Single Carbon Differences 
The cytotoxicity increased as the number of carbons in the backbone or sidechain 
increased in both cell lines. Thus, cytotoxicity decreased (and the relative metabolic 
activity increased) as the binding constant increased (Figures 6C-6F). 
 
III. Effect of Endcaps 
There was not significant cytotoxicity in the MDA-MB-231 cell line in the 44, 442, 444, 
446 and 447 Low endcap series, whereas there appeared to be some cytotoxicity in the 
GBM319 cell line with the primary and tertiary amine endcaps. Secondary amine 
endcaps may be particularly less cytotoxic in the GBM319 cell line (Figures 6G and 
6H). There was not a clear trend in the relative metabolic activity when varying the type 
of endcap. 
 
3.3.11 Heparin Competition Release 
The 44 polymer associated with the weakest binding constant (526 M-1) released 
its DNA with the lowest amount of heparin (<2 μg/mL) (Figure S14). 447 Low Mw was 
associated with a binding constant of 4.2x103 M-1 and released its DNA at a heparin 
concentration between 16 to 64 μg/mL (Figure S14). The 446 and 447 High Mw 
polymers were associated with 7.97x103 and 1.23x105  M-1, respectively and both 
released their DNA between 128 and 256 μg/mL. The 446 polymer has a faint 
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supercoiled DNA band at 128 μg/mL, suggesting 446 polymer likely releases its DNA at 
a lower heparin concentration than does 447 High Mw (Figure S14). The DNA release 
from the polyplexes appears inversely proportional to the binding affinity between DNA 
and the polymers.  
 
3.3.12 Comparison of Poly(β-amino ester) Binding to Poly(L-lysine), and Linear 
and Branched Polyethyleneimine 
Branched polyethyleneimine (PEI), linear PEI and poly(L-lysine) (PLL) had 
binding constants per amine (K; M-1) of (5.1±0.1)x103 M-1, (4.3±0.2)x103 M-1, and 
(5.5±0.2)x103 M-1, respectively; the Hill coefficients, α, were 3.78, 3.16, and 2.63.35 All 
of the PBAE αs were less than one, with the exception of polymer 646. In light of this, 
the overall binding constants, Kα, of the branched and linear PEI, as well as PLL were 
significantly higher than PBAE’s. When considering the structure of PBAEs versus the 
other polymers of interest, there are also significantly less primary amines which are 
mainly responsible for binding; in contrast to tertiary amines which are more responsible 
for buffering the endosomes to allow the cargo to escape unscathed from the lysosomal 
degradation pathway. Primary amines, secondary amines, and tertiary amine pKa values 
are approximately 11, 8, and 5, respectively. It appears that the primary amines binding to 
anionic nucleic acid may results in a positive cooperativity effect due to avidity. 
Generally speaking, the binding ranking for each of the polymers would be: branched and 






Evaluation of polymer-DNA binding constants using TCSPC compared to 
transfection efficacy allowed us to observe that binding constants between 1-6x104           
M-1 were optimal for both human cancer cell lines tested. Our data reveals that polymer-
DNA binding affinity for PBAEs is biphasic with transfection efficacy, with an 
intermediate binding affinity being optimal. A binding constant in the optimal range is 
necessary but not sufficient for effective transfection.  This intermediate binding affinity 
can be independently tuned by adding single carbons to the backbone or side-chain 
structure, varying monomer ratios during synthesis and/or using GPC fractionation to 
tune the polymer molecular weight, and by modifying a small molecule endgroup used to 
endcap a linear polymer.  By probing a specific gene delivery bottleneck with a class of 
polymers that were synthesized to have subtle structural differences, new quantitative and 











3.5  Figures 
 
Figure 1.  GPC curves of fractionated polymers by group (relative RI shift (mV/max 
mV) versus elution time (min.); varying molecular weight (Low, Med, and High) (A), 






























Figure 3. Hill plots of polymer series varying Mw (A), backbone (B), sidechain (C), and 




Figure 4. Binding constants (M-1) of each of the series comparing Mw (A), backbone (B), 
sidechain (C), and endcaps (D). (Statistical analysis was accomplished by a one-way 
ANOVA and a Tukey post-hoc analysis; *=P-value < 0.05; **=P-value < 0.01; ***=P-





Figure 5. The effect of binding constant on transfection efficacy in MDA-MB-231 cells 
(A, C, E, G) and GBM319 cells (B, D, F, H) for each of the series comparing Mw (A and 




Figure 6. The effect of binding constant on relative metabolic activity in MDA-MB-231 
cells (A, C, E, G) and GBM319 cells (B, D, F, H) for each of the series comparing Mw (A 






Figure S1. 1H NMR spectra of polymers 44 High (A, C), Med (E), Low Mw (G), 442 (B), 
444 (D), 446 (F), and 447 (H). These spectra are consistent with NMR analyses published 
previously (Sunshine, Akanda, et al.) along with spectra of the other polymers used in 





Figure S2. Decay-associated spectra. The fluorescence lifetimes of ethidium bromide 
bound to DNA and free in the solution are 22.58 and 1.81 ns, respectively, in this 



















Figure S4. The relationship between polyplex diameter and the binding constant (M-1) of 

















Figure S5. All diameters versus binding constants (A); dependence of transfection 



















Figure S6. Diameter of four representative polymers at various pHs and ionic strengths. 










Figure S7. The relationship between zeta potential and the binding constant (M-1) of each 






















Figure S8. All ZP values irrespective of series versus binding constants (A); dependence 






































Figure S10. Normalized geometric (A) and arithmetic (B) means versus transfection 





















Figure S11. Positive (Lipofectamine 2000 at 100 and 200 ng/well) and negative controls 
(naked DNA and untreated) for transfection and relative metabolic activity in MDA-MB-















Figure S12. All binding constants for each of the series of comparison against 
transfection efficacy in MDA-MB-231 cells (A) and GBM319 cells (B), as well as 












Figure S13. All binding constants against transfection efficacy using 70% serum in the 











Figure S14. Heparin (ranging from 0 to 512 μg/mL) competition release assay of four 
representative polymers using gel electrophoresis; binding constants range from 526 











Scheme 1. Nanoparticle formulation, extracellular and intracellular barriers for 














Scheme 2. Reaction of PBAE synthesis; backbone (B3-6), sidechain (s3-6) and various 
endcap (E2, E4, E6, E7) monomers used in the PBAE library. A representative polymer 


























Table S1. List of PBAE polymers and their number average molecular weights (Mn), 
weight average molecular weights (Mw), polydispersity indices (PDI), degree of 
polymerizations (DP), Hill coefficients (α), binding constants (K), diameters (nm), and 
































3.8  References 
 
(1) Nielsen, L. L.; Maneval, D. C. Cancer Gene Ther. 1998, 5, 52-63. 
(2) Ziady, A. G.; Kelley, T. J.; Milliken, E.; Ferkol, T.; Davis, P. B. Mol. Ther. 2002, 5, 
413-9. 
(3) Thomas, M.; Klibanov, A. M. Appl. Microbiol. Biotechnol. 2003, 62, 27-34. 
(4) Pearson, S.; Jia, H. P.; Kandachi, K. Nat. Biotechnol. 2004, 22, 3-4. 
(5) Sunshine, J. C.; Bishop, C. J.; Green, J. J. Ther. Deliv. 2011, 2, 493-521. 
(6) Sunshine, J. C.; Akanda, M. I.; Li, D.; Kozielski, K. L.; Green, J. J. 
Biomacromolecules 2011, 12, 3592-3600. 
(7) Green, J. J. Ann. Biomed. Eng. 2012, 40, 1408-1418. 
(8) Green, J. J.; Langer, R.; Anderson, D. G. Acc. Chem. Res. 2008, 41, 749-759. 
(9) Shmueli, R. B.; Sunshine, J. C.; Xu, Z. H.; Duh, E. J.; Green, J. J. Nanomed.-
Nanotechnol. 2012, 8, 1200-1207. 
(10) Sunshine, J.; Green, J. J.; Mahon, K. P.; Yang, F.; Eltoukhy, A. A.; Nguyen, D. N.; 
Langer, R.; Anderson, D. G. Adv. Mater. 2009, 21, 4947-+. 
(11) Tzeng, S. Y.; Guerrero-Cazares, H.; Martinez, E. E.; Sunshine, J. C.; Quinones-
Hinojosa, A.; Green, J. J. Biomaterials 2011, 32, 5402-10. 
(12) Bhise, N. S.; Shmueli, R. B.; Gonzalez, J.; Green, J. J. Small 2012, 8, 367-73. 
(13) Akinc, A.; Lynn, D. M.; Anderson, D. G.; Langer, R. J. Am. Chem. Soc. 2003, 125, 
5316-23. 
(14) Akinc, A.; Langer, R. Biotechnol. Bioeng. 2002, 78, 503-8. 
(15) Sunshine, J. C.; Peng, D. Y.; Green, J. J. Mol. Pharm. 2012, 9, 3375-83. 
(16) Sunshine, J. C.; Sunshine, S. B.; Bhutto, I.; Handa, J. T.; Green, J. J. PloS one 2012, 
7, e37543. 
(17) Huang, Y. H.; Zugates, G. T.; Peng, W.; Holtz, D.; Dunton, C.; Green, J. J.; Hossain, 
N.; Chernick, M. R.; Padera, R. F., Jr.; Langer, R.; Anderson, D. G.; Sawicki, J. A. 
Cancer Res. 2009, 69, 6184-91. 
(18) Eltoukhy, A. A.; Siegwart, D. J.; Alabi, C. A.; Rajan, J. S.; Langer, R.; Anderson, D. 
G. Biomaterials 2012, 33, 3594-3603. 
(19) Wang, J.; Gao, S. J.; Zhang, P. C.; Wang, S.; Mao, M. Q.; Leong, K. W. Gene Ther. 
2004, 11, 1001-1010. 
(20) Zelikin, A. N.; Trukhanova, E. S.; Putnam, D.; Izumrudov, V. A.; Litmanovich, A. 
A. J. Am. Chem. Soc. 2003, 125, 13693-13699. 
(21) Plank, C.; Tang, M. X.; Wolfe, A. R.; Szoka, F. C., Jr. Hum. Gene Ther. 1999, 10, 
319-32. 
(22) Schaffer, D. V.; Fidelman, N. A.; Dan, N.; Lauffenburger, D. A. Biotechnol. Bioeng. 
2000, 67, 598-606. 
(23) Leong, K. W.; Mao, H. Q.; Truong-Le, V. L.; Roy, K.; Walsh, S. M.; August, J. T. J. 
Control. Release 1998, 53, 183-193. 
(24) Tam, P.; Monck, M.; Lee, D.; Ludkovski, O.; Leng, E. C.; Clow, K.; Stark, H.; 
Scherrer, P.; Graham, R. W.; Cullis, P. R. Gene Ther. 2000, 7, 1867-1874. 
(25) Yu, R. Z.; Geary, R. S.; Leeds, J. M.; Watanabe, T.; Fitchett, J. R.; Matson, J. E.; 
Mehta, R.; Hardee, G. R.; Templin, M. V.; Huang, K.; Newman, M. S.; Quinn, Y.; Uster, 




(26) Green, J. J.; Zugates, G. T.; Tedford, N. C.; Huang, Y. H.; Griffith, L. G.; 
Lauffenburger, D. A.; Sawicki, J. A.; Langer, R.; Anderson, D. G. Adv. Mater. 2007, 19, 
2836-+. 
(27) van der Aa, M. A. E. M.; Huth, U. S.; Hafele, S. Y.; Schubert, R.; Oosting, R. S.; 
Mastrobattista, E.; Hennink, W. E.; Peschka-Suss, R.; Koning, G. A.; Crommelin, D. J. 
A. Pharm. Res. 2007, 24, 1590-1598. 
(28) Ketola, T. M.; Hanzlikova, M.; Urtti, A.; Lemmetyinen, H.; Yliperttula, M.; 
Vuorimaa, E. J. Phys. Chem. B 2011, 115, 1895-1902. 
(29) Vuorimaa, E.; Ketola, T. M.; Green, J. J.; Hanzlikova, M.; Lemmetyinen, H.; 
Langer, R.; Anderson, D. G.; Urtti, A.; Yliperttula, M. J. Control. Release 2011, 154, 
171-176. 
(30) Vuorimaa, E.; Urtti, A.; Seppanen, R.; Lemmetyinen, H.; Yliperttula, M. J. Am. 
Chem. Soc. 2008, 130, 11695-700. 
(31) Nanduri, V.; Sorokulova, I. B.; Samoylov, A. M.; Simonian, A. L.; Petrenko, V. A.; 
Vodyanoy, V. Biosens. Bioelectron. 2007, 22, 986-92. 
(32) Michel, D. Biophys. Chem. 2007, 129, 284-288. 
(33) Gelamo, E. L.; Tabak, M. Spectrochim. Acta A 2000, 56, 2255-2271. 
(34) Gelamo, E. L.; Silva, C. H. T. P.; Imasato, H.; Tabak, M. BBA-Protein Struct. M 
2002, 1594, 84-99. 
(35) Ketola, T. M.; Hanzlikova, M.; Leppanen, L.; Ravina, M.; Bishop, C. J.; Green, J. J.; 
Urtti, A.; Lemmetyinen, H.; Yliperttula, M.; Vuorimaa-Laukkanen, E. Journal of 



























4 Chapter 4: Degradable Polymer-Coated Gold 
Nanoparticles for Co-delivery of DNA and siRNA 5 
4.1 Introduction 
There is a need for improved nanobiotechnologies that enable intracellular 
delivery of difficult to deliver biologics such as nucleic acids. Ideally, a delivery material 
would be capable of delivering both large molecules such as DNA as well as small 
molecules such as siRNA, and thus be capable of both positive and negative regulation of 
genes. It also is necessary that such a delivery material is non-cytotoxic and desirable that 
it can enable multi-functionality through imaging and/or other therapeutic modalities.  
Gold nanoparticles (AuNP) are easy to synthesize 1, monodisperse 1, 
biocompatible in various applications 2,3, have optical properties 2 useful for colorimetric 
sensor applications, and can be diversely functionalized with chemical moieties via thiol 
(R-SH) groups 2. They can be used as biosensors or imaging agents, and can also be used 
as a therapeutic for theranostic applications. Their nanoscale size allows for the ability to 
passively target tumors via the enhanced permeability and retention (EPR) effect, and 
they can be functionalized with tumor/cancer-specific small molecules or antibodies for 
active targeting 4-6.  It has been shown that NPs up to 400 nm can leak through 
neovasculature around tumors due to abnormal endothelial cell fenestrations 7,8.   
AuNPs have been imaged in vitro, ex vivo, and in vivo via various modalities, 
either natively or with further chemical modification, such as: x-ray computed 
                                                     
Chapter 4 was published as “Bishop CJ, Tzeng SY, Green JJ. Degradable polymer-coated gold 
nanoparticles for co-delivery of DNA and siRNA. Acta Biomater. 2015;11:393-403.” 
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tomography, transmission electron and dark-field microscopies, multiphoton, and surface 
enhanced Raman spectroscopies, two-photon luminescence and photoacoustic 
tomography 9-11.  
AuNPs are also able to be physicochemically tuned for use in photothermal 
therapy. When light is directed to AuNPs at the surface plasmon resonance (SPR) 
wavelength, heat is produced. If the nanoparticles (NPs) are engineered appropriately, 
cellular damage due to heat can be directed towards tumors through NP targeting and by 
the decreased ability of tumors to self-thermoregulate 12. SPR wavelengths may be tuned 
in the near infrared (NIR) region which is useful as NIR is transparent to biological tissue 
on the order of centimeters 13.  
AuNPs are able to deliver a payload through conjugation or ionic complexation to 
small molecules 14, or various nucleic acids, such as DNA 15, short hairpin RNA or short 
interfering RNA (siRNA) 16 for promoting or inhibiting protein expression. Layer-by-
layer (LbL) approaches coat a surface or a core with multiple layers of charge-alternating 
polyelectrolytes 15,17-21. NP LbL approaches are ideal for complexing ionically charged 
macromolecules into EPR-relevant sizes. LbL approaches can be accomplished using 
aqueous solvents, are versatile regarding molecular structure as natural and synthetic 
polyelectrolytes are able to be used, and are easily tuned by varying the number and order 
of the layers 18,22.  
Although viruses may be effective nucleic acid delivery vectors, many have been 
associated with immune complications and/or insertional mutagenesis and therefore we 
have focused our efforts using safer, non-viral methods 23. In this work, we report a proof 
of concept of simultaneous non-viral knockdown and exogenous gene expression via an 
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LbL theranostic platform technology with biodegradable polymers as outer layers.  This 
system was validated in vitro using human primary glioblastoma multiforme (GBM) cells 
24,25. The hybrid NPs employ two uniquely degrading polymers for release, one based on 
hydrolysis of ester groups and the other based on environmentally-triggered degradation 
of disulfide linkages once the particles are in the cytoplasm. The ability to both inhibit 
and generate proteins of interest simultaneously with these NPs has many applications in 
cancer therapeutics, such as overcoming drug resistance, promoting apoptosis, and 
inhibiting migration as well as the rectification of diseases caused by aberrant proteins 
26,27.  
 
4.2 Materials and Methods 
4.2.1 Materials 
Materials: The AuNPs were synthesized using tetrachloroauric acid (HAuCl4) trihydrate 
(Ted Pella, Inc.), sodium citrate (Na3-Citrate) tribasic dehydrate (Sigma Aldrich), a reflux 
condenser (Sigma Aldrich), mineral oil (Sigma Aldrich), a hot plate with magnetic stir 
bar (Fisher Scientific), and 11-mercaptoundecanoic acid (11-MUA). The polymers were 
synthesized from commercially available monomers N,N'-bis(acryloyl)cystamine (BSS) 
(Alfa Aesar), 3-amino-1-propanol (S3) (Alfa Aesar), and 1-(3-Aminopropyl)-4-
methylpiperazine (E7) (Alfa Aesar), 1,4-Butanediol diacrylate (B4) (Alfa Aesar), and 4-
amino-1-butanol (S4) (Alfa Aesar). Other reagents used included sodium acetate (NaAc), 
ethanol (EtOH), anhydrous dimethyl sulfoxide (DMSO) (Sigma Aldrich), methanol 
(MeOH) (Sigma Aldrich), 25 kDa branched polyethyleneimine (Sigma Aldrich), 
anhydrous tetrahydrofuran (THF) (Sigma Aldrich), anhydrous ethyl ether (Fisher 
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Scientific), Lipofectamine® 2000 (Invitrogen), OptiMEM I (Invitrogen), YO-PRO®-1 
(Y3603; Invitrogen), Picogreen® (P7589; Invitrogen), Ribogreen® (Q10213; 
Invitrogen), Fluoraldehyde™ OPA assay (26025; Thermo Scientific). Cell culturing 
reagents included: fetal bovine serum (FBS), DMEM:Ham’s F12 (1:1) (Invitrogen), 1x 
antibiotic-antimycotic (Invitrogen), anti-eGFP siRNA (sense: 5′-
CAAGCUGACCCUGAAGUUCTT; anti-sense: 3′-
GAACUUCAGGGUCAGCUUGCC), scrambled siRNA as a negative control (sense: 5′-
AGUACUGCUUACGAUACGGTT; anti-sense: 3′-
CCGUAUCGUAAGCAGUACUTT), plasmid enhanced green fluorescent protein DNA 
(eGFP-N1; referred to as eGFP) (Clontech), amplified and purified by Aldevron, 
pDsRed-Max-N1 DNA (dsRed) (Addgene), and CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (Promega). 
 
4.2.2 Colloidal Gold Nanoparticle Synthesis 
Similar to the Frens Method 1, 20 mL of 0.01% solution of HAuCl4 was 
vigorously boiling in a round bottom flask using mineral oil, a hot plate with magnetic 
stirring capabilities and a reflux condenser when 1 mL of a 1% solution of Na3-Citrate 
was quickly injected therein and boiled for an additional 6 min. As the nucleation and 
growth of the AuNPs proceeded, the solution turned from a slightly yellow to a deep red 
solution. After boiling, the citrate-stabilized AuNPs (CAu) were cooled on ice for 
approximately 10 minutes. 11-MUA was conjugated to the AuNPs (MAu) to help ensure 
charge stability throughout the layering process. To do so, a 20 mM solution of 11-MUA 
was made in 95% EtOH and diluted to 1 mM using 70% EtOH which had been diluted 
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from 95% using 150 mM NaAc. The CAu was centrifuged at 20 krcf for 10 minutes and 
after the supernatant was removed an equal amount of the 1 mM 11-MUA solution was 
used to resuspend the CAu. The solution was sonicated at an amplitude of 1 for 2 seconds 
using a Misonix Ultrasonic Liquid Processor. The conjugation took place over 48 hours 
at room temperature and sonicated at approximately 4 hours and 40 hours during the 
conjugation process. The solution was washed in water twice by centrifugation (21 krcf 
for 10 minutes) and became a deep purple and cloudy with sonication as the 11-MUA 
crashed out of solution in the water. This solution was washed twice in ethanol again and 
then twice in 4.5 mg mL-1 of Na3-citrate via centrifugation (21 krcf for 10 minutes). The 
solution retained its purple hue but was no longer cloudy. The resulting MAu solution in 
4.5 mg mL-1 of Na3-citrate was stable. The MAu solution was diluted to 0.31 nM and 
used in the LbL process. 
 
4.2.3 Citrate-stabilized and 11-mercaptoundecanoic acid-stabilized Gold 
Nanoparticle Characterization 
Transmission Electron Microscopy (TEM; Philips/FEI BioTwin CM120) was 
used to ascertain the diameter of the AuNPs on carbon-coated copper grids (FCF400-Cu; 
Electron Microscopy Sciences) which was also used to calculate the extinction 
coefficient ε according to Huo, et al. according to Equation 1 28: 
ln 𝜀 = 3.32111 ln 𝐷𝑖𝑎𝑚𝑒𝑡𝑒𝑟𝐴𝑢𝑁𝑃 𝑖𝑛 𝑛𝑚 +  10.80505                                             (1) 
 The concentration was determined by dividing the normalized absorbance (A cm-
1) which was measured using UV-Vis spectroscopy (Synergy2, Biotek®, Gen5 software) 
by ε according to the Beer-Lambert Law. The aggregation differences of naked CAu and 
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MAu were assessed by placement into increasingly more concentrated sodium acetate 
solutions which was the buffer used for layering (pH 5.2). The final concentration of 
sodium acetate after the first layer (PEI) was added to the AuNPs was 63 mM.  
 
4.2.4 Polymer Synthesis and Characterization 
The reducible disulfide-containing poly(amido amine) (BSS-S3-E7 or SS37) 29-31 and the 
hydrolytically degradable poly(beta-amino ester) (B4-S4-E7 or 447) 24 polymers were 
synthesized as previously reported (Scheme S1).  
Briefly, polymer SS37 was synthesized by adding the BSS monomer in a 4:1 v/v 
mixture of MeOH and water, and subsequently adding the S3 monomer in a 1.05:1 molar 
ratio under nitrogen. The reaction was kept in the dark, with constant stirring under 
positive nitrogen pressure via a balloon syringe at 45C for 14 days (Scheme S1). The 
solution became clear after the first couple of hours. Once the reaction was complete the 
polymer was purified using reverse-dialysis with a molecular weight cut-off of 2 kDa in 2 
L of pH 3 Milli-Q water with constant stirring for 24 hours. Fresh pH 3 water was 
changed out at 8 hours. After washing in water using centrifugation, the polymer was 
frozen in liquid nitrogen and lyophilized. The polymer was then made into a 167 mg mL-1 
solution using anhydrous DMSO. 0.5 M E7 in DMSO was added to dilute the 167 mg 
mL-1 solution to 100 mg mL-1 in a 0.5 M solution.  
 Polymer 447 was synthesized by mixing neat monomers B4 and S4 in a 1.2:1 
molar ratio. The reaction was carried out for 24 hours at 90C in the dark with constant 
stirring. The diacrylate-terminated base polymer was dissolved in anhydrous THF. E7 in 
anhydrous THF was added for a final concentration of 100 mg mL-1 B4-S4 base polymer 
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and 0.2 M E7 endcap, and the mixture was left to react for 1 hour while shaking at 1000 
RPM (Scheme S1). The endcapped polymer was then precipitated into anhydrous ethyl 
ether in a 4:1 v/v ratio of ether to THF. The polymer was collected by centrifugation at 
4000 RPM for 5 min, the supernatant was decanted, and the polymer was washed once 
more with ether and collected by centrifugation. Polymer was allowed to dry for 2 days 
under vacuum, was then dissolved in anhydrous DMSO at a final polymer concentration 
of 100 mg mL-1, and was subsequently stored at -20 C with desiccant until use. 
GPC (Waters®, Breeze 2 software) was used to assess the Mn, Mw, and PDI using 
three 37.8 x 300 mm columns in series at a flow rate of 1 mL min-1 of GPC solvent (94% 
THF, 5% DMSO, 1% piperidine containing approximately 10 mg of butylated 
hydroxytoluene).  
 
4.2.5 Polyelectrolyte Layering Process 
The layering process is depicted in Scheme 1 18,22 80 μL of 25 kDa branched PEI was 
added to 112 μL of the 0.31 nM MAu (1.9x1011 particles mL-1) in water, shaken for 30 
minutes at 500 RPM at room temperature, and centrifuged twice at 10 krcf for 10 minutes 
to remove uncomplexed polyelectrolytes (extracted 182 μL). The supernatant after the 
first and second washing was replaced with 182 μL and 102 μL of 150 mM NaAc, 
respectively. Each subsequent layer was added to the previous resuspended complexes 
using 80 μL of the polyelectrolyte in 150 mM NaAc. The order in which the 
polyelectrolytes were layered with their associated concentrations are as follows: MAu 
(0.31 nM)-PEI (10 mg mL-1)-DNA (0.5 mg mL-1)-PEI (10 mg mL-1) or SS37 (5 mg mL-1) 
or 447 (5 mg mL-1)-DNA (0.5 mg mL-1) or anti-eGFP siRNA (4 μM)-447 (1.25, 2.5, or 5 
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mg mL-1) or PEI (0.25 mg mL-1). The supernatant of the second wash just prior to adding 
the last layer was replaced with 25 mM NaAc and the last polyelectrolyte layer was also 
added in 25 mM NaAc.  
 
4.2.6 Diameter and Zeta Potential 
The diameter and ZP at each of the layered stages of the DNA/siRNA co-delivery NP 
formulation with a 447 concentration of 5 mg mL-1 were ascertained via NP tracking 
analysis using a NanoSight NS500 (n ≥ 2), and a Malvern Zetasizer Nano ZS (Malvern 
Instruments, detection angle 173o, 633 nm laser; Smoluchowski model) (n=3), 
respectively. The diameters were calculated after the two washing steps, just prior to 
adding the subsequent layer in the same diluent (0 to 3.1-fold dilution) as in the usual 
polyelectrolyte layering process. The unknown diffusivity (D) was calculated from the 
root mean square distance (<x>) and time (t) in Equation 2 (2-dimensional) below: 
< 𝑥 >= √4𝐷𝑡                                                                                                           (2) 
which can then be used to calculate the unknown hydrodynamic radius using the Stokes-
Einstein equation shown in Equation 3 (KB = Boltzmann constant, T = temperature in 




                                                                                                                    (3) 
The ZPs were measured after the second washing at each layer after a 3.6-fold 
dilution in ultra pure distilled water.   
 Although the diameter quantified using the NanoSight NS500 instrument is also 
an indicator of aggregation, we endeavoured to corroborate these findings via TEM. In 
doing so, 30 μL of the sample of interest was placed onto corona plasma-treated, carbon-
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coated copper grids. CAu in water was air dried; the PEI to 447 layers (using the 11-
MUA conjugated CAu or MAu) layers were adsorbed for 30-45 minutes, followed by 
wicking and rinsing in water. Similar to when the diameter and ZP were assessed, the 447 
layer was at 5 mg mL-1. 
 
4.2.7 Nucleic Acid Loading and Layering Efficiency 
To quantify the amount of nucleic acid loaded in the various formulations, three different 
nucleic acid-intercalating probes were used. When quantifying the amount of DNA in the 
absence of siRNA, YO-PRO®-1 was used. YO-PRO®-1 can fluoresce in the presence of 
either DNA or siRNA, therefore nucleic acid-specific intercalating probes were used 
when quantifying DNA and siRNA in the presence of the other, namely, Picogreen® and 
Ribogreen®, respectively.  
 When quantifying the amount of nucleic acid present using DNA intercalators, it 
is important to ensure that ionically complexed nucleic acid is all detected as the 
complexed form is less accessible to the nucleic acid-intercalating probes. To ensure all 
nucleic acid present was detected in the presence of polymer, branched PEI with a known 
amount of DNA or siRNA using 10 w/w was used for optimization of the disassembly 
process (n ≥ 3) by adjusting the salt and heparin concentrations. When quantifying the 
amount of DNA in the absence of siRNA, the formulation is brought to 10 μM YO-
PRO®-1, 650 mM salt (PBS and NaAc) and 300 μg mL-1 of heparin and measured using 
a fluorescence plate reader (excitation and emission of 485 nm and 528 nm). When 
quantifying the amount of DNA in the presence of siRNA, the formulation tested is 
brought to 650 mM salt (PBS and NaAc) and 110 μg mL-1 of heparin at the completion of 
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the layering process and measured using a 1:200 dilution of Picogreen® in a 1x tris and 
EDTA (TE) buffer using an excitation and emission of 485 and 528 nm (1 μL of sample 
+ 199 μL of 1:200 dilution Picogreen® in 1x TE buffer). When quantifying siRNA in the 
presence of DNA, the formulation is brought to 8 mM salt (PBS and NaAc), 1040 μg mL-
1 heparin and was measured using a 1:200 dilution of Ribogreen® in the provided RNA 
BR buffer using an excitation and emission of 644 and 673 nm (10 μL of sample + 200 
μL of 1:200 dilution Ribogreen® in RNA BR buffer). The co-delivery DNA/siRNA LbL 
formulation’s DNA and siRNA content was quantified after adding polymer 447 at 5 mg 
mL-1 (highest w/w formulation). The same DNA and siRNA content was used to 
calculate the w/w values when 2.5 or 1.25 mg mL-1 of polymer 447 was added as the last 
layer as there is the same amount of nucleic acid present before the 447 polymer is 
complexed (Table S1).  
The content of DNA and siRNA quantified in the supernatants during the washing 
steps was performed with a NanoDrop 2000 Spectrophotometer (Thermo Scientific). The 
layering efficiency was calculated by multiplying the amount of nucleic acid ionically 
complexed per vial by 100 and dividing by the total amount of nucleic acid added per 
vial.  
 
4.2.8 Polymer Weight/DNA Weight Ratio 
The w/w values for the layered formulations were calculated by dividing the mass 
of the unwashed polymer on the outer layer of the various formulations per mass of DNA 
or siRNA loaded per vial. Although the majority of the polymer in the layered 
formulations is the unwashed outer layer, we investigated the extent to which an earlier 
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washed polymer layer could be contributing to the w/w values. The amount of PEI 
complexed was calculated by subtracting the uncomplexed PEI extracted in the 
supernatants from the amount of PEI added which was calculated using a 
Fluoraldehyde™ OPA assay which detects primary amines using an excitation and 
emission of 340 and 420 nm, respectively. 
 
4.2.9 Cell Culture and Transfection 
The human glioblastoma multiforme cell line (GBM319) was derived from brain tumor 
stem cells (79 year old patient) and cultured as previously described 25 in a humid 37C 
and 5% CO2 atmosphere
 using DMEM:Ham’s F12 (1:1) (Invitrogen) and supplemented 
with 1x antibiotic-antimycotic (Invitrogen) and 10% FBS. These eGFP negative cells 
were used to assess expression in layered formulations delivering DNA only (eGFP). To 
assess the ability to co-deliver DNA and siRNA using layered formulations (termed LD 
or HD), stably expressing eGFP-positive GBM319 cells were used which were 
previously transfected with B4-S5-E3/eGFP polyplex and retained eGFP positivity in 
1.2% of the cells 3 months post-transfection 32; these cells were cell sorted multiple times 
to obtain a more pure eGFP positive population of 81%. Knockdown in the stably 
expressing eGFP-positive GBM319 cells was assessed using anti-eGFP siRNA and a 
scrambled siRNA as a control. Expression in the stably expressing eGFP-positive cells 
was assessed using red fluorescence protein transcribed and translated from dsRed DNA. 
Lipofectamine® 2000 was used as a positive control for knockdown and expression. All 




The GBM319 cells (eGFP-positive and negative) were seeded in 96-well plates at 
10,000 cells well-1 1 day prior to transfection. The positive controls and various layered 
formulations were delivered to the cells and the 96-well plates were gently rocked 
manually. 2 hours after delivery the media was changed. 
 
4.2.10 Transfection Assessment and Quantification 
Fluorescence microscope images (Zeiss) were taken of the various formulations on days 
1 through 3 (10x magnification) for expression and day 7 (5x magnification) for 
knockdown. The exposure times for the eGFP and dsRed channels were 200 and 600 ms, 
respectively.  
A Synergy2 fluorescence plate reader was used to assess knockdown each day 
until the strongest knockdown reached a maximum, and then the knockdown was 
assessed using the more sensitive method of flow cytometry. To ensure the knockdown 
assessment is due solely to RNA interference and not as a result of cytotoxicity, a 
scrambled control was used. The knockdown was calculated using Equation 4 using an 
excitation and emission of 485 and 528 nm (Fsi = fluorescence of the well using anti-
eGFP siRNA; Fsc = fluorescence of the well using scrambled siRNA; FBackground = 
fluorescence background of media without cells; Fosi = initial fluorescence of well just 
prior to delivery for the anti-eGFP formulations; Fosc = initial fluorescence of well just 
prior to delivery for the scrambled siRNA formulations): 





)                                (4)       
 ImageJ analysis was performed on days 1 through 3 to determine the day of 
maximal expression. A BD Accuri™ C6 flow cytometer equipped with an automatic 
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HyperCyt sampler was used to assess expression at day 2 and knockdown at day 7. The 
singlet population was identified using FSC-H vs SSC-H; the FL1-H vs FL3-H channel 
was used to assess the eGFP and dsRed population percentages. When the stably 
expressing eGFP GBM319 cells were used to assess co-delivery of DNA and siRNA, an 
FL1 90% filter was used to ensure the FL1 detector was not saturated. FL1-H vs FL3-H 
were chosen as this minimizes overlapping fluorescence. Knockdown was calculated by 
flow cytometry by quantifying the geometric mean for the anti-eGFP siRNA and 
scrambled groups of the eGFP-positive region using FL1-A, according to Equation 5:  
𝐾𝑛𝑜𝑐𝑘𝑑𝑜𝑤𝑛 % = 100 − 100
𝑎𝑛𝑡𝑖−𝑒𝐺𝐹𝑃 𝑠𝑖𝑅𝑁𝐴 𝐺𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐 𝑀𝑒𝑎𝑛
𝑠𝑐𝑟𝑎𝑚𝑏𝑙𝑒𝑑 𝑠𝑖𝑅𝑁𝐴 𝐺𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐 𝑀𝑒𝑎𝑛
                                    (5) 
 
4.2.11 Cytotoxicity 
An MTS assay, CellTiter 96®, was used to assess the RMA relative to an untreated group 
which was normalized to 100% 24 hours post-transfection. The MTS assay is an indicator 
of cytotoxicity or viability. We wished to evaluate if the nanoparticles became 
increasingly cytotoxic following the degradation of the outer layer, which was composed 
of biodegradable polymer 447.  This polymer has been shown to have a half-life of 2-5 
hrs 33. We therefore incubated the particles at 37C in complete media for 18 hrs and then 
subsequently, these particles were added to GBM319 cells at the same concentration and 
dosage as the HD5 formulation. Cellular viability was measured using an MTS assay at 
24 hours post-transfection. A two-tailed Student’s t-test was used to compare the 





4.2.12 Cellular Uptake 
TEM was also used to assess cellular uptake of the co-delivery LbL formulation. The 
GBM319 cells, after 2 hours of LbL formulation incubation using the 300 ng DNA and 
240 ng of siRNA formulation at respective w/w values of 56 and 69, were fixed, 
dehydrated, and infiltrated with Epon, and then using an ultramicrotome were sectioned 
into 70-100 nm slices. 
More specifically, the cells were washed with PBS and were fixed using a 
glutaraldehyde buffer (2.5% v/v; 0.1 M sodium cacodylate buffer (CaCO), 3 mM CaCl, 
1% sucrose, pH 7.2-7.4) and rocked overnight at 4C. The following day, the cells were 
washed 3x in a new glutaraldehyde buffer (0.1 M CaCO, 3 mM CaCl, 3% sucrose) for 15 
minutes each while being vigilant to not allow the cells to dry out. The cells were then 
left in the dark with a 1% osmium tetroxide solution (0.1 M CaCO, 3 mM CaCl) for at 
least 1 hour on ice and then the cells were washed twice in fresh deionized water for 5 
minutes. Filtered (0.22 μm) 2% uranyl acetate solution in water was used to cover the 
cells for a maximum of 1 hour in the dark. The cells then underwent a dehydration series 
using 50, 70, 90 and then freshly opened 100% ethanol. Subsequently, Epon (1:1 solution 
of propylene oxide: Epon) was added in a swirling fashion and left overnight. The 
following day Epon with 1.5% DMP-30 (Ted Pella, Inc.) catalyst was added and placed 
in a vacuum chamber (15 inches of Hg) for two hours twice and then placed on a rocker 
for another 2 hours. The Epon was again replaced and put into an oven at 37C and was 
allowed to cure for 72 hours. The cells were then placed at 60C for 24 hours. Pliers were 
then used to break the edges carefully. The dish was snapped off to allow clean breaks 
and to minimize the creation of aberrant lines in the sample. The samples were then cut 
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out and sliced using an ultramicrotome and imaged on formvar-coated notched grids 
(Electron Microscopy Sciences). 
 
4.2.13 Statistics 
All errors reported are standard error of the means (SEM). The errors reported in 
Figure 2A (n ≥ 2) and 1B (n = 3) are independently prepared samples with at least 3 TR, 
except CAu and MAu are technical replicates (TR) (n = 3) as they are from a single batch 
synthesis. The errors in Figure S3 are TR (n ≥ 3). The errors reported in Table 1 and 
Figure S4 are n ≥ 3 with at least 3 TR. Figure 3 errors are TR (LD and HD n = 20; 
Lipofectamine® 2000 n = 4); a one-way ANOVA was performed using a Bonferroni’s 
Multiple Comparison Test to assess knockdown differences between the day of 
maximum knockdown and day 7 when flow cytometry was performed (p-value > 0.05 is 
not significant). Errors reported in Figure 4 are TR (LD, HD, and untreated are n ≥ 16; 
Lipofectamine® 2000 is n = 4); a one-way ANOVA was performed using a Bonferroni’s 
Multiple Comparison Test post hoc where *** is a p-value < 0.0001. Figure S6, S7, and 
S9 are TR with n = 4, n ≥ 4, and n ≥ 4, respectively. A one-way ANOVA was performed 
on Figure 7 and Figure S9 using a Dunnett’s Multiple Comparison Test to assess 
significance between Lipofectamine® 2000 where *** is a p-value < 0.0001. 
 
4.3 Results 





Citrate-stabilized AuNP (CAu) batches were synthesized following a modified 
Frens Method 1 (see methods).  CAu NPs were then conjugated with 11-
mercaptoundecanoic acid (11-MUA) to obtain MAu NPs that were 17 ± 2 nm in diameter 
(Figure 1; far left). Based on the TEM diameter of the CAu, the extinction coefficient, ε, 
was calculated to be 6.3x108 M-1 cm-1. Using the absorbance from UV-Visible (UV-Vis) 
spectrometry, the working concentration of MAu was calculated to be 0.31 nM which is 
equivalent to 1.9x1011 particles mL-1. The SPR wavelength of the 11-MUA-unconjugated 
CAu was 520 nm in 4.5 mg mL-1 (pH 7.1) of sodium citrate (Na3-citrate) and was red-
shifted to 526 nm after 11-MUA conjugation (Figure S1) indicating the 11-MUA was 
conjugated successfully. The MAu solution aggregated far less than the CAu solution as 
indicated by the degree to which the SPR wavelengths red-shifted when placed in acidic 
NaAc buffer (Figure S2). 
 
4.3.2 Polymer Characterization Via Gel Permeation Chromatography 
 
         1-(3-aminopropyl)-4-methylpiperazine end-modified poly(N,N'-
bis(acryloyl)cystamine-co-3-amino-1-propanol) (abbreviated here as SS37) containing 
disulfide bonds. The 1-(3-aminopropyl)-4-methylpiperazine end-modified poly(1,4-
butanediol diacrylate-co-4-amino-1-butanol) (abbreviated here as 447) is a poly(beta-
amino ester) (PBAE) containing ester linkages. 
Polymer molecular weight was ascertained by gel permeation chromatography 
(GPC).  SS37 had a number average molecular weight (Mn) and weight average 
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molecular weight (Mw) of 2.5 kDa and 2.7 kDa respectively. 447 had an Mn of 10.2 kDa 
and an Mw of 39.8 kDa. 
 
4.3.3 Layer-by-layer Notation 
 
Throughout the paper the notation to describe layered NPs is as follows: 
polyethyleneimine (PEI) is abbreviated as “P”; DNA as “D”; and the synthetic polymers 
as “SS37” and “447.”  The specific mutilayered formulation that contains DNA and 
siRNA, MAu-P-D-SS37-siRNA-447, are referred to as “LD” or “HD,” corresponding to 
low nucleic acid dose (LD) or high nucleic acid dose (HD). We investigated 6 different 
co-delivery multilayer particle formulations: 2 nucleic acid dosages at 3 different 447 
concentrations (1.25, 2.5 or 5 mg mL-1) as the last layer. These formulations are referred 
to as the low (LD) or high dosage (HD), following by 1.25, 2.5, or 5 mg mL-1 to indicate 
the polymer concentration of the last layer (for example: “LD2.5” or “HD5”).   
 
4.3.4 Diameter and Zeta Potential 
 
By dynamic light scattering (DLS; Malvern Zetasizer) the measured intensity-
weighted diameters for CAu and MAu were 23 ± 1 and 27 ± 2 nm, respectively. 
NanoSight calculated the concentration of layered particles for the HD5 formulation 
(MAu-P-D-SS37-siRNA-447) to be (2.6 ± 0.5)x109 particles per mL. The largest increase 
in size following layering was observed when transitioning from MAu-P to MAu-P-D, 
when the DNA was added, leading to AuNP clusters consisting of several AuNPs within 
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each larger particle of approximately 230 nm (Figure 2A). Despite using higher 
concentrations of DNA (0.75 and 1.0 mg/mL) the diameter of the MAu-P-D formulation 
was not able to be significantly decreased. The diameters of the MAu-P-D formulation 
using 0.75 and 1.0 mg/mL were 180 ± 10 nm (n=3; p-value=0.20) and 170 ± 10 nm (n=3; 
p-value=0.18). As each subsequent polyelectrolyte layer was added to the NPs and 
washed, the zeta potential (ZP) of the NPs reversed in charge (Figure 2B). 
TEM indicated a progressive increase in size up to the DNA layer.  At this layer, TEM 
showed clustering of AuNPs into larger nanoparticles (Figure 1). 
 
4.3.5 Nucleic Acid Loading and Layering Efficiency 
 
 Nucleic acid loading and layering efficiency was determined through evaluation 
with nucleic acid binding dyes.  For measurements, heparin and salt concentrations 
(phosphate buffered saline (PBS) and NaAc) were optimized to displace polymer and 
allow the intercalating fluorescence dyes to detect the total nucleic acid present in the 
presence of 25 kDa PEI at 10 weight/weight (w/w; mass ratio of polymer to nucleic acid). 
YO-PRO®-1, Picogreen, and Ribogreen were able to detect 94.8 ± 0.8%, 101 ± 2%, and 
100 ± 2% of the present nucleic acid, respectively (Figure S3).  The amount of nucleic 
acid delivered per 96-well plate well in 20 μL volumes for the layered formulations is 
shown in Table 1 (w/w discussed in section 2.6). The DNA doses delivered by the 
layered formulations ranged from 200 to 2400 ng DNA and the siRNA doses ranged from 
160 and 240 ng siRNA. 
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In contrast to the MAu-P-D-P-D-447 formulation, the loading of the MAu-P-D-
447-D-447 and MAu-P-D-SS37-D-447 formulations were determined to have lower 
loading than would be otherwise anticipated based on the loading of the MAu-P-D 
formulation. We observed that DNA loading was maximum when only non-degradable, 
highly charged polymers were used in the middle layers of the formulation, rather than 
more weakly charged and biodegradable polymers. This loading difference may be due to 
the differences in binding affinity between the varying cationic polymers and DNA 24,34.  
When one DNA layer was utilized, the average percent of nucleic acid retained in 
the layering process, or the layering efficiency, was 24.1 ± 0.4%. When either polymers 
SS37 or 447 were used as the middle polymer layers with two layers of DNA, the 
average layering efficiency decreased to 5.8 ± 0.5%.  When nondegradable and highly 
charged PEI was used as the first and middle layer with two layers of DNA, the layering 
efficiency was similar to the single DNA layer efficiency at 29 ± 1%. The nucleic acid 
layering efficiencies of DNA and siRNA for the co-delivery formulations were 12 ± 2% 
and 80 ± 3%, respectively. Further details on the quantification of layering efficiencies 
(Supplemental Experimental Section), nucleic acid content contained in the 
supernatants washes (Figure S4), and nucleic acid adsorbed to plasticware during 
formulation (Figure S5) are discussed in the supplemental information.  
 
4.3.6 Polymer Weight/DNA Weight Ratio 
 
The 447 polymer w/w for LbL formulations are listed in Table 1 and Table S1. The 
DNA and siRNA co-delivery formulations were assessed at two different dosages and 
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three different concentrations of the outer polymer layer (1.25, 2.5 and 5 mg mL-1 of 
447). The siRNA-free, “DNA only” LbL formulations had a polymer to nucleic acid 
weight ratio (w/w) that ranged from 0 to 92. The 447 w/w for the DNA and siRNA co-
delivery formulations ranged from 14 to 83 w/w for DNA and 17 to 104 w/w for siRNA. 
The degree to which the inner ionically complexed layer of polymer could contribute to 
w/w was investigated using the PEI layer and was determined to range from 6-9 and 8-12 
w/w for DNA and siRNA, respectively, according to the OPA assay.  
 
4.3.7 Transfection and Cytotoxicity 
4.3.7.1 siRNA-mediated Knockdown 
SiRNA-mediated knockdown over time in human brain cancer cells was obtained 
by measuring decreased endogenous GFP expression of GFP+ human brain cancer cells 
following transfection with LbL particles containing GFP siRNA (Figure 3). The 
maximum knockdown during the time course for each co-delivery formulation occurred 
on days 5 and 6 and was highest with MAu-P-D-SS37-siRNA-447 LD5 and HD5, the 
formulations with the greatest concentration of polymer 447 as the outside layer of the 
particles. Relative fluorescence over time was measured by fluorimetry on a plate reader 
and fluorescence of individual cells was measured by flow cytometry at 7 days. There 
were no significant differences between the maximum and day 7 which was when flow 
cytometry was performed on all formulations (p-value > 0.05). 
The knockdown varied according to the siRNA dosage and w/w, ranging from 
near 0% to 44 ± 5% according to the plate reader by measuring average fluorescence 
(Figure 3) and near 0% to 34 ± 3% by flow cytometry (Figure 4).  Relative metabolic 
173 
 
activity (RMA) or normalized viability (to the untreated group) ranged from 73 ± 4% to 
91 ± 6% among the layered NP formulations.  
Lipofectamine® 2000, a commercially available leading non-viral transfection 
reagent, was used as a positive control at the same dosages as the co-delivery LD and HD 
formulations. According to the plate reader and flow cytometry assessment, the strongest 
knockdown observed with Lipofectamine® 2000 was with a volume to siRNA mass ratio 
(μL:μg) of 0.5:1 and 2.5:1 with an siRNA dosage of 240 and 160 ng, respectively. The 
240 (0.5:1) and 160 ng (2.5:1) dosages reached their maximum knockdown on days 6 and 
7, respectively (Figure S6). According to the flow cytometer and the plate reader, the 
240 ng dosage reached 20 ± 2% and 25 ± 7% knockdown, respectively, and the 160 ng 
dosage reached 6 ± 3% and 19 ± 5% knockdown, respectively with the human brain 
cancer cells (Figure S6 and S7). The 160 ng 2.5:1 Lipofectamine® 2000 condition was 
quite toxic, with an RMA of 44 ± 1%, whereas the 240 ng 0.5:1 was 90 ± 2% (Figure 
S7). Figure S6 shows all knockdown time courses of Lipofectamine® 2000 positive 
controls tested at various dosages and ratios to siRNA with RMAs greater than 70% 
according to the CellTiter assay.  
Fluorescence microscope images of the enhanced green fluorescence protein 
(eGFP) channel showing the strength of knockdown at day 7 from the co-delivery DNA 
and siRNA LbL formulations with varying dosages and w/w, as well as Lipofectamine® 
2000 at 240 ng (0.5:1) and 160 ng (2.5:1) as positive controls are shown in Figure 5.  
4.3.7.2 DNA-mediated Expression 
 The exogenous DNA expression of the co-delivery DNA and siRNA LbL 
formulation reached maximal expression on day 2 and day 2 was chosen to assess 
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expression efficacy for all formulations in the study 24,35 The expression of each of the 
co-delivery LbL formulation dosages at various w/w are shown in fluorescence 
micrograph images (Figure 6). The expression ranged from near zero to 10.8 ± 0.5% 
(Figure 7). There was no statistical difference in the expression efficacy as measured by 
the percentage of positively transfected cells between HD5 and Lipofectamine® 2000 at 
a 100 ng dosage (2.5 μL:1 μg DNA). The RMA ranged from 73 ± 4 to 91 ± 6%.  
The fluorescence images of the expression at day two of other non-siRNA 
containing LbL formulations, as well as their quantified expression according to flow 
cytometry are shown in Figure S8 and S9, respectively. The expression for the DNA 
only layered formulations ranged from near 0 to 37 ± 2%. The MAu-P-D-P formulation 
was associated with approximately 3% transfection and an RMA of 26 ± 2% which was 
the most cytotoxic layered formulation investigated. The layered NP formulation that 
delivered two nucleic acid layers of DNA (no siRNA) that resulted in the highest 
transfection (28 ± 1%) was MAu-P-D-SS37-D-447.  This is the same formulation of 
polymer layers chosen to co-deliver DNA and siRNA and was associated with a high 
RMA of 91 ± 2%. Lipofectamine® 2000 at a 100 ng dosage (2.5 μL:1 μg DNA) was 
associated with a transfection of 14 ± 2% and an RMA of 72 ± 5%. Formulations MAu-
P-D-447, MAu-P-D-SS37-D-447, and MAu-P-D-447-D-447 were statistically 
significantly higher (p-value < 0.0001) than the Lipofectamine® 2000 positive control for 
exogenous DNA expression by 2.6, 2.0, and 1.6 fold, respectively (Figure S9).  
 




The HD5 formulation which had undergone 18 hours of degradation was 
statistically similar (p-value=0.34) to the non-degraded formulation in terms of its 
relative metabolic activity (cytotoxicity). 
4.3.9 Cellular Uptake 
 
Cellular uptake of the co-delivered LbL formulation HD5 is shown in Figure 8 as 
measured by TEM. Inlaid images Figure 8A and Figure 8B show particles on the order 
of ~200 nm. Figure 8C shows putative endosomes (far two left arrows) containing 
multiple aggregates of AuNPs in the endosome.  
 
4.4 Discussion 
4.4.1 Citrate-stabilized and 11-mercaptoundecanoic acid-stabilized Gold 
Nanoparticle Characterization 
 
The tendency for MAu to aggregate less throughout the layering process indicates 
that MAu was superior for layering purposes in comparison to CAu. The differences in 
the UV-Vis spectra in Figure S2 also further validate that the 11-MUA conjugation was 
successful. 
 




SS37 is a disulfide-containing poly(amido amine) that was chosen as a degradable 
polyelectrolyte for layering because: 1) it is cationic to allow for nucleic acid 
complexation; 2) it contains tertiary amines to contribute to the proton sponge effect and 
endosomal escape 36; 3) it contains disulfide linkages to facilitate triggered degradation 
following cytoplasmic delivery as the cytosol is a reducing environment. The 447 PBAE 
was chosen as a degradable polyelectrolyte for layering as: 1) it is also cationic; 2) it 
contains tertiary amines for aiding in the proton sponge effect and endosomal escape 36; 
3) it degrades hydrolytically due to its ester groups 37. 
 When we evaluated two layers of PEI coating AuNPs without using 
biodegradable polymers, we found the system to be less effective and excessively toxic 
(refer to section 3.5.2) compared to LbL AuNPs with less PEI that utilized biodegradable 
polymers. When we evaluated two layers of PEI coating AuNPs without using 
biodegradable polymers, we found the system to be less effective and excessively toxic 
(refer to section 3.5.2) compared to LbL AuNPs with less PEI that utilized biodegradable 
polymers. This finding is in agreement with previous literature, which has shown that 
PBAE polyplexes, such as 447/DNA polyplexes that have polymer 447 on their surface, 
have improved cellular uptake and are more effective than PEI/DNA polyplexes for gene 
delivery 38-40. We believe this same phenomenon makes 447 better than PEI as an outer 
layer on our particles.  Further variation of the degradability of the polymers that make up 
the multilayers may be useful for controlling expression and knockdown over time.  
 




The NanoSight NS500 is able to directly measure number-averaged NP diameter 
by Nanoparticle Tracking Analysis (NTA), rather than intensity-averaged NP diameter 
like DLS in aqueous media.  In our testing, the uncoated CAu and MAu were unable to 
be accurately measured by NTA as the particle sizing limitation of the NanoSight NS500 
with these materials was near 40 nm.  However, for particles larger than 40 nm, the 
NanoSight measurements were similar to DLS measurements when measuring 
polyplexes or AuNPs layered with polymer. For example, DLS reported the diameters for 
MAu-P to be 80 ± 10 nm which is near the NanoSight measurement of 113 ± 3 nm 
(errors are standard deviation; n=6). Based on the TEM images (Figure 1) and the DLS 
particle size data (Figure 2), most MAu-P were singlets that had a PEI layer thickness of 
approximately 30 nm. 
We hypothesize that the clustering effect during the layering process of positively 
charged polymer-coated AuNPs is due to multivalent interactions with DNA, as DNA is a 
large, anionic biomolecule.  As the layering process proceeded, the NPs with outermost 
layers of SS37, siRNA, and 447 were all relatively similar in diameter to the DNA layer, 
approximately 200 nm. Assuming that no MAu was lost throughout the layering process, 
this would suggest that there are 43 ± 9 MAu cores per layered NP (initial number of 
MAu nanoparticles divided by the final number of LbL particles based on NTA). Because 
of the 3D aggregation of the MAu, it is difficult to directly count individual MAu in the 
final LbL nanoparticles by TEM (Figure 1, far right). Assuming the highest possible 
density of packing by the 17 nm MAu in a packed regular lattice to be 0.74, the 
maximum theoretical number of MAu that could fit into the volume of a 200 nm diameter 
spherical NP would be approximately 1200. Because we estimate that there are 
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approximately 43 MAu, rather than 1200, in an LbL NP this finding suggests 
approximately 4% of the occupied volume is MAu.  
The reversal of the ZP demonstrates successful ionic complexation of each 
subsequent layer as the LbL coatings were built. TEM agreed well with the NanoSight 
measurements in that the largest increase in diameter occurred at the DNA layer and that 
the layered particles reached approximately 200 nm in size.  
The inclusion of PEG-conjugated 447 as the last layer could perhaps further 
optimize the system and minimize clearance by the reticulo-endothelial system 41. 
Furthermore, hyaluronic acid could be another polyelectrolyte candidate to help control 
biodistribution 42. 
4.4.4 Nucleic Acid Loading and Layering Efficiency 
 
PEI was demonstrated to be more efficient at binding nucleic acid than the 
degradable and less positively charged polymer 447. On a mass basis, the siRNA had 
higher loading efficiency into the LbL NPs than the DNA did (Figure S4). The packing 
densities for the HD5 formulation by volume for DNA and siRNA were approximately 
3x10-4 and 5x10-2 molecules per nm3, respectively (the mass per particle was calculated 
using the particle concentration determined by NTA). Figures S4 and S5 demonstrate 
that the two washing steps during the layering process are sufficient to ensure removal of 
free polyelectrolyte from solution prior to the addition of subsequent polyelectrolyte 
layers to the particles. Previous work by our group has shown that it is possible to 
lyophilize PBAE/DNA polyplexes in the presence of a cryoprotectant, such as sucrose, 
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resulting in the ability to store the gene delivery formulations long-term (>2 years) 
without compromising transfection efficacy 43. 
Nucleic acid in solution during layering steps that does not electrostatically coat the NP is 
recovered in the supernatant following centrifugation or is removed from the solution due 
to adsorption to the surface of the plasticware used during fabrication.  These 
inefficiencies were calculated during the fabrication of the LbL NPs.  The accumulation 
of nucleic acid content contained in the two supernatants during washing steps is shown 
in Figure S4. Approximately 80% of all nucleic acid was accounted for in the LbL NPs 
and in the supernatants. The remainder of nucleic acid was observed adsorbed to the 
plasticware that was in contact with the nucleic acid solution during layering steps 
(Figure S5). A pipette tip and vial without the LbL solution are shown in Figures S5A-B. 
The LbL solution in the vial without and with YO-PRO®-1 are shown in Figures S5C-D, 
respectively. Figure S5E-F shows the vial and pipette tip that came in contact with the 
LbL solution with YO-PRO®-1 to quantify nucleic acid. 
 Knowing the amount of nucleic acid in the second supernatant washings allows 
the calculation of the amount of free DNA or siRNA in the layered formulations when 
the subsequent polyelectrolyte layer is added. The amount of free DNA and siRNA after 
the second washing was determined to be negligible, less than the error of measurement 
of the dosages listed in Table 1. This finding supports the two washings during the 
layering process are sufficient to ensure a negligible amount of free polyelectrolyte in 




4.4.5 Transfection and Cytotoxicity 
 
4.4.5.1 siRNA-mediated Knockdown 
 
The w/w values in large part determined the time course of the knockdown; as the 
w/w increased for either 160 ng (LD) or 240 ng (HD) dosages, the knockdown increased 
in all cases. A decreased siRNA dosage did not necessarily result in decreased 
knockdown, depending on the w/w. The knockdown of the LD5 and HD5 formulations 
were statistically significantly higher than Lipofectamine® 2000 at 160 ng 2.5:1 by 1.4 
and 1.8 fold, respectively, whereas formulations HD2.5, LD5, and HD5 were statistically 
significantly higher than Lipofectamine® 2000 at 240 ng 0.5:1 (Figure 4) by 5.8, 4.7, 
and 2.3 fold. The trends observed in the qualitative images are in agreement with the 
fluorescence plate reader and the flow cytometer’s assessment of knockdown as well.  
 
4.4.5.2 DNA-mediated Expression 
 
The expression of the co-delivery HD and LD formulations increased with 
increasing dosage and w/w. Generally, the RMA increased as the expression efficacy 
decreased. The most efficacious NP formulation for expression of DNA was MAu-P-D-
447. The biodegradable polymer 447 was demonstrated to be superior to the 
conventionally used nondegradable polymer, PEI, as an outer layer. It was necessary to 
have an outer layer of 447 polymer as the last layer in light of MAu-P-D-P’s results as 
well as the observation that MAu-P-D (0 w/w) was associated with very low transfection 
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(0.12 ± 0.07%).  MAu-P-D’s results suggest that the inner layer of PEI was insufficient 
alone at promoting transcription and translation and was not contributing substantially to 
toxicity. 
 
4.4.6 Cytotoxicity of the Co-delivery HD5 Formulation 18 Hr Post-degradation 
 
The relative metabolic activities of the degraded and freshly prepared, non-
degraded HD5 formulations were similar.  Neither of these conditions showed significant 
cytotoxicity in GBM319 cells. 
 
 
4.4.7 Cellular Uptake 
 
One of the advantages of using gold as the core of the NPs is that it can be tracked 
by imaging. The hybrid LbL particles were able to enter the cells, be tracked by TEM, 
release siRNA into the cytoplasm to achieve knockdown, and release DNA that reaches 
the nucleus for exogenous expression. In contrast to viruses where a multiplicity of 
infection of even 1 can result in transduction, non-viral methods are less efficient and 
therefore require a much higher effective multiplicity of infection to get sufficient 
number of plasmids within the cell for sufficient expression, as just a few particles are 
observed to be within the cell in Figure 8. However, further studies would need to be 




4.5 Conclusions  
We have successfully demonstrated that we can layer siRNA and DNA for co-
delivery on AuNPs using polymers which degrade through different mechanisms. We 
found that the zeta potential reverses upon the addition of each oppositely charged layer 
of polyelectrolytes  and the diameter reaches approximately 200 nm in size. PEI was 
found to be the most efficient polymer for loading nucleic acid, and polymer 447, the 
most effective outer layer polymer for gene delivery. The gene knockdown achieved with 
the HD5 and LD5 formulations was superior to optimized Lipofectamine® 2000 at 
comparable dosages in human brain cancer cells. These formulations also enabled 
exogenous DNA expression and intracellular tracking of the AuNPs by TEM.  These LbL 
formulations are an enabling theranostic technology that can deliver combinations of 
















Figure 1. TEM images of each of the layered stages showing nanoparticle size.  The 
addition of the DNA layer results in initial clustering of multiple gold nanoparticle cores 


























Figure 3. SiRNA-mediated knockdown over time of GFP in human brain cancer cells 
resulting from delivery of MAu/DNA/siRNA LbL particles.  Nanoparticle dosages and 
amount of 447 polymer in the outer layer were varied.  Optimized particles had higher 
knockdown than the optimized formulation of the leading commercially available reagent 






Figure 4. SiRNA-mediated knockdown of MAu/DNA/siRNA LbL particles on day 7 and 






Figure 5. Fluorescence microscope images of the eGFP channel showing GFP 
knockdown following transfection with various MAu/DNA/siRNA LbL nanoparticles; 
the Lipofectamine® 2000 conditions shown are 240 ng 0.5:1 and 160 ng 2.5:1 (200 ms 
eGFP exposure time; magnification of 5x; “scr” refers to scrambled siRNA and “si” 





Figure 6. Fluorescence microscope images showing exogenous dsRed expression 
following transfection of MAu/DNA/siRNA LbL nanoparticles. Lipofectamine® 2000 
was added at a 100 ng dosage 2.5 μL:1 μg dsRed DNA; (200 ms eGFP and 600 ms dsRed 





Figure 7. DNA transfection efficacy and relative metabolic activity of 
MAu/DNA/siRNA LbL nanoparticles. Lipofectamine® 2000 was added at a 100 ng 
(2.5:1) dose and is not statistically different from nanoparticle formulation HD5. 
Lipofectamine® 2000’s expression was statistically significantly greater than all other 










Figure 8. TEM of MAu/DNA/siRNA LbL nanoparticles of formulation HD5 in GBM319 
cells. A and B: show particles that are ~200 nanometers. C: Two left arrows indicate 









Figure S1. Absorbance spectra of citrate-stabilized CAu and 11-MUA-conjugated MAu 
at pH 7.1, similar to the storage conditions. MAu resists aggregation whereas CAu 

















Figure S2. UV-Vis spectra of CAu (left) and MAu (right) solutions in various 
concentrations of NaAc ranging from 0 to ~100 mM. The NaAc concentration after the 

















Figure S3. Fluorescence recovery percentages using YO-PRO®-1, Picogreen, and 






Figure S4. Compartmentalization percentages of nucleic acid. DNA and siRNA content 
of what was ionically complexed during the layering process and in the two supernatants 


























Figure S5. Nucleic acid lost to plasticware surface contact. A-B: Pipette tip and vial 
without contact with the co-delivery LbL formulation and without YO-PRO®-1, 
respectively. C: Vial with LbL formulation without YO-PRO®-1. D: Vial with LbL 
formulation and YO-PRO®-1. E-F: Vial and pipette tip with all of the LbL formulation 




















Figure S6. Optimization of siRNA delivery to human brain cancer cells using 
Lipofectamine® 2000 over time with varying ratios.  Efficacy measured by fluorescence 
on a plate reader for conditions where the relative metabolic activity was greater than 






Figure S7. Optimization of siRNA delivery to human brain cancer cells using 
Lipofectamine® 2000 and polymer 447 on day 7. Knockdown on day 7 and relative 
metabolic activity at 24 hours post transfection using Lipofectamine® 2000 (Lipo X:Y; 






Figure S8. Fluorescence images of the various LbL formulations showing eGFP 





Figure S9. DNA transfection efficacy of dsRed expression and relative metabolic activity 



































Table 1. Nucleic acid dosages and mass ratio of the 447 polymer to DNA (w/w) values 
of the various layered formulations. The w/w values are calculated from the most outer 




Mass Ratio  
[w/w] 
MAu-P-D 980 ± 30 0 
MAu-P-D-P  1050 ± 30 79 
MAu-P-D-447 950 ± 50 44 
MAu-P-D-P-D-447 2400 ± 100 17 
MAu-P-D-447-D-447  510 ± 20 82 
MAu-P-D-SS37-D-447 450 ± 40 92 



















Table S1. Nucleic acid dosages and weight/weight (w/w) values of the various layered 
formulations of polymers 447 for DNA and siRNA. 
Formulation DNA  
[ng] 
447/DNA [w/w] siRNA  
[ng] 
447/siRNA [w/w] 
LD1.25 200 ± 20 21 160 ± 9 26 
HD1.25 300 ± 40 14 240 ± 10 17 
LD2.5 200 ± 20 42 160 ± 9 52 
HD2.5 300 ± 40 28 240 ± 10 35 
LD5 200 ± 20 83 160 ± 9 104 
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5 Chapter 5: Inorganic/Polymeric Layer-by-Layer 




Gene therapy is capable of curing or treating many genetic disorders and cancer 1. 
Polymeric gene delivery techniques have advantages over viral methods in that they are 
chemically customizable, are able to be manufactured on a large scale, are associated 
with far less insertional mutagenesis, and are less immunogenic. However, the balance 
between safety and efficacy remains elusive, as there are yet any U.S. FDA approved 
viral or non-viral gene therapies available.  
Delivering DNA in conjunction with biocompatible gold nanoparticles (AuNP)s 
enables a therapeutic function (gene/thermotherapy) as well as a diagnostic (imaging). 
AuNPs are effective clinical X-ray contrast agents with extended imaging times and 
sharper contrast than traditional iodine-based agents 2. AuNPs are also able to be imaged 
via photoacoustics 3. Additionally, photothermal therapy, in which AuNPs are excited by 
incident electromagnetic radiation (at its surface plasmon resonance wavelength typically 
in the near-infrared region as it is transparent to tissue on the order of centimeters), has 
been shown to effectively thermally ablate tumors in mammalian in vivo models 4. 
AuNPs are also attractive due to their monodispersity 5, their ability to be highly charged 




for layer-by-layer (LbL) complexation processes, their ability to be easily chemically 
modified via thiol groups 6, and their optical properties.   
 LbL assembly involves the sequential addition of oppositely charged 
polyelectrolytes onto a given substrate. DNA loading can be modified by the number and 
the order of the DNA layers 7. If DNA layers were able to be transcribed and translated at 
different time points, it would improve temporal control over the cellular 
microenvironment. Stem cell differentiation is one type of potential application that could 
benefit from such control over expression time profiles, as exposure to growth factors at 
different time points can heavily influence differentiation pathways 8,9. As a proof of 
principle, this work demonstrates the ability to control the expression time profiles of two 
proteins using a single theranostic-enabling AuNP LbL platform.  
 
5.2 Materials and Methods 
5.2.1 Gold Nanoparticle Synthesis and Characterization 
 
The AuNPs used in this study were synthesized via a modified Frens method 5 
and previously reported 10. Briefly, a 0.01% tetrachloroauric acid trihydrate, HAuCl4 
(Fisher Scientific), in ultra pure distilled water was vigorously boiling when a 1% sodium 
citrate tribasic dihydrate (Sigma Aldrich) solution (in water) was injected to reduce the 
gold ions.  
 
 
5.2.2 Gold Nanoparticle 11-MUA Stabilization 
 
To maintain monodispersity and create a stably charged anionic coating on the 
AuNPs, 11-mercaptoundecanoic acid (MUA) was conjugated to the AuNPs via a thiol 
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bond as previously reported and was previously shown to be superior for ionic 
complexation LbL processes compared to citrate-stabilized AuNPs 10. The 11-MUA at 1 
mM in ethanol was added to the citrate stabilized AuNPs and allowed to thiolate for 48 
hours. The solution was then washed twice in ethanol and re-solvated in a 0.45% solution 
of sodium citrate. The resulting conjugated AuNPs were then diluted to 0.31 nM in 
preparation for the layering process. 
 
5.2.3 Polymer Synthesis and Characterization 
 
To synthesize the hydrolytically degradable cationic poly(β-amino ester) (PBAE) 
polyelectrolyte layer, diacrylate (1,4-Butanediol diacrylate) and amine small molecules 
(4-amino-1-butanol) were reacted neat in a 1.2:1 molar ratio 11and were allowed to react 
for 24 hours (>100 RPMs) before being end-capped for 1 hour at 1000 RPM via 1-(3-
aminopropyl)-4-methylpiperazine in anhydrous tetrahydrofuran (THF), resulting in 
poly(1,4-butanediol diacrylate-co-4-amino-1-butanol). The cationic PBAE polymer is 
referred to as B4-S4-E7 or 447 (Figure S1). Polymer 447 was then ether-purified to 
remove any unreacted monomers and then solvated to 100 mg/mL in anhydrous dimethyl 
sulfoxide (DMSO) and was stored at -20°C until use. We have previously reported NMR 
spectra on 447 [1]. 
The molecular weight was quantified using gel permeation chromatography 
(Waters®, Breeze 2 software). The solvent constituted 94% THF, 5% DMSO, 1% 
piperidine and a trace amount of butylated hydroxytoluene at a flow rate of 1 mL min-1.  
 




The LbL process is shown in Scheme 1. 80 μL of 25 kDa branched 
polyethyleneimine (PEI) was added to 112 μL of 0.31 nM (1.9x1011 particles mL-1) 
aqueous AuNPs which had been MUA-conjugated. The AuNP-PEI solution was shaken 
at room temperature for 30 minutes at 500 RPM, and then washed twice at 4°C via 
centrifugation for 10 minutes at 10 krcf. The supernatant was replaced with 150 mM 
sodium acetate (NaAc) up to 192 μL for the first wash, and then up to 112 μL for the 
second wash. Subsequent layers were deposited by adding 80 μL of polyelectrolyte 
suspended in 150 mM NaAc, followed by the same washing procedure. PEI was added at 
10 mg mL-1 (Layers 1, 3, 5), dsRed-Max-N1 (dsRed; Addgene) plasmid DNA (pDNA) at 
0.5 mg mL-1 (Layer 2), poly(acrylic acid) (PAA; Mw ~1800 Da; Sigma Aldrich) at 0.5 mg 
mL-1 (Layer 4), enhanced Green Fluorescent Protein (eGFP-N1, referred to as eGFP; 
Clontech) pDNA at 0.5 mg mL-1 (Layer 6), and PBAE 447 at 2.5 mg mL-1 (Layer 7). To 
reduce cell toxicity 25 mM NaAc was used instead of 150 mM NaAc for the final wash 
of the eGFP pDNA layer. In addition, PBAE 447 was solvated in 25 mM NaAc and was 
not washed as we have previously found excess 447 is necessary for transfection 10.  
 The rationale behind having 3 polymer layers between the dsRed and eGFP 
pDNA layers was to space the layers such that the outer eGFP layer would be transcribed 
and translated first, followed by the expression of the more inner dsRed layer at a later 
point in time. 
 
5.2.5 Particle Diameter and Zeta Potential 
 
Nanoparticle tracking analysis (NTA) was performed with a NanoSight NS500 at 
each of the 7 layering stages (n=2). Particles were diluted up to a total of 500 uL in 150 
210 
 
mM NaAc and mixed thoroughly immediately prior to loading into the NanoSight. 
Transmission electron microscopy (TEM) was accomplished on the complete LbL 
formulation to confirm the diameter ascertained via NTA (n=3). ImageJ (NIH) was also 
used to quantify diameters of the TEM images based on the area of the particles. 
Dynamic light scattering (DLS) analysis was performed with a Zetasizer 
(Malvern) at each of the 7 layers after the washing steps (except for the last layer) to 
measure the zeta potential (n=2 per layer). Particles were diluted up to a total of 700 uL 
in UltraPure™ Distilled Water (Invitrogen). 
 
5.2.6 Nucleic Acid Loading 
 
Based on our previously reported decomplexation process 10, the nucleic acid 
content was quantified via a calibration curve; A fluorescence dye at 10 µM (YO-PRO®-
1) at a high salt (650 mM) and heparin (300 µg/mL) concentration was used to quantify 
the decomplexed nucleic acid content using a fluorescence plate reader (Synergy2; 
485/528 nm excitation/emission). Previously reported data shows that the salt and heparin 
concentration used was sufficient to measure the nucleic acid content present in the 
layered formulation [2]. The nucleic acid content was assessed after the dsRed layer and 
after both the dsRed and eGFP layers were complexed. The eGFP content was quantified 
via simple arithmetic by subtracting the total nucleic acid content from the dsRed content. 
The uncomplexed nucleic acid content was also assessed in the supernatants of the 
washing steps just after the dsRed and eGFP layers as well. The efficiency of layering 
was calculated by multiplying 100 by the fraction of nucleic acid retained in the LbL 




5.2.7 Cell Culture and Transfection 
 
Human glioblastoma cells (GB319) cultured in T-75 flasks were cultured at 37°C 
and 5% C02 atmosphere using DMEM:F12 (1:1), 1x antibiotic-antimycotic and 10% fetal 
bovine serum (FBS). The cells were seeded at 10,000 cells/well in 96-well tissue culture 
treated polystyrene plates. Transfection was accomplished by diluting the 192 µL of the 
final LbL formulation up to 256 uL using 25 mM NaAc. From the diluted 256 µL, 20 µL 
was delivered per well and allowed to incubate with the seeded cells in the 96-well plates 
for 2 hours at 37°C before the media was replaced with complete media. The full layered 
nanoparticles were incubated using 10 and 50% serum by volume for the 2 hour time 
period to assess any differences, as the 50% serum concentration more closely resembles 
in vivo conditions. 
As a positive control, Lipofectamine® 2000 (Lipo2k) was also incubated with the 
cells in like manner. Lipo2k was mixed with dsRed and eGFP pDNA using ratios of 
0.5:1, 1.5:1, 2.5:1, and 3.5:1 (Lipo2k µL: pDNA µg) at the same dsRed:eGFP pDNA 
ratio and dosages as the LbL formulation. Total dosages of dsRed:eGFP pDNA of 100 
and 200 ng were also assessed at the same Lipo2k:pDNA (µL:µg; n=4) ratios. 
 
5.2.8 Expression and Relative Metabolic Activity 
 
Fluorescence microscopy images were obtained with a Carl Zeiss fluorescence 
microscope on days 2, 5, 9, 14, and 21 post-transfection (5x magnification). The eGFP 
and dsRed channel exposure times were 300 and 600 ms, respectively. 
Flow cytometry was performed with a BD AccuriTM C6 flow cytometer on days 2, 
5, 9, 14, and 21 post-transfection as well; a HyperCyt sampler was used to automate data 
collection. Cells were detached via incubation at 37°C with trypsin-
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ethylenediaminetetraacetic acid (0.05%) for five minutes, followed by immediate 
quenching with 2% FBS in phosphate buffered saline (PBS). FSC-H vs. SSC-H was used 
to isolate the singlet population; expression of eGFP and dsRed were analyzed using 
FL1-H vs. FL3-H (FloJo). 
An MTS-based Promega assay CellTiter 96® was used to determine the relative 
metabolic activity of transfected cells as compared to untreated controls at 24 hours for 





Figure 2: left (n=2): A one-way ANOVA with a Bonferroni post-hoc analysis was 
performed; right: n=2.  Figure 3: 10% serum: n=12; 50% serum: n=4. Figure S2, S4, and 
S5 were n≥4, ≥4, =4, respectively. When comparing the positive control (Figure 3 vs 
Figure S5) to the LbL formulation at 2 days post-transfection, a two-tailed Student’s t-
test was used. All error bars in figures are standard errors of the mean (SEM). Other error 




5.3.1 Gold Nanoparticle Characterization and 11-MUA Stabilization 
 
TEM analysis confirmed that the stabilized AuNPs were monodisperse as well as 
uniform in size at 17 ± 2(StDev) nm 10. SPR results showed a red-shift of the wavelength 
from 520 nm for solely citrate stabilized AuNPs to 526 nm for 11-MUA conjugated 





5.3.2 Polymer Characterization 
 
The number-average (Mn) and weight-average (Mw) molecular weights of PBAE 
447 were 11.9 kDa and 35.5 kDa, respectively, with a polydispersity index of 2.98. 
  
 
5.3.3 Particle Diameter and Zeta Potential 
 
The TEM of the complete LbL formulations with all 7 layers is shown in Figure 
1. The arithmetic and geometric means of cores per aggregate were 4.3 and 2.7, 
respectively. According to the area of the particles assessed by ImageJ, the dry core 
diameters were 104 ± 0.8 nm (StDev) in diameter and the larger dry aggregate diameters 
were 210 ± 10 nm (StDev) between the 3 images. The diameter according to TEM 
corroborated the hydrodynamic diameter findings according to NTA, which was 
approximately 300 nm for all 7 layers (Figure 2; left).  
According to NTA, the hydrodynamic radius increased with each layer out to 
layer 6. There was no statistical difference in diameter between layers 5-7. The largest 
increase in diameter occurred at the first DNA layer similarly to what was observed 
previously 10.  The zeta potential reversed at each of the 7 stages (Figure 2; right). 
 
 
5.3.4 Nucleic Acid Loading 
 
The inner (dsRed) and outer (eGFP) pDNA layers contained 208 ± 9 and 120 ± 10 
ng/well, respectively, with a total of 328 ± 9 ng of pDNA. The layering efficiency of the 
inner and outer layers were 6.6 ± 0.6 and 4 ± 1%. The nucleic acid content in the 
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supernatant of the first and second washings accounted for 79 ± 2% and 4 ± 1% of the 
dsRed pDNA used for layering, respectively; for eGFP, 77 ± 3% and 4 ± 2%, 
respectively. The mass ratio of polymer 447 to pDNA was 48. 
5.3.5 Expression and Relative Metabolic Activity 
 
In regards to the 10% serum condition (Figure 3; left), the transfection levels of 
the outer (eGFP) pDNA layer was 22 ± 2% (Figure 3; top) and remained similar out to 
day 9 and then decreased to approximately 7% thereafter. In contrast, the inner (dsRed) 
pDNA layer (Figure 3; top) had low expression initially and steadily increased to a 
maximum at 16 ± 6% on day 9. The expression thereafter was similar to the outer eGFP 
levels near 7%. Figure S3 shows the dot plots of the dsRed and eGFP fluorescence 
channels (FloJo) for the 10% serum condition on days 2, 5, 9, 14, and 21. Qualitatively, it 
can be seen that the eGFP and dsRed expression maxima are on days 2 and 9, 
respectively. The fluorescence microscope images showing the 10% serum condition in 
Figure 4 also qualitatively corroborate these findings. 
 In regards to the 50% serum condition (Figure 3; right) the outer (eGFP) layer 
was higher at 12 ± 1% initially and steadily decreased to near 0% on day 14 (Figure 3; 
top). The inner (dsRed) layer was similar to the 10% serum condition, except there was a 
peak on day 5 rather than 14 and the transfection efficacy was lower, with a maximum at 
6.5 ± 0.8% (Figure 3; top).  
 Figure 3 (bottom) shows the normalized transfection levels for the 10% serum 
condition (bottom left) and the 50% serum condition (bottom right) which accentuates the 
time differences in the maximum expression levels; the outer layers for the 10 and 50% 
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serum conditions were highest on day 2 whereas the inner layers for the 10 and 50% 
serum conditions peaked on days 9 and 5, respectively. 
 The relative metabolic activities (untreated = 100%) of the 7 layers incubated in 
10% and 50% serum at 24 hours post-transfection were 93 ± 4% and 88 ± 2%, 
respectively, as shown in Figure S4.   
 Generally speaking, as the dosage increased for the Lipo2k formulations both the 
transfection efficacies of eGFP and dsRed increased and the relative metabolic activities 
decreased (Figure S5). At comparable dosages to the full 7 layers (eGFP: 120 ± 10 ng; 
dsRed: 208 ± 9 ng; see Nucleic acid loading section), the 3.5:1, 2.5:1, 1.5:1, and 0.5:1 
(Lipo2k µL: µg pDNA) had relative metabolic activities of 30 ± 2%, 53 ± 1%, 79 ± 1%, 
and 96 ± 1%, respectively. The transfection levels for the same Lipo2k:pDNA ratios for 
eGFP and dsRed were 21 ± 5%, 22 ± 4%, 27 ± 4%, 22 ± 1% and 28 ± 2%, 25 ± 2%, 32 ± 
3%, 13 ± 1%, respectively. The highest transfection level achieved with the positive 
control at the same dosage as the LbL formulation was thus with the 1.5:1 formulation 
which was similar statistically to the full 7 layers in 10% serum for both eGFP (p-value = 
0.53) and dsRed (p-value = 0.14) (Figure S5).  
 While holding the eGFP and dsRed mass ratio for the Lipo2k similar to the full 7 
layers (0.34:0.66 ng), the highest transfection level was found to be using a pDNA 
dosage of 200 ng and a Lipo2k µL: µg pDNA ratio of 2.5:1. The eGFP and dsRed 
transfection levels were 28 ± 1% and 32 ± 3% which were statistically similar to the full 
7 layers in 10% serum as well for both eGFP (p-value = 0.38) and dsRed (p-value = 
0.13). However, the optimized Lipo2k formulation (200 ng; 2.5:1) also had a much lower 




As expected the hydrodynamic radius of the LbL formulation was slightly larger 
than the dry diameter and the reversal of the zeta potential at each successive layer after 
multiple washings indicated successful ionic complexation of each subsequent layer.  
 The layering efficiencies of the LbL formulation of interest were comparable to 
our previously reported layering efficiencies (2 layers of nucleic acid with polymers SS37 
or 447 as a middle layer) 10. Future endeavors to minimize formulation costs by re-using 
the nucleic acid supernatants would be potentially worthwhile. The supernatants’ 
concentration would decrease with each layering process; the supernatants could be 
potentially lyophilized and re-constituted at the original concentration. Post-
lyophilization, the NaAc could be removed with multiple washings. However, possible 
uncomplexed polyelectrolytes may be present in the supernatant and would need to be 
fully characterized. For quality control and reproducibility purposes, re-using the 
supernatant was not investigated for the purposes of this study 10. 
Because the backbones of the plasmids are similar, any differences in the 
expression time profiles could possibly be contributed to the inner plasmid being 
secluded from transcription and translation for a longer time period within the non-
degradable inner polymer layers of PEI and PAA. Despite there being approximately 
75% more dsRed pDNA than eGFP, the dsRed was secluded sufficiently that there was 
still a separation of the expression in time. 
Interestingly, the maximum expression efficacy for the 10% serum condition for 
the outer and inner layers were on days 2 and 9, respectively, whereas the 50% serum 
resulted in the inner layer to be maximally expressed on day 5; little toxicity was 
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observed in either case. In the 50% serum condition, it is possible that the 
decomplexation process may be enhanced by the presence of more serum proteins. We 
have found that not all uptake mechanisms (i.e., clathrin, caveolae, and 
macropinocytosis) are equally effective for the eventual transcription and translation of 
exogenous plasmids 12. It is possible that the LbL nanoparticles in the presence of more 
serum proteins may be uptaken by the cell through a different mechanism, which could in 
part explain the disparity between the expression profiles between the 10 and 50% serum 
conditions. Further studies would be required to elucidate the mechanism. 
 At the same pDNA dosages, the LbL formulation was comparable in both the 
dsRed and eGFP expression in comparison to the optimized Lipo2k formulation (1.5:1; 
Lipo2k µL: pDNA µg) on day 2. 
 
5.5 Conclusions 
 Using an LbL approach, we were able to successfully develop a theranostic-
enabling platform technology which is capable of loading two different types of plasmids 
separated by a polymer barrier: PEI-PAA-PEI. The most inner layer is transcribed and 
translated at a later point in time than the most outer plasmid layer. Such control over the 
timing of expression is of great interest to the scientific community for controlling the 








































Figure 3. Transfection efficacies (top) and normalized transfection efficacies (bottom) in 
time for the outer (eGFP) and inner (dsRed) pDNA layers using 10% (left) and 50% 






Figure 4. Fluorescence microscopy images of the GB319 cells in 10% serum transfected 


































Figure S2. Layered nucleic acid content of the inner (dsRed) and outer (eGFP) pDNA 
layers; nucleic acid content in the supernatant of the first and second washings (SN1 and 






Figure S3. The flow cytometry dot plots of the eGFP and dsRed channels in time of the 
10% serum condition which qualitatively shows the expression maxima of the outer 








Figure S4. The relative metabolic activities of GB319 cells incubated with the full 7 












Figure S5. dsRed and eGFP expression efficacies of Lipo2k dosages at 100, 200, or 328 
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6 Chapter 6: Cellular and Nuclear Uptake Rate 
Evaluation of Exogenous DNA via Flow Cytometry7  
6.1 Introduction 
Gene therapy has the potential to treat and cure inheritable diseases such as cystic 
fibrosis [1], Duchenne muscular dystrophy [4,10], and hemophilia [15]. In general, 
viruses are highly efficient in delivering nucleic acid with a multiplicity of infection as 
low as one, but are immunogenic and can cause insertional mutagenesis. Non-viral 
methods, although generally less efficient at delivering nucleic acids, are easier to scale-
up from a manufacturing standpoint, are easily chemically modified for optimization of 
function and toxicity, and have a low host immune response, comparatively.   
Although high-throughput methods have enabled the screening of vast numbers of 
monomer combinations and polymer types for non-viral gene delivery, understanding the 
polymeric structure-function relationships would enable a more rational engineering 
approach for designing new delivery vectors. Quantifying plasmid cellular and nuclear 
uptake rate differences elucidates salient functional differences between polymer 
structures and reveals bottlenecks associated with specific vectors. PCR is a well-
established method to quantify the number of plasmids within the cell or nucleus [7,8], 
however, lysing cells and nuclei, isolating and purifying DNA, and then subsequently 
running PCR on the samples is a time-consuming process compared to flow cytometry 
analyses. 




This work lays forth the foundation as a proof of principle to quantify the number 
of plasmids within the cell and associated or internalized within isolated nuclei based on 
flow cytometry.  Through the use of mathematical fitting to a system of differential 
equations, this method also allows the quantitative determination of cellular and nuclear 
uptake rate constants. We synthesized an already well-established vector, poly(β-amino 
ester) B4-S4-E7 or 447 [3,5] to transfect human primary glioblastoma multiforme 
(GBM319) cells and subsequently used a set of first order mass-action differential 
equations to quantify the rate constants associated with cellular entry, nuclear envelope 
association, and nuclear internalization. This more efficient flow cytometry method to 
quantify rate constants can be used to methodically elucidate how polymer structure 
determines intracellular gene delivery function.  
 
6.2 Materials and Methods 
6.2.1 Polymer Synthesis 
Polymer B4-S4-E7 (447) was synthesized via a Michael addition reaction 
(Scheme S1) by adding 4-amino-1-butanol (S4) neat to 1,4-butanediol diacrylate (B4) in 
a 1.2:1 B4:S4 monomeric ratio, immediately vortexed, and placed in a 90ºC oven for 24 
hours in the dark using a stir bar greater than 100 RPM, resulting in a B4-S4 acrylate-
terminated base polymer [3]. The B4-S4 polymer was then solvated to 166.7 mg/mL 
using anhydrous tetrahydrofuran (THF) and subsequently endcapped using a 0.5 M 
solution of 1-(3-aminopropyl)-4-methylpiperazine, or E7, solvated in anhydrous THF for 
1 hour at a final concentration of 100 mg/mL (Scheme S1). We have previously reported 
NMR data for polymer 447 [3,12]. The polymer was then precipitated using anhydrous 
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ethyl ether using two centrifugation washing steps at 4000 RPM for approximately 4 
minutes. After decanting the ether the second time, the polymer was placed in a vacuum 
chamber for at least 24 hours in the dark. The polymer was then stored neat at -20ºC until 
the fractionation process. 
 
6.2.2 Polymer Fractionation 
Gel permeation chromatography (GPC) (Waters Corp.) was used to obtain a 
similar number- and weight-average molecular weight (Mn and Mw, respectively) of 
polymer 447 used previously which had high transfection efficacy in GBM319 cells [3]. 
The GPC setup included an autosampler, a refractive index detector, a Styragel column 
(WAT025861), and an autofractionator (Waters Corporation). The GPC diluent flowed at 
1 mL/min and constituted 94% THF, 5% dimethyl sulfoxide (DMSO), 1% piperidine and 
a few 100 mg of butylated hydroxytoluene to inhibit free radical formation. The 39.7-
41.7 minute time fraction was collected and again precipitated and vacuum dried as 
previously described. The polymer was then solvated in anhydrous DMSO to 100 mg/mL 
and frozen in 20 μL aliquots at -20ºC until use. Each aliquot used for further study 
underwent one freeze-thaw cycle only. Post-fractionation, the Mn and Mw was quantitated 
via GPC against polystyrene standards. 
 
6.2.3 Cy3-plasmid DNA conjugation 
A Mirus Label IT® Tracker™ Cy™3 Kit was used to conjugate Cy3 to enhanced 
Green Fluorescent Protein (eGFP-N1; 4733 base pairs (bp)) plasmids. In brief, 75 μg 
plasmid DNA (pDNA; 1 μg/μL), 60 μL of Mirus Buffer A and 415 μL of ultrapure 
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distilled water (DNase and RNase free) was added to 50 μL of the Cy3 dye reagent and 
incubated for at least 3 hours; at each hour the vials were briefly centrifuged to ensure all 
reagents were homogeneously reacting. Subsequently, 60 μL of 3 M sodium acetate 
(NaAc) and 1880 μL of ice cold 190 proof ethanol (EtOH) was added and the solution 
was kept at -20 ºC for at least 30 additional minutes. After which, the sample was 
centrifuged at 4 oC for 15 minutes at 13 krcf, the supernatant was discarded and the pellet 
was then resuspended in 2 mL of 70% EtOH at room temperature. The sample was again 
centrifuged and the supernatant was discarded and the pellet was resuspended in 300 μg 
(1 mg/mL) of Cy3-unconjugated eGFP pDNA (1 μg:4 μg conjugated:unconjugated).  
Prior to adding the unconjugated pDNA the cap was left open and covered with 
aluminum to protect from light to allow the EtOH to evaporate for approximately 10 
minutes. The sample was then characterized via a NanoDrop 2000 Spectrophotometer 
(Thermo Scientific). The absorbance of the DNA was corrected for Cy3-spectral overlap 
using the following equation (obtained from Mirus): 
 𝐴𝑏𝑎𝑠𝑒 = 𝐴260 𝑛𝑚 −  0.08𝐴550 𝑛𝑚 




(εbase = 6,600 M−1cm−1)




The eGFP-N1 plasmid contained a 77 bp Simian virus-40 (SV40) DNA-targeted 
sequence (DTS): 5’-AACCAGCTGT GGAATGTGTG TCAGTTAGGG 
TGTGGAAAGT CCCCAGGCTC CCCAGCAGGC AGAAGTATGC AAAGCAT-3’. 
The sequence binds to a transcription factor which then undergoes a morphological 
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change, revealing its nuclear localization signal (NLS) [17]. The DNA and its indirectly 
associated NLS can then be transported into the nucleus. 
 
6.2.4 Cy3 pH-sensitivity 
Various uptake pathways such as macropinocytosis, and caveolae- and clathrin-
mediated endocytosis lead to the lysosomal degradation pathway, referred to as the 
proton sponge effect [6]. The cargo must have the ability to buffer the endosome to 
escape without degradation [6]. Because the pH of the Cy3-conjugated pDNA during the 
delivery process may range anywhere from approximately 5 to 7.4, the pH-sensitivity of 
Cy3 was assessed using a fluorescence plate reader (excitation and emission of 550 and 
570 nm, respectively; Synergy2, Gen5) by using equal molar concentrations of the Cy3-
eGFP pDNA in 150 mM sodium acetate (pH 5.2) and 150 mM phosphate buffered saline 
(PBS; pH 7.4) in triplicate. A Student’s t-test was used to assess significance (α = 0.05). 
 
6.2.5 Cell Culturing 
The GBM319 cells used for transfection were derived from human primary brain 
cancer and were cultured in a 5% CO2 atmosphere at 37ºC, using DMEM:Ham’s F12 
(1:1) (Invitrogen) and was supplemented with 10% fetal bovine serum and 1x antibiotic-
antimycotic (Invitrogen).  
 
6.2.6 Polyplex Formation and Cell Incubation 
Polymer 447 at a working concentration of 100 mg/mL in anhydrous DMSO was 
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diluted to 1.35 mg/mL which was used for preparing the 30 weight/weight (w/w; mass of 
polymer to mass of DNA) in 25 mM NaAc and mixed in a 1:1 v/v ratio with 45 μg/mL of 
plasmid DNA which was diluted from 1 mg/mL (originally in water) using 25 mM NaAc. 
Uptake studies utilized Cy3-conjugated pDNA, whereas qPCR and expression studies 
used Cy3-unconjugated pDNA, as the presence of Cy3 within such close proximity to the 
pDNA would inhibit primer annealing or the transcription and translation processes. 
Polyplex diameter and concentration were assessed in PBS via nanoparticle tracking 
analysis in triplicate via a NanoSight NS500 (Malvern Instruments, Ltd.). 24-well plates 
(2.0 μm2) were seeded with 93,750 GBM319 cells (625 μL) 24 hours prior to 
transfection. 125 μL (2813 ng of pDNA) was delivered to each well. Separate 24-well 
plates for each time point were used to ensure that the cells containing Cy3-pDNA at 
later time points did not have more exposure to light, ensuring photobleaching was not a 
confounding factor. 
 
6.2.7 Nuclei Isolation 
Nuclei isolation was accomplished using an isolation kit (Nuc101; Sigma 
Aldrich). At each time point of interest after transfection the cells were placed on ice and 
1 mL of an ice cold solution of heparin sodium salt from porcine intestinal mucosa 
(Sigma-Aldrich H3393) at 50 μg/mL in PBS (refer to the Washing Extracellular and 
Extranuclear pDNA section below) was quickly used to wash the cells twice with gentle 
trituration. Subsequently, 150 μL of ice cold lysis buffer (Nuc101; Sigma Aldrich) was 
placed on the cells and the cells were immediately scraped thoroughly and transferred to 
a 15 mL conical tube on ice. The cells were then homogenized using a round-bottom 
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glass tube while on ice and were by volume approximately 1/3 froth at completion and 
sat on ice for an additional 5 minutes. The samples were then transferred to 0.5 mL 
microcentrifuge tubes and centrifuged at 4ºC for 5 minutes at 500 rcf. The supernatant 
was carefully aspirated as to not agitate the pellet. 30 μL of ice cold lysis buffer was used 
to resuspend the pellet, followed by vortexing for 1-2 seconds. 120 μL of ice cold lysis 
buffer was then added to the samples and vortexed for a fraction of a second. The 
samples were placed on ice for another 5 minutes. The centrifugation and resuspension 
were completed twice and the samples were filtered into a new 0.5 mL microcentrifuge 
tube with a 40 μm nylon filter. The time points were divided into two tubes. 350 μL of 
ice cold 50 μg/mL heparin was added to half of the divided tubes and vortexed briefly. 
Samples were then centrifuged for 6 minutes at 600 rcf at 4ºC, the tubes were carefully 
aspirated, and the pellets were resuspended in 30% glycerol (3:7 v:v glycerol: ultrapure 
distilled water), and frozen at -80 ºC until further use for either flow cytometry analysis 
or genomic DNA (gDNA)/pDNA isolation and purification. 
The nuclei isolation efficiency was calculated via a hemacytometer by dividing 
the number of cells used for the nuclei isolation process by the number of 2-(4-
amidinophenyl)-1H-indole-6-carboxamidine (DAPI)-stained nuclei isolated and 
multiplying by 100 (n=3).  
 
6.2.8 Nuclei Purity from Cytoplasm 
To confirm nuclei purity, stably expressing eGFP(+) GBM319 cells [5] 
underwent the same culturing, transfection, and nuclear isolation process and were 
assessed via flow cytometry (n=2). The singlet nuclei population was identified using 
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FSC-H and SSC-H. The percent of eGFP(+) cells and nuclei were quantified by 
multiplying the ratio of the number of eGFP(+) cells to singlets by 100. Furthermore, 
DAPI stained nuclei with a combined brightfield image for qualitative purposes were 
taken to show the purity of the nuclei. 
 
6.2.9 Washing Extracellular and Extranuclear Plasmid DNA 
To ensure the heparin washing was sufficient to remove uninternalized plasmid 
pDNA from the cells (n=3) and nuclei (n≥2), the 24-well plates were placed at 4 ºC to 
inhibit ATP-dependent uptake mechanisms. Any fluorescence above the untreated groups 
associated with the cells or nuclei was thus attributed to unwashed plasmids on the 
phospholipid bilayer membrane of the cells or nuclei.  
To assess how well cells were washed, polymer 447-pDNA polyplexes were 
incubated with the cells for 1 hour using 30 w/w (and 60 w/w which would likely be 
more difficult to wash). After the incubation period, the cells were either not washed or 
quickly washed with gentle trituration using heparin twice (1 mL; 50 μg/mL of heparin in 
PBS) and subsequently washed with 1 mL of PBS. Heparin is a highly anionic 
macromolecule used to destabilize the uninternalized polyplexes which frees the pDNA, 
causing the pDNA to be easily removed. The washed cells were immediately trypsinized 
after the PBS wash, quenched using 2% fetal bovine serum (FBS) in PBS, and then used 
for flow cytometry.  
The nuclei were also challenged similarly at 4 ºC for 1 hour. Similar to the nuclei 
isolation process, one heparin wash was used (350 μL at 50 μg/mL) which was followed 
by centrifugation (600 rcf for 6 minutes). Furthermore, to more closely assimilate the 
237 
 
intracellular condition, rather than polyplexes, naked pDNA was used to challenge the 
nuclei as the plasmid in contact with the nuclei would likely have little or even no 
polymer ionically complexed at that stage due to degradation and dissociation from 
charged intracellular molecules (Varga and et al., used an unpackaging rate of 1x109 min-
1 in their model) [18–20]. The amount of plasmids per nuclei (1x105 plasmids/nuclei) 
used to assess the thoroughness of the heparin washing procedure was chosen to be 
exceedingly higher than previously reported values for plasmids found in the nucleus 
using non-viral methods [7,8].  
For cellular and nuclear uptake studies all samples were washed at either the time 
point of interest up to two hours (0 (aspirated nearly simultaneously), 1, and 2 hours) or 
at two hours for all time points thereafter (4, 7, 18, and 24 hours). Cells were washed 
before nuclei isolation at the time point of interest. Unwashed and washed nuclei were 
then used for flow cytometry to assess the amount of plasmids either tightly associated 
(extranuclear (Pne) + intranuclear (Pni)) or internal to the nuclei (Pni), respectively. The 
word “tightly” is used as pDNA which is loosely associated with nuclei would likely not 
retain association with the nuclei throughout the nuclei isolation process.  
 
6.2.10 Cellular and Nuclear Uptake 
Cellular and nuclear uptake were assessed in triplicate at 0, 1, 2, 4, 7, 18, and 24 
hours. To prepare the cells (n=3) for flow cytometry, the cells were washed as previously 
discussed (refer to the section entitled Washing Extracellular and Extranuclear pDNA). 
After the PBS washing step, 150 μL of warm 0.05% Trypsin-ethylenediaminetetraaceteic 
acid (EDTA) was added. After incubating at 37ºC for approximately 5 minutes, 850 μL 
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of 2% Trypsin in PBS was added to each well to quench the reaction. Each well was 
transferred to a 1.5 mL microcentrifuge tube and placed on ice before analysis. To 
prepare the nuclei (n=3) for flow cytometry, nuclei were taken from the -80 ºC freezer, 
thawed and diluted to approximately 150 μL using 2% FBS in PBS. Flow cytometry 
using a BD Accuri™ C6 Cytometer at a flow rate of 66 μL/min (note FL2-A = function 
of flow rate) was then used to identify the singlet populations and to assess the presence 
and intensity of Cy3. All gating and analysis was accomplished using FloJo. The singlet 
populations of nuclei and cells were identified using FSC-H and SSC-H; the amount of 
Cy3 per cell or nucleus was quantified using the geometric mean of FL2-A of the singlet 
population and normalized to an untreated group.  
Of note, we would like to emphasize that what is being directly measured by the 
flow cytometer are fluorescences of the cell (plasmids within the cytoplasm (Pcyto + Pne + 
Pni), the unwashed nuclei (Pne+Pni), and washed nuclei (Pni)). By simple arithmetic, the 
fluorescences associated with each compartment could be quantified. 
 
6.2.11 Plasmid and Genomic DNA Isolation and Purification 
The cells at their respective time points after transfection with unconjugated 
pDNA were prepared in triplicate for gDNA/pDNA isolation and purification by washing 
with heparin as previously described, trypsinizing, quenching with 2% FBS, and then 
doing a centrifugation washing step in a 1.5 mL tube to remove the trypsin. After the 
supernatant was trypsinized the samples were resuspended in 30 µL of PBS. The samples 
(7 time points in triplicate and the untreated group) were then incubated in a lysis buffer 
which constituted 0.5% sodium dodecyl sulfate (SDS), 100 μg/ml proteinase K, and 20 
μg/ml DNase-free RNase [8]. The samples were placed in an oven at 50ºC while shaking 
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at 200 rpm for 4 hours. Tris-EDTA-saturated phenol was used to do a 1x volume 
extraction where an appropriate amount of phenol was added and the emulsion was 
vortexed briefly. To separate the layers, the samples were placed in a quickspin 
apparatus. The aqueous top layer was placed in a new vial and a 1x volume extraction 
with 25:24:1 phenol/chloroform/isoamyl alcohol was completed twice. The same 
procedure from the previous extraction was followed and the aqueous top layer was 
collected.  The samples were set on ice and washed with ice-cold water-saturated ether 
twice. Water-saturated ether was prepared by mixing ultrapure distilled, RNase-/DNase-
free water and ether in a 1:1 volume ratio. After the water-saturated ether was added, the 
samples were briefly vortexed and spun to separate the layers. The top ether layer was 
aspirated and the aqueous bottom layer was set on ice. To evaporate the remaining ether 
in the solution, the vials were left open for ~5 minutes. DNA was precipitated using 3x 
volumes of ice cold 95% EtOH at a final concentration of 0.3 M NaAc. The samples were 
incubated for at least 30 minutes at -20 ºC, and then centrifuged at 21 krcf at 4 ºC for 15 
minutes. The supernatants were then removed and the pellets were resuspended in 3x 
volumes of 70% EtOH at room temperature. The same centrifugation steps were 
followed, and the supernatant was aspirated. The samples were allowed to dry by leaving 
the caps open for ~15 minutes. Ultrapure distilled, RNase-/DNase-free water was used to 
resuspend the samples to 30 µL before storing at -80 ºC. After storage, the concentrations 
of the isolated and purified gDNA and pDNA at each of the respective time points were 
assessed via UV-vis spectroscopy. The 260 nm/280 nm absorbance ratios were also 
assessed (n=24) as an indicator for nucleic acid purity. Aromatic amino acids absorb at 
the 280 nm wavelength which can used as an indicator of protein contamination. 
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6.2.12 Cy3 Fluorescence to Plasmid Number Conversion for Cells 
The normalized geometric mean (NGM) of the samples were calculated using 
flow cytometry by dividing FL2-A (Cy3) by the untreated FL2-A. Because there may be 
slight variations in the intensity of the flow cytometry from day to day, the samples were 
normalized to their own untreated at each time point. When there is no Cy3 present in the 
samples the NGM is 1. Since we are interested in the increase in the fluorescence in time 
above the untreated group, NGMSample – (NGMUnt = 1) versus time was plotted thus Cy3’s 
fluorescence began at 0 at the 0 hour time point. NGMSample – NGMUnt is the equivalence 
of the relative-fold fluorescence of Cy3 above the untreated. Within the manuscript NGM 
will refer to NGMSample – NGMUnt = 
𝐹𝑙𝑢𝑜𝑟𝐴𝑏𝑜𝑣𝑒 𝑈𝑛𝑡 
𝐶𝑒𝑙𝑙
. Other values needed in converting 
Cy3 fluorescence to plasmid number included the bulk fluorescence (550/570 nm 
excitation/emission) via a fluorescence plate reader (𝐹𝑙𝑢𝑜𝑟𝑃𝑅) associated with a known 
number of cells, quantified via a hemacytometer (# 𝑐𝑒𝑙𝑙𝑠𝐻𝑒𝑚𝑎𝑐𝑦𝑡𝑜𝑚𝑒𝑡𝑒𝑟). The plasmid 
number (# 𝑃𝑙𝑎𝑠𝑚𝑖𝑑𝑠) contained within all of the cells was calculated using a pre-
determined calibration curve (𝑛 = 4;  # 𝑃𝑙𝑎𝑠𝑚𝑖𝑑𝑠 = (𝑚 = 𝑠𝑙𝑜𝑝𝑒)𝐹𝑙𝑢𝑜𝑟𝑃𝑅 + (𝑏 =
𝑦 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡)). The following equation was used to calculate how much fluorescence 













In order to be above the bulk fluorescence background 3 wells of a 24-well plate were 





 value was measured (n=3) multiple times at multiple time points to 
ensure it was constant. 
 
6.2.13 Cy3 Fluorescence to Plasmid Number Conversion for Nuclei 
It was more challenging to calculate the 
𝐹𝑙𝑢𝑜𝑟𝐴𝑏𝑜𝑣𝑒 𝑈𝑛𝑡 (𝑁𝑢𝑐𝑙𝑒𝑖)
𝑃𝑙𝑎𝑠𝑚𝑖𝑑
 in the same way as 
the cells with the fluorescence plate reader for two reasons: 1) there are far fewer 
plasmids per nucleus than plasmids per cell and thus the Cy3 fluorescence signal was not 
able to break out of the background fluorescence even when 12 wells of isolated nuclei 
were combined (with volume held constant at 100 µL similar to calibration curve); 2) we 
lose fluorescence signal due to the nuclei isolation process itself as the nuclei isolation 
efficiency is approximately 25%. Re-optimizing the isolation protocol to accommodate 
larger volumes may alter variables, such as the washing process, and may confound 
results further.  
As an alternative, we were able to scale the 
𝐹𝑙𝑢𝑜𝑟𝐴𝑏𝑜𝑣𝑒 𝑈𝑛𝑡 (𝐶𝑒𝑙𝑙𝑠)
𝑃𝑙𝑎𝑠𝑚𝑖𝑑 
 value to be 
applicable for nuclei by multiplying by the relative fluorescence of untreated cells and 











For each time point for either the cells or nuclei the fluorescence by flow cytometry was 













6.2.14 Intracellular Plasmid DNA Degradation Kinetics 
Cy3 is not an intercalating dye and its fluorescence intensity does not change if 
the plasmids structural integrity is compromised because Cy3 is conjugated to the pDNA 
via a reactive alkyl group to heteroatoms within the plasmid. Because quantifying 
fluorescence of Cy3-pDNA does not necessarily correspond to intact plasmids, qPCR 
was used in order to correct for pDNA degradation in time.  
After the isolated and purified gDNA/pDNA samples from the GBM319 cells 
(n=3) were quantified via NanoDrop of, each sample was diluted to 1 μg/mL in ultrapure 
distilled water (DNase and RNase free). Each qPCR well contained 6 ng of the purified 
gDNA/pDNA, 14 μL of SYBR® Green PCR Master Mix (2x concentration; Life 
Technologies), and 2 μL of the reverse and forward primers for eGFP and human β-
cytoskeleton actin (β-actin), totaling 20 μL. β-actin is a housekeeping gene and was used 
to compare the relative amounts of eGFP present. The eGFP and β-actin primer 
amplicons were 95 and 250 nucleotides in length, respectively. The eGFP and β-actin 
sequences were as follows: forward eGFP primer: AGGGCATCGACTTCAAGG (55.6% 
GC; Tm: 54.7ºC); reverse eGFP primer: CTACGTCTATATCATGGCCG (50% 
GC: %Tm: 52.1ºC); forward β-actin primer: CATGTACGTTGCTATCCAGGC (52.4% 
GC; Tm: 60.8ºC); reverse β-actin primer: CTCCTTAATGTCACGCACGA (50.0% GC; 
Tm: 60.2ºC). The thermal cycling conditions for qPCR were set at 95ºC for the first 10 
minutes to fully denature the template and activate the enzymes. Immediately thereafter, 
a temperature cycle was repeated between 95ºC and 60ºC for 15 seconds and 1 minute, 
respectively, 40 times.  
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PCR was performed on a dilution series for each gene of interest in order to 
calculate the efficiency of replication (ER) and was calculated using the cycle threshold 
value (CT) as follows: 
  
𝐸𝑅 =  −1 + (𝑓𝑜𝑙𝑑 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑠𝑎𝑚𝑝𝑙𝑒𝑠)1/|𝑎𝑣𝑒𝑟𝑎𝑔𝑒 ∆𝐶𝑇 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛𝑠| 
 
We ensured the ERs for the eGFP and the β-actin amplicon amplifications were between 
0.95-1.05 which allowed 2-ΔΔCT to be a valid quantification of the relative amounts of 
genes present [13]. It is important to note the log(DNA content: concentration or mass) 
versus CT plot is sigmoidal. The ER should be calculated for the linear range in this plot 
and the unknown samples’ CT values should also be within this same linear CT range. 
ΔΔCT was calculated as follows: 
ΔΔCT =  (𝐶𝑇𝑒𝐺𝐹𝑃 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐶𝑇𝛽−𝑎𝑐𝑡𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒)
− (𝐶𝑇𝑒𝐺𝐹𝑃 𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 − 𝐶𝑇𝛽−𝑎𝑐𝑡𝑖𝑛 𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑) 
Because β-actin is a single copy gene, there are two copies per cell. By multiplying 2-ΔΔCT 
by 2, the total number of plasmids per cell can be obtained [8]. Thus: 
 
𝑃𝑙𝑎𝑠𝑚𝑖𝑑𝑞𝑃𝐶𝑅 =  2(2
−ΔΔCT)  
 
 Once qPCR was completed, melt curves of the qPCR products were examined for 
quality control; furthermore, the qPCR products were assessed for off-target 
amplification and primer dimers using gel electrophoresis (4% agarose; 1µg/mL ethidium 
bromide) and a DNA ladder.  
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The structural integrity of the plasmids was taken into account (𝑃𝑙𝑎𝑠𝑚𝑖𝑑𝐶𝑜𝑟𝑟) by 
multiplying 𝑃𝑙𝑎𝑠𝑚𝑖𝑑𝑃𝑅 by the ratio of intact plasmids (of the 447 polymer in the 
GBM319 cells) at each time point, using the following equation: 
 





The polymer chosen for this poof of principle paper has a 𝑃𝑙𝑎𝑠𝑚𝑖𝑑𝐶𝑜𝑟𝑟 value 
equal to the 𝑃𝑙𝑎𝑠𝑚𝑖𝑑𝑠𝑞𝑃𝐶𝑅 447 value. If additional polymer structures were compared to 
assess structure-function relationships at gene delivery, the (
𝑃𝑙𝑎𝑠𝑚𝑖𝑑𝑠𝑞𝑃𝐶𝑅 447
𝑃𝑙𝑎𝑠𝑚𝑖𝑑𝑠𝑃𝑅 447 
) ratios at 
each time point could be used without repeating qPCR. The corrected plasmid values for 
the cytoplasm, the extranuclear space, and the intranuclear space are represented as 
follows: PCorr cyto, PCorr ne, and PCorr ni, respectively. Each plasmid compartment (Pcyto, Pne 
and Pni) was assumed to have the same degradation kinetics for simplicity. For the 
investigation of other polymers, the polymer-pDNA binding strength would also likely 
need to be relatively similar for the degradation kinetics to be comparable [3,14].  
 The intracellular plasmid degradation time constants were calculated from using 
exponential decay fittings from 2 to 24 hours. The reason we chose to not include 0-2 
hours was because there are plasmids being imported from the media 0-2 hours which 
would confound the intracellular degradation computation. We investigated fittings with 





6.2.15 Expression Efficacy and Relative Metabolic Activity 
Fluorescence microscopy (10x magnification, 200 ms eGFP exposure time) and 
flow cytometry (66 μL/min) were performed to assess expression 48-hours post 
transfection (n=3). The relative metabolic activity (viability) was assessed using a 
CellTiter 96® AQueous One assay at an absorbance of 490 nm using a UV-Vis 
spectrophotometer (Synergy2, Gen5) (n=3). 
 
6.2.16 Modeling via First Order Mass-action Kinetics 
The set of first order mass-action differential equations used in this work was 
simplified to the extent possible such that the experimental data could be sufficiently 
recapitulated using the minimum number of fitted variables and without taking 
information from a variety of sources which can confound the interpretation [2]. The 
model included 4 compartments from 0 to 2 hours: the media, cytoplasm, nuclear 
envelope (ne; tightly-associated extranuclear space), and nucleus (ni; intranuclear space) 
(Scheme 1) and 3 compartments after 2 hours because the plasmid number in the media 
drops to zero at the completion of the polyplex-cell incubation time period.  
The number of plasmids in the media, cytoplasm, associated with the nuclear 
envelope, and internal to the nucleus are represented by Pmedia, Pcyto, Pne, and Pni, 
respectively. The rate contributing term transferring plasmids from the media into the 
cytoplasm, kcellPmedia, in the set of differential equations included a Heaviside or unit step 
function (𝔄) which was able to bring the non-zero term to zero at 2 hours by multiplying 
kcellPmedia by 𝔄[−(𝑡 − 2)]; where t = time (hours). The Heaviside step function greatly 
simplified the differential equations because without the unit step function, two sets of 
differential equations would have been required. Using the plasmid number at 2 hours 
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from the 4 compartmental model for the 3 compartmental model’s initial conditions 
would have rendered the same results had the Heaviside step function not been used.  
The rate constants for plasmids transferring from the media to the cytoplasm, the 
cytoplasm to the nuclear envelope, and the nuclear envelope to the nucleus are 
represented as kcell, kne, and kni, respectively (Scheme 1). kbd is a backflow rate term from 
the nuclear envelope and the nucleus back to the cytoplasm. The backflow could be due 
to active plasmid transport from the nucleus or from nuclear envelope breakdown.  
In some cases rate constants are normalized to volume; in this model because Pne 
represents plasmids on a surface area and Pmedia, Pcyto and Pni represent plasmids within a 
volume, it is not reasonable to normalize the compartments plasmid variables or their 
respective rate constants to a volume or a surface area. 
Any plasmids that were tightly associated with the extranuclear space or within 
the intranuclear space would be effectively in the cytoplasm at the time of nuclei isolation 
if the cell were undergoing mitosis. For simplification, we used the same kdeg term for all 




= 𝑘𝑐𝑒𝑙𝑙  𝑃𝑚𝑒𝑑𝑖𝑎  𝔄[−(𝑡 − 2)] + 𝑘𝑏𝑑(𝑃𝑛𝑒 + 𝑃𝑛𝑖) − (𝑘𝑛𝑒 + 𝑘𝑑𝑒𝑔)𝑃𝑐𝑦𝑡𝑜 
𝑑𝑃𝑛𝑒
𝑑𝑡
= 𝑘𝑛𝑒  𝑃𝑐𝑦𝑡𝑜 − (𝑘𝑛𝑖 + 𝑘𝑏𝑑 + 𝑘𝑑𝑒𝑔)𝑃𝑛𝑒 
𝑑𝑃𝑛𝑖
𝑑𝑡
= 𝑘𝑛𝑖  𝑃𝑛𝑒 − (𝑘𝑏𝑑 + 𝑘𝑑𝑒𝑔)𝑃𝑛𝑖  
The MatLab code automatically fitted the experimental data through for loops. Random 
rate constants from 0.0000 to 1.0000 hours-1 were assigned to kne, kni, and kbd. At every 
value varied for kcell, MatLab’s ODE23s solver was used to assess the model plasmid 
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values (Pcyto, Pne, Pni) and the sum of the residuals squared (SRS) was calculated using the 
experimental data as follows:  
𝑆𝑅𝑆 = ∑ (|𝑃𝐶𝑜𝑟𝑟 𝑐𝑦𝑡𝑜 − 𝑃𝑐𝑦𝑡𝑜|
2
+ |𝑃𝐶𝑜𝑟𝑟 𝑛𝑒 − 𝑃𝑛𝑒|





After varying kcell, the minimum SRS was determined and used as a constant value. After 
which the other 3 remaining rate constants were independently scanned in like manner 
one at a time to find the rate constant values associated with their SRS minima. Once all 
4 rate constants were optimized once, these same rate constant values were used for the 
whole process again rather than using random variables. This continued until the rate 
constants were optimized and did not change with further iterations. The entire process 
where random variables were used and optimized until there were no changes in the rate 




All errors reported are standard errors of the mean and are independently prepared 
samples. Sample numbers are reported in their respective method sections. A Student’s t-
test was performed for Figure S1 (n=3) and Figure S2 (n=2). Two independent one-way 





6.3.1 Polymer Synthesis and Fractionation 
Polymer 447’s Mn and Mw were 9.5 kDa and 12.3 kDa, respectively. A 
polydispersity index (PDI) close to unity of 1.30 was obtained. 
 
6.3.2 Cy3-plasmid DNA Conjugation 
The number of nucleotides per dye immediately post-conjugation and before 
dilution into unconjugated pDNA was approximately 35 nucleotides/dye. 
 
6.3.3 Cy3 pH-sensitivity 
The Cy3 fluorescence at pH 7.4 (150 mM PBS) and 5.2 (150 mM NaAc) were not 
different (p-value = 0.63) as shown in Figure S1. 
 
6.3.4 Polyplex Formation 
The diameter of the polyplexes was 98 ± 7 nm. The polyplex concentration was 
(4.3 ± 0.7)x1010 particles/well. Based on the dosage delivered there were 6.0x1011 
plasmids per well assuming 600 Da/base pair. This would suggest there were 14 ± 2 
plasmids on average per polyplex. At the time of seeding there were approximately 
93,750 cells, which suggests there were on average 6.4x106 plasmids available per cell 




6.3.5 Nuclei Isolation and Purity from Cytoplasm 
The isolated nuclei were close to 20 µm in diameter. The efficiency of the nuclei 
isolation process was 25 ± 5%. Figure 1 shows isolated nuclei stained with DAPI. The 
background fluorescence of the gated nuclei (eGFP negative) from the eGFP-stably 
expressing cells (79%+) according to flow cytometry was 0.4%+ as shown in Figure S2 
(p-value = 0.02), which is more than a 99% drop in eGFP.  
 
6.3.6 Washing Extracellular and Extranuclear Plasmid DNA 
The heparin wash regimen was sufficient in removing the pDNA from both cells 
and nuclei which would not have been uptaken at 4 ºC as endocytosis is an ATP-
dependent process for both cells (30 and 60 w/w) and nuclei (100k plasmids/nucleus) 
(Figure 2).  
 
6.3.7 Cellular and Nuclear Uptake 
As expected, the nuclei on flow cytometry was associated with a lower FSC-H 
than the cells which can be qualitatively seen in the ungated FSC-H vs SSC-H dot plot 
(Figure S3; top) and in the FSC-H histogram of gated singlet cells and nuclei (Figure 
S3; bottom). The 0 hour time point for the cells and nuclei were as expected in that the 
fluorescence values were near the untreated groups’. As an example, a dot plot of FL1-A 
and FL2-A for the untreated, and 0 and 2 hour time points for cells are shown in Figure 
S4. This can also be observed for cells and nuclei by the 0 hour time points’ closeness in 
proximity to the origin in Figure 3.   
 The percent positive time profiles for Cy3-pDNA in cells (top left) and nuclei 
(bottom left) are shown in Figure 3. The Cy3(+) percent for cells increased from zero to 
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a relatively constant value of ~75% at 2 hours (top left), with the 18 and 24 hour time 
points being ~80%; the Cy3(+) percent value for nuclei (bottom left) reached a maximum 
at 2 hours. The NGM fluorescence increased from 0 to a maximum at 2 hours for both 
cells (top right) and nuclei (bottom right) (Figure 3).  
It was determined that the maximum uptake occurred at the time the particles 
were washed from the cells and nuclei by also observing that the maximum was at 4 
hours when the cells were allowed to incubate with polyplexes for 4 hours rather than 2 
hours.  
 
6.3.8 Plasmid and Genomic DNA Isolation and Purification 
The concentrations of the gDNA and pDNA isolated and purified from the cells 
for qPCR was 16 ± 2 μg/mL. The 260 nm/280 nm absorbance ratio was 2.03 ± 0.08. 
 
6.3.9 Cy3 Fluorescence to Plasmid Number Conversion for Cells and Nuclei 
The background fluorescence for cells without Cy3 was equivalent to the 
background for the known plasmid standard below 1x108 plasmids per well which was 
approximately 1000. A calibration curve (Figure S5) was used to convert the bulk 







 values were (1.8 ± 0.2)x10-4 per 
plasmid and (3.5 ± 0.4)x10-3 per plasmid, respectively. Because the deviation between 
multiple time points was small, it demonstrates a linear relationship which helps validate 




Confirming the scaling of the 
𝐹𝑙𝑢𝑜𝑟𝐴𝑏𝑜𝑣𝑒 𝑈𝑛𝑡 (𝑁𝑢𝑐𝑙𝑒𝑖)
𝑃𝑙𝑎𝑠𝑚𝑖𝑑
 value, a Student’s t-test at the 2 
hour time point between the PlasmidqPCR and PCorr ni values showed no statistical 
difference (p-value = 0.25). 
 
6.3.10 Intracellular Plasmid DNA Degradation Kinetics 
The replication efficiencies of the eGFP and β-actin primers were 0.97, and 0.95, 
respectively. The eGFP and β-actin qPCR products were the same lengths as the 
amplicon lengths; 95 and 250 bp, respectively, according to gel electrophoresis (Figure 
S6). No primer dimers or off-target amplification was observed on the gel as well which 
corroborated the melt curve findings. 
Figure S7 shows the plasmid numbers in time of cells (Pcyto + Pne + Pni) based on 
PlasmidPR and PlasmidqPCR which separated further in time as intracellular nucleases 
continued degrading the exogenous pDNA. The similarity of the PlasmidPR and 
PlasmidqPCR values for the initial time points further validate the conversion from 
fluorescence to plasmid number. The PlasmidPR and PlasmidCorr values for both cells and 
nuclei are shown in Figuare S8 on the top and bottom, respectively. 
 The PlasmidqPCR values in time from 2 to 24 hours are shown in Figure S9 with 
mono-(dotted line) and bi-exponential degradation (solid line) fittings. The bi-exponential 
degradation fits the experimental data more stringently, suggesting there are likely two 
terms involved in the degradation process. For simplicity, we initially used the mono-
exponential kdeg value of 0.350 hours
-1
 in the model and the plasmid values reached zero 
at a much earlier time point after the 2 hour peak than the experimental data suggested 
which prompted us to explore the bi-exponential degradation approach for kdeg. The bi-
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exponential degradation analysis is based on a mechanism of faster degradation in one 
state (such as when the DNA is free from polymer) and slower degradation of the DNA 
when it is in a second state (such as bound to polymer).  The kdeg incorporating the two 
exponential degradation terms in the set of differential equations was calculated using 
Supplemental derivation 1, where A, B, kdeg1, and kdeg2 were obtained from the bi-
exponential fitting (Figure S9; Plasmids (Pcyto + Pne + Pni) = 𝐴𝑒−𝑘𝑑𝑒𝑔1𝑡 + 𝐵𝑒−𝑘𝑑𝑒𝑔2𝑡) and is 







 The initial number of plasmids available per cell for uptake in the media was 
6.36x106 , which was based on the dosage delivered per well (2813 ng). The number of 
plasmids available to be uptaken per cell in time is shown in Figure S10 which was 
calculated by subtracting the amount of plasmids uptaken in time from the initial dosage. 
At 2 hours, all plasmids in the media were washed away, which is why Figure S10 drops 
to zero immediately after 2 hours.  
 
6.3.11 Expression Efficacy and Relative Metabolic Activity 
The expression efficacy of 447 30 w/w (2813 ng; 2 hour polyplex incubation) 48 
hours post transfection was 70.6 ± 0.6% (Figure S11; bottom). The relative metabolic 
activity was 101 ± 3%, normalized to the untreated group (100%). 
 
6.3.12 Modeling via First Order Mass-action Kinetics 
19 iterations of optimization were required to obtain the converged rate constant 
values for the bi-exponential degradation model (Figure S12). kcell, kne, kni, and kbd were 
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6.8x10-4, 0.72, 1.1, and 1.8 hour-1, respectively. The minima of the sum of the residuals 
squared (SRS) between the experimental data and the bi-exponential model are shown in 
Figure S13 for the last iteration of the optimization. The experimental data in 
conjunction with the bi-exponential and mono-exponential degradation models are shown 
in Figure 4 and Figure S14 (kcell, kne, kni, and kbd were 7.1x10
-4, 0.85, 1.3, and 2.1 hour-1, 
respectively), respectively. 
6.3.13 Polymer Rate Comparison 
Polymers 44, 446, and 447 (Scheme 2 in chapter 3.6.2) were assessed in like 
manner, according to the methods outlined above. The experimental data and the first-
order mass action kinetic models overlaid can be found in Figure 5 for polymers 44 
(Figure 5A), 446 (Figure 5B), and 447 (Figure 5C). The auto-fitted rate constants can 
be found in Table 1, as well as the Mn, Mw, and PDIs. 
 
6.4 Discussion 
The fractionation process allowed for the targeted molecular weight to be obtained 
which had shown to previously work well in GBM319 cells [3]. The obtained PDI of 
1.30 was similar to previously reported PDIs of fractionated polymer [3]. Because Cy3 is 
not pH-sensitive in the range of interest (pH 5.2-7.4), no intracellular fluorescence 
intensity corrections based on the intracellular location of the plasmids were needed for 
the uptake experiments. The gated nuclei from stably-expressing eGFP(+) cells were 
nearly free from a detectable amount of eGFP by flow cytometry, indicating there was 
very little false-positive Cy3-pDNA signal in the cytoplasm on the nuclei. The washing 
experiments successfully demonstrated the feasibility of removing extracellular and 
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extranuclear plasmids from the surface of the cells and nuclei, which would have 
otherwise contributed false-positively to the fluorescence.  
 The percentage of cells with a detectable amount of eGFP according to flow 
cytometry increased from zero and even increased slightly after 2 hours which may have 
been because the cells preparing to enter mitosis would have an increased endocytosis 
rate, enabling the expansion of their phospholipid bilayer membranes [16]. This could 
result in a greater proportion of cells with a detectable amount of Cy3-pDNA after the 
polyplex incubation time period. Asynchronous cell populations with respect to cell cycle 
stages were used for uptake studies because there have been reports suggesting that the 
cell cycle stage synchronization process itself affects multiple cellular processes, 
confounding the interpretation of the results [9]. Furthermore, an asynchronous cell 
population would more closely resemble an in vivo environment. 
There was a decrease in FL2-A’s fluorescence intensity after the incubation time 
period which corroborates the heparin washing experiments; we have found that when 
not all of the unuptaken Cy3-pDNA is washed sufficiently from the wells that the NGM 
FL2-A values at later time points can be 2-3 fold higher. The decrease in the fluorescence 
was likely due to dilution from cell division (doubling time of GBM319 cells is 
approximately 1 day) and also, to some degree, exocytosis or the endosome recycling 
pathway.  
 The mono-exponential degradation value for kdeg of 0.350 hour
-1 was similar to 
Varga, et al.’s reported value of 5x10-3 min-1 or 0.3 hour-1 [21]. Usage of the bi-
exponential degradation allowed for a better fit for the first order mass-action kinetic 
model which suggested that there may be two different plasmid states as has been 
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reported previously in literature: 1) an unbound or free plasmid state where the plasmids 
are more susceptible to nuclease activity and 2) the plasmid-polymer bound state, where 
the plasmids are better protected from nuclease activity [14]. The polymer degradation or 
unpacking of the plasmid cargo would lead to more degradation in time accounting for 
the greater differences between the PlasmidPR and PlasmidqPCR values in time [14]. 
 When utilizing this approach, the degradation rate constants should be re-
evaluated for each cell type of interest using qPCR as the plasmid degradation rate 
constants can vary by cell type. If the binding affinity between the polymer types of 
interest vary substantially it may also be beneficial to assess the degradation rate even 
within the same cell type [3]. Furthermore, if the Cy3 density conjugated to pDNA 
varies, re-calibrating the plasmid conversion would also be necessary. 
The cellular and nuclear uptake rates observed were similar to other rates 
previously reported in literature  [2,11,21,22] which further validates the flow cytometry 
approach used. The bi-exponential degradation model provided superior fits compared to 
the mono-exponential degradation model as the latter caused the plasmid values to drop 
to zero prematurely compared to the experimental data. The maximum plasmid number 
for each compartment (Pcyto, Pne, and Pni) as indicated by the model shifted slightly in 
time with Pcyto at 2 hours and Pni nearer to 2.5 hours.   
Despite there being 6.4x106 plasmids (4.6x105 polyplexes) available per cell, 
around ~25% of the cells did not uptake plasmids sufficiently to be Cy3(+) and ~30% of 
cells did not transcribe and translate enough protein to be considered eGFP(+) according 
to flow cytometry. Only 0.1% of the pDNA delivered in the media was uptaken by the 
cells. The high number of unuptaken plasmids for non-viral gene delivery delineates the 
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need for more efficient delivery systems at the cellular level. Of the 0.1% of the plasmids 
containing the DTS, 12% of what was in the cell successfully entered the nucleus.  The 
rate limiting barrier for polymer 447 was at the cellular level. Incorporating a cell 
penetrating/targeting ligand may improve the cellular uptake efficiency and perhaps 
require far fewer plasmids for successful transfection. 
The rate constants demonstrate that the plasmid amount present in one 
compartment at any given time is dependent upon the concentration in the 
compartment(s) driving the mass transfer. Therefore, for comparison of different 
polymers, the overall rate transfer should be compared and not just the rate constants. The 
rate constants also indicate the bottlenecks in intracellular delivery for each polymer.  
The content of DNA in the nucleus was directly proportional to the amount of eGFP 
expressed in all 3 polymer cases. 
 
6.5 Conclusions 
In these experiments, we were able to develop a new flow cytometry based 
method to quantify intracellular steps in gene delivery.  We were able to demonstrate the 
needed methodlolgy including:  washing cells and nuclei sufficiently to remove 
uninternalized false-positive Cy3-pDNA; Isolating nuclei with a minimal amount of 
cytoplasm to assess the amount of labeled Cy3-pDNA in the cytoplasm, on the nuclear 
envelope, and internal to the nucleus; first order mass-action modeling using MatLab to 
auto-fit the relevant rate constants using a minimal number of compartments and with no 
information extrapolated from literature. A bi-exponential degradation model was also 
able to recapitulate the experimental data with good agreement.  This methodology can 
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be easily combinatorially combined with other intracellular fluorescent measurments to 
better elucidate intracellular gene delivery.  It can also be scaled with high-throughput 
plate-based flow cytometry to assay arrays of biomaterials and/or cell lines for 





































6.6 Figures  
 









Figure 2. Cells and nuclei washing challenge (polyplex incubation for 1 hour at 4ºC) 
using 50 μg/mL heparin in PBS to eliminate associated DNA or DNA that was not 
uptaken. The washed cells and nuclei returned to their untreated fluorescence values, 





Figure 3. Percentages (left) and NGM (right) of Cy3 for both cells (top) and nuclei 
(bottom). Pcyto, Pne, and Pni are plasmids which are in the cytoplasm, and plasmids 








Figure 4. First order mass-action model (dotted lines; bi-exponential degradation) for the 































Figure 5. The experimental and first order mass action kinetic models overlaid for 


















Figure S1. Normalized fluorescence of Cy3, showing no statistical difference at pH 7.4 










Figure S2. Purity of nuclei. Flow cytometry was used to assess the eGFP presence of 
eGFP-stably expressing cells and their isolated nuclei to ascertain the purity of the nuclei; 





Figure S3. Top: Ungated cells and nuclei (FSC-H vs SSC-H). The nuclei had a lower 
FSC-H value as expected due to their smaller size. Bottom: FSC-H Histogram for gated 




Figure S4. Cell flow cytometry data for the untreated, and the 0 and 2 hour time points. 
There is a great deal of population overlap for the untreated and the 0 hour time point, as 
























Figure S6. Gel electrophoresis of qPCR products (left, middle and rights lanes: DNA 















Figure S7. Plasmids in time calculated using the plate reader (PlasmidPR) method 















Figure S9. PlasmidqPCR values from 2 to 24 hours for fitting the degradation constant, 









Figure S10. Available number of plasmids in the media per cell in time. The dotted line 








Figure S11. Fluorescence microscopy images of the eGFP channel (left) and the eGFP 
and brightfield channels combined (right) for untreated (top) and for 447 30 w/w 










Figure S13. Error minimizations for the 19th or last iteration of optimization for kcell, kne, 




Figure S14. First order mass-action model (dotted lines; mono-exponential degradation) 














Scheme S1. Reaction scheme of polymer B4-S4-E7 (447). 1,4-butanediol diacrylate (B4) 



































kni (hr-1) kbd (hr-
1) 
44 9590 12300 1.30 1.5E-5 1.4 11 5.8 
446 8650 11700 1.35 3.2E-4 0.16 0.48 0.29 





6.9 Supplemental Derivation 
Derivation 1. Derivation of degradation term in the differential equations. 
𝑃 =  𝐴𝑒𝑘𝑑𝑒𝑔1𝑡 + 𝐵𝑒𝑘𝑑𝑒𝑔2𝑡 
 
ln 𝑃 = ln(𝐴𝑒𝑘𝑑𝑒𝑔1𝑡 + 𝐵𝑒𝑘𝑑𝑒𝑔2𝑡) 
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7 8Chapter 7: Poly(β-amino ester) Monomer and 
Polymer Structure Function Relationships 
Elucidated Via Principal Component Analysis 
 
7.1 Introduction 
Viral methods for gene therapy have been actively investigated for many years in 
more than 2,000 world-wide clinical trials, but due in part to reported toxicological and 
immunological concerns, have not been approved for use in the United States.1 Polymeric 
vectors are an alternative for gene delivery worth investigating as they can be physico-
chemically modified to enhance function and minimize toxicity.  They also benefit by 
being easier and less expensive to manufacture than viruses and, unlike viruses, do not 
have a restriction to their nucleic acid cargo capacity. While high-throughput screening 
methods have recently been adapted to allow for evaluation of biomaterial libraries, it is 
difficult to use this data to isolate key structural drivers of biological activity or to predict 
characteristics of untested structures.2,3 Understanding fundamental structure-function 
relationships for gene delivery polymers would allow for improved rational engineering 
and enhanced chemical delivery systems. 
Principal Component Analysis (PCA) is a powerful tool for reducing complex data 
sets that contain many variables with unknown correlations. The data set is reduced into 
orthogonal, linearly uncorrelated variables, termed principal components (PC). PCs are 




useful in helping to determine underlying relationships between variables.4,5 While to our 
knowledge these methods have not been previously used to elucidate how polymer 
structure can affect biological function including gene delivery efficacy, we hypothesized 
that we would find trends based on our recent work on evaluating how polymer structure 
can tune DNA binding and gene delivery.6 We chose hydrolytically degradable poly(β-
amino ester)s (PBAE) to study as a PBAE polymer library can be readily synthesized by 
semi-high throughput methods and we have previously shown utility of these polymers 
for both in vitro and in vivo  gene therapy applications.7,8 We report the use of PCA to aid 
our understanding of the physico-chemical properties of polymers that drive transfection, 
uptake, and viability in human cells. 
 
7.2 Methods, Results, and Discussion (Communication 
Format) 
7.2.1 Polymer Library 
A PBAE library consisting of 75 polymers with varying backbone (B), sidechain 
(S), or endcap (E) were synthesized as previously reported (Scheme 1).9 In brief, the base 
polymer was synthesized by mixing B and S monomers (Scheme 1) neat in 1.05:1, 1.1:1, 
or 1.2:1 B:S monomeric ratios and the reaction was allowed to stir for 24 hours at 90˚C in 
the dark; after which the B-S base polymer solvated in anhydrousn dimethyl sulfoxide 
(DMSO) to 167 mg/mL. 480 μL of the 167 mg/mL base polymer was then endcapped in 
DMSO for 1 hr (no shaking) using approximately a 10:1 E (0.5 M solution in DMSO; 
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320 μL) to B-S  ratio (Scheme 1).9 The 100 mg/mL endcapped polymer was then stored 
at -20˚C until use.9 
The B to S monomeric ratio (B:S) dictates the molecular weight of the polymer, 
with molecular weight increasing as the ratio approaches unity. The numbers associated 
with the B and the S monomer names are the number of carbons between the backbone’s 
acrylate groups and the sidechain’s amine and hydroxyl groups, respectively (Scheme 1). 
“B+S” refers to the sum of these numbers for an individual polymer, or the number of 
carbons in its repeating unit. As the carbons in the backbone and sidechain increase, the 
overall hydrophobicity of the polymer increases. The numbers associated with the “E” 
term are randomly assigned and are not indicative of endcap structure.  
The polymers were characterized using gel permeation chromatography (GPC). In 
brief,  the polymers were solvated in 94% tetrahydrofuran (THF), 5% DMSO, 1% 
piperidine with a few 100 mg of butylated hydroxytoluene.9 The solvated polymer was 
then filtered using a 0.2 μm polytetrafluoroethylene filter and compared against 
polystyrene standards using GPC (Waters, Milford, MA) to obtain the number- and 
weight-average molecular weights (Mn and Mw), the polydispersity indices (PDI) and 
the degree of polymerization (DP).9  
 
7.2.2 Physicochemical Properties  
 
Other physical parameters were calculated with the aid of ChemDraw, the Joback 
fragmentation method, and the Crippen’s fragmentation method. These include  boiling 
point (BP); melting point (MP); critical volume (CV), which is the volume of 1 mole at 
the critical temperature and pressure; Gibb’s free energy (GFE), which is the 
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thermodynamic potential to perform work; LogP, the partition-coefficient between two 
immiscible phases at equilibrium which is proportional to hydrophobicity; molar 
refractivity (MR), which is a measurement of the total polarizability of 1 mole;  the heat 
of formation (HtF), which is the change in enthalpy of 1 mole from the formation the 
elemental constituents; and the topological polar surface area (tPSA), which is the total 
area of all polar atoms (predominantly oxygen and oitrogen) including their affixed 
hydrogen atoms. Properties associated with the polymer repeating unit are differentiated 
from those of the full polymer, by the presence of an asterisk in their name (i.e., LogP* 
vs. LogP). In vitro studies were performed on primary human glioblastoma cells using 
this described cationic PBAE library as previously reported (Supplementary Methods).9  
 
7.2.3 Transfection and Viability 
 
 
In vitro studies were performed on primary human glioblastoma multiforme cells 
using the library set and previously reported 9. In brief, the primary human glioblastoma 
cells were seeded in 96-well tissue cultured plates at 15,000 cells/well (100 μL) and 
incubated overnight at 37˚C and 5% CO2 for 24 hours.
9
 eGFP-N1 plasmid DNA was 
diluted to 0.06 mg/mL in sodium acetate (NaAc) and mixed in a 1:1 vol:vol ratio with 
each of the polymers at 3.6 mg/mL in NaAc (diluted from 100 mg/mL); thus the polymer 
to DNA mass ratio (w/w) was 60.9 The solution was thoroughly triturated and allowed to 
ionically complex for 10 minutes at room temperature to self-assemble into 
nanoparticles.9 The total incubation time for the polyplexes with the cells (final dose of 5 
μg/mL) was 2 hours.9 To assess uptake Cy™3 (Mirus Bio LLC; MIR 7020)-conjugated 
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plasmid DNA was used and directly assessed via the flow cytometer after the 2 hour 
incubation time period.9 A viability assay (Cell Titer 96®AQueous One) was used at 24 
hours to assess cell viability. Transfection efficacy was assessed at 48 hours using flow 
cytometry.9 
 
7.2.4 Principal Component Analysis 
 
 
PCA was carried out using the standard “princomp” function in MatLab to 
calculate the coefficients, scores, and variances. All included variables were first scaled 
from 0 to 1 for normalization and included the following 27 parameters: B, B:S, B+S, BP, 
BP*, CV, CV*, DP, GFE, GFE*, HtF, HtF*, LogP, LogP*, Mn, MP, MP*, MR, MR*, 
Mw, MW*, PDI, S, tPSA, transfection efficacy, cell uptake, and cell viability. 24 of the 
27 are physico-chemical variables determined by the structure of the polymers; the 
remaining 3 are cell-based functional variables determined experimentally. As a control, a 
random variable, the “E” number assigned to each endcap but not meaningful when 
normalized from 0 to 1, was incorporated into the set of parameters.  
 
7.2.5 Variance Explained  
 
The variance of a particular PC divided by the sum of all of the PC variances 
multiplied by 100 is the percentage that a particular PC recapitulates the data set. Since 
there are 27 variables, there is a potential maximum of 27 PCs. The first and second PCs 
were responsible for 58.2% and 24.3% of the variance in the data set, respectively 
(Figure 1, top). Cumulatively, the first 5 PCs capture 96.6% of the variance in the data 
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set. Although there are 27 variables, it is striking that 5 PCs can cover almost all the 
variance in the data and just the first two PCs cover 83% of this variance, significantly 
decreasing the complexity of this multivariate data.  
 
7.2.6 Variable Contribution to Principal Components  
 
We can rank the variables by the degree to which they contribute positively or 
negatively to each PC using their associated coefficients. The top four variables 
contributing to each of the first five PCs are listed above the variances of each PC 
(Figure 1; top) and are indicated in parentheses as “(-)” if it is a negative contribution. 
Table S1 contains a full list of the 27 variables ranked for the first five PCs. 
 
7.2.7 Correlative Relationships Between Variables 
 
The loading plot, generated using the first and second coefficients associated with 
each variable (Figure 1; bottom), reveals the correlative relationships between the 
variables. Variables within the same quadrant of the loading plot indicate that they are 
positively correlated. B, transfection, uptake, Mn, Mw, PDI, MR, CV and LogP are all 
positively correlated in quadrant IV. The color in the figure is utilized to enhance contrast 
between lines. Hydrophobicity (LogP) positively correlating with transfection efficacy 
has been previously observed3 as well, corroborating the findings. As expected, increased 
cellular uptake correlated strongly to higher transfection efficacy. 
Variables in opposite quadrants indicate that they are inversely correlated. As such, 
viability is negatively correlated with the variables in quadrant IV. For example, 
polymers that transfect strongly generally correlate to also slightly lowering cell viability. 
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As an example of how PCA reduces the complexity of multiple variables and assembles 
correlated variables together, the B:S ratio as well as the molecular weights, Mn and Mw, 
and DP all lie along the PC2 axis, but with B:S in an opposing direction as it is inversely 
correlated to other parameters. Variables in adjacent quadrants are positively correlated 
with respect to one PC but not the other. Figure S1 shows the other variables (PDI, Mn, 
Mw, MR, CV), which were also positively correlated to transfection and uptake which 
are difficult to differentiate visibly. As expected, the random variable of the normalized 
“E” number, when included as a variable for analysis (totaling 28 variables), was found 
to be at the origin of the loading plot (0.0041, -0.0238). Coefficients of approximately 
zero were expected for E because the normalized “E” number is not related to polymer 
structure and therefore  should not make a meaningful contribution to the PCs. 
  
7.2.8 Assessing which and to what Degree Physicochemical Properties Drive 
Transfection, Uptake, and Viability 
 
Based on the loading plot, variables can be ranked according to the degree to which 
they correlate to a reference variable using Acos(Θ); where A is the magnitude of the 
vectors of the variables being compared to the reference and Θ is the angle between the 
variables and the reference. Variables corresponding to a positive Acos(Θ) value are 
positively correlated with the reference variable of interest; whereas negative Acos(Θ) 
values are negatively correlated. Thus, the most positive and the most negative variables 
drive the reference variable. The Acos(Θ) values near neutral contribute relatively little to 
the reference variable. Table 1 shows the reference variables of interest, namely, 
transfection, uptake and viability, and the remaining 26 variables ranked accordingly. As 
expected, when the random variable E was included in the data set, totaling 28 variables, 
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the Acos(Θ) values for transfection, uptake, and viability were 0.02, 0.01, and -0.01, 
respectively, which were the most neutral values observed. This validates that PCA 
successfully identified the normalized “E” number a random variable and not a chemical 
parameter for analysis. 
The top 4 positively correlated physico-chemical variables driving the biological 
parameters, transfection, uptake and viability were: B, uptake, LogP*, and B+S; LogP*, 
B+S, GFE*, and MW*;  HtF*, B:S, HtF, and GFE, respectively. Whereas the top 4 
negatively correlated variables driving transfection, uptake and viability were: B:S, HtF*, 
HtF, and GFE; HtF*, B:S, HtF, and GFE; LogP*, MR*, CV*, and MP*, respectively. 
Because uptake and transfection are highly positively correlated, it would be 
expected that many of the variables would rank similarly, which is what was observed. In 
contrast, because viability is negatively correlated with transfection and uptake, it would 
be expected that the ranking for the variables would be reversed, which was also 
observed. For example, LogP* and B+S were highly positively correlated with 
transfection and uptake but were negatively correlated with viability. This data 
quantitatively demonstrates how the same factor can both positively and negatively drive 
biological functional outcomes. 
 
7.2.9 Scores Plot  
 
Because there are 27 variables being analyzed there are 27 scores associated with 
each of the 75 polymer samples within the PBAE library. The scores plot (Figure S2) 
depicts all of the 1st and 2nd scores of the 75 polymers in the PBAE library associated 
with the 1st and 2nd PCs. The Mn and Mw are listed in kDa to the right of the polymer 
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names (i.e., 447, 8.8, 28.3), respectively. According to the ranking in Table S1, B+S 
contributes positively to PC1 and Mn and Mw contribute negatively to PC2 which is 
observed in the scores plot; as PC1 increases, B+S increases and as PC2 increases, the 
molecular weight generally decreases.  
The PC1 and PC2 scores for the 75 polymers in Figure S2 were plotted against 
transfection efficacy in the 3rd dimension in Figure 2A. A supplemental auto-rotating 
video created using MatLab of Figure 2A can also be found online. The color in Figure 
2 corresponds to the level of transfection with red being the highest and yellow the 
lowest. Figure 2A demonstrates that the 75 polymers self-cluster into three groups along 
3 regions of PC1.  These are named as B, C, and D in Figure 2A and these three groups 
are plotted in 2-dimensions vs. PC2 in Figures 2B, 2C, and 2D, respectively. 
Surprisingly, the self-clustered regions B, C, and D correspond to polymers that have 
B+S values equal to precisely 7, 8, and 9, respectively. Intriguingly, the number of 
carbons within a polymer’s repeat unit was found to group the polymer’s behavior more 
than any other parameter. Furthermore, this B+S grouping dictated the role of PC2 on 
transfection efficacy among the polymers within the group.  For example, polymers in 
group B (B+S=7) had generally very low transfection efficacy, with transfection efficacy 
increasing to ~half the maximum for more negative PC2 values (indicating a higher 
molecular weight, higher degree of polymerization, and a smaller B:S ratio closer to 
unity).  For polymers in group C (B+S=8), transfection is higher, reaching the maximum.  
Like with the B+S=7 group, lower values of PC2 (and higher MW) increased transfection 
efficacy.  In both of these groups, a lower value of PC2 could increase transfection 
efficacy by larger than an order of magnitude. In contrast, group D (B+S=9) transfection 
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was uniformly high near the maximum and PC2 did not influence transfection efficacy.  
Thus these two principal components, PC1 (hydrophobicity, B+S) and PC2 (molecular 
weight), were found to cluster and elucidate the polymer structures and their biological 
efficacy in new ways. In general, as B+S increased from 7 to 9, a greater portion of 
polymers had higher transfection levels. The optimal transfections were associated with 
PC2 values of -1, -1, and 0 for groups B, C, and D,  respectively.  
Previous research in our lab6 has demonstrated that transfection levels can be 
biphasic with respect to binding constants and also that binding constants increase with 
increasing molecular weight. Our results in the current PCA study are consistent with 
these past results as the highest transfection efficacy among all polymers occurs at 




We have been able to successfully demonstrate that PCA is a useful tool for helping 
elucidate how physico-chemical properties of polymers drive transfection, uptake, and 
viability in human primary glioblastoma cells. By determining the principal components, 
one can design next generation materials by tuning the chemical parameters that matter 
most (such as hydrophobicity and molecular weight) in the particular ranges determined 
to lead to the desired biological functional outcomes (such as high transfection). This 
type of analysis could potentially be used across a wider type of polymeric vectors10 (i.e., 
poly(l-lysine), polyethyleneimine, chitosan, dendrimers, and β-cyclodextrin-containing 
vectors) and various types of cargo (i.e., siRNA/miRNA, shRNA, mRNA).  Such a large 
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scale analysis would undoubtedly further elucidate additional structure-function 












Figure 1. Top: the variances are explained for the first 5 PCs. The top 4 variables of 
the 27 are ranked by the degree to which they contribute to the PCs according to 
their associated coefficients and listed above the variances. The “(-)” indicates a 












Figure 2: A: The scores plot versus transfection efficacy with red being the highest level 
of transfection; B: region B of 3A with a B+S (sum of carbons in backbone and 
sidechain) value of 7; C: region C of 3A with a B+S value of 8; D: region D of 3A with a 















Figure S1. The loading plot of the variables in the boxed region of Figure 1 showing 
other variables (Mw, PDI, Mn, MR, CV) which are positively correlated to transfection 



















Figure S2. The scores plot of all polymers used for PCA. The numbers listed are the 
polymer type xyz (Bx-Sy-Ez), Mn (kDa), and Mw (kDa), respectively. The 3 lists are 
positioned near their respective groups and the list order is the same as the data points 































Scheme 1. Top: the general reaction scheme of PBAEs with a representative polymer, 
B3-S4-E5; bottom: lists of backbone (B), sidechain (S), and endcap (E) monomers used 

























Table 1. Ranking of variables for transfection, uptake and viability. The value of 

















Table S1. The ranking of all variables according to the degree to which they contribute to 
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8 Chapter 8: Future Perspective9 
8.1 Biomolecule Delivery to Engineer the Cellular 
Microenvironment 
In this work, I have discussed the work of many world leaders involved in 
delivering biomolecules for regenerative medicine applications. The different types of 
delivery include extracellular delivery of soluble biomolecules, either as a bolus or 
through controlled release systems; delivery of insoluble factors, often through 
biomaterial-based scaffolds; and intracellular nucleic acid delivery to program a target 
cell on a genetic level. Examples of applications were presented in diverse areas of 
regenerative medicine such as tissue engineering of bone1,2, cartilage, muscle, blood 
vessels3-5, the heart, and the eye, neuroengineering6, and wound healing (Figure 5; Table 
1).  
Many of the future directions in this field are associated with delivery that is 
engineered to be more biomimetic.  This includes more precise spatial and temporal 
control of delivery as well as sequential delivery of multiple factors in the manner that 
best mimics natural healing mechanisms. Future directions include greater investigation 
and characterization on the microscale and nanoscale of the microenvironment in 
developing and healing tissues as well as creating synthetic bioengineered 
microenvironments that successfully reproduce their complexity of signals, both 
                                                     
Chapter 8 is in part published as “Bishop CJ, Kim J, Green, JJ. Biomolecule delivery to engineer the 
cellular microenvironment for regenerative medicine. Ann. Biomed. Eng. 2014;42(7):1557-72” and 
“Sunshine JC, Bishop CJ, Green, JJ. Advances in polymeric and inorganic vectors for nonviral nucleic acid 
delivery. Ther. Deliv. 2011;2(4):493-521”. 
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insoluble and soluble, to cells developing in that microenvironment.  Regulatory hurdles 
for cellular, tissue, and gene therapies are in many ways more complicated than for small 
molecules due to the added safety concerns associated with cellular materials.  For 
example, characterization and purity of cells is critical, but as cell populations can often 
contain heterogeneity, ensuring purity and homogeneity of cells and their combination 
with biomaterials and signaling biomolecules in a precisely controlled way is a future 
direction of the field.  Cell fate in vivo and ensuring that any delivered cells do not 
differentiate, proliferate, migrate, or behave in an unintended manner is key as well for 
both safety and efficacy.  These concerns make the pathway from discovery of a new 
regenerative medicine therapy on the bench to translation in the clinic more tortuous.  
In the past few years research efforts developing highly specific genome editing 
tools such as zinc nuclease fingers could possibly open the doors for safer, more 
efficacious methods to control gene expression to promote regeneration.7-10 Zinc nuclease 
fingers alleviate some complications more traditional types of gene vectors face such as 
insertional mutagenesis, immune reactions, and high long-term expression. Methods to 
pattern topologies11,12 for spatially controlled protein expression and presentation of 
biomolecules, as well as gene switches13,14 which are able to turn on and off in the 
presence or absence of a molecule will be invaluable for engineering spatiotemporally 
controlled materials for regenerative applications. Regenerative medicine has enormous 
potential to treat many areas of medicine and as new basic discoveries are made and new 
bioengineered technologies invented, therapeutic modalities move closer to helping 




8.2 Polymeric and Inorganic Vectors for Nucleic Acid 
Delivery 
While non-viral nucleic acid delivery remains less effective and efficient than 
viral delivery, recent advances offer the promise that soon there will be significant 
clinical effect from these approaches. Cyclodextrin-based polymers have found early 
clinical successes and additional biocompatible polymers are likely soon to follow suit. 
Incorporation of inorganic materials into such particles can also enable multimodality and 
theranostic applications. Several new directions are evolving which offer interesting 
approaches to achieve the goal of targeted, efficient, non-viral nucleic acid delivery. 
Mesenchymal Stem Cells (MSC) and Neural stem/progenitor cells (NSPCs) are 
capable of migration toward pathological sites such as tumors and associated metastases. 
MSCs can be used to carry cargo while evading the immune system, as they are 
hypoimmunogenic and  can then engraft into the stroma after arrival 15,16 For these 
reasons, MSCs are a very promising avenue for non-viral targeted gene delivery. 
Recently it was shown that virally-transduced NSPCs coud be implanted intracranially as 
an anti-cancer therapy. The NSPCs were transduced to stably express cytosine deaminase 
(CD), which converts 5-fluorocytosine (5-FC) to active 5-fluorouracil (5-FU). Following 
systemic 5-FC treatment 3-days later, there was a significant (71%) reduction in tumor 
burden 17. Another group has modified human neural stem cells (NSCs) to secrete anti-
HER2 immunoglobulin molecules as a tool to target and attack metastatic breast cancer 
in the brain. They were able to show that anti-Her2-secreting NSCs exhibit preferential 
tropism to tumor cells and can deliver antibodies to human breast cancer xenografts in 
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mice 18. Potential complications for non-viral delivery approaches using stem cells could 
include timing of gene expression, differentiation of NSPCs/MSCs, and the possibility 
that these cells become tumorigenic. It is critical that all potential safety concerns with 
this approach are thoroughly investigated in non-human primates before clinical trials 
commence.  
Translocation of pDNA to the nucleus and nuclear import remain critical barriers 
for gene delivery. This is because in many ways, non-viral gene delivery researched has 
focused on transporting plasmid DNA safetly and effectively into the cell, but has not 
focused on its subcellular location. Moreover, many biomaterials are designed to release 
naked DNA to the cytoplasm even though nuclear import is known to be inefficient. 
Enhancing nuclear import by other modalities in addition to NLS sequences and simple 
diffusion would be of great interest. Dynein mediates retrograde transport along 
microtubules towards the nucleus and kinesin mediates transport in opposite direction 19. 
It is known that viruses such as HIV are able to exploit the cytoskeleton for directed 
movement towards the nucleus 20. With further characterization of microtubule associated 
transport, perhaps synthetic approaches could similarly use endogenous cell machinery to 
enhancing nuclear uptake. 
 Finally, addition of targeting moieties is a widely used and important technique in 
the field. In addition to targeting ligands to cell surface receptors, a complementary 
approach is targeting specific enzymes at a specific microenvironment such as matrix 
metalloproteinases (MMPs). MMPs are upregulated during tumor growth (i.e., MMP-3, 
7, and 13) and play a role in cell growth, death, malignant conversion, and tumor-
associated angiogenesis 21. siRNA has been used to downregulate MMP-9 and was 
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shown to aid the inhibition of invasion and migration of prostate cancer cells, leading to 
apoptosis both in vitro and in vivo 22. In one approach, quantum dots have been 
conjugated to folic acid which is sterically shielded from the environment by MMP-7 
cleavable PEG (exhaustively cleaved at 5 nM)23. This work combines the passive 
targeting of the EPR effect with MMP-sensitive release of cargo to take a two-fold 
approach for the targeted delivery of the nanoparticles. The cancer stage and type are 
important in determining which MMP should be used to cleave cargo or be a target itself 
21.  Compared to conventional cancer chemotherapies, gene therapy can enable a much 
wider therapeutic window due to increased specificity. Nanoparticles can be passively 
targeted by the EPR effect, targeted to a microenvironement through enzyme activity, 
targeted to a cell receptor through a ligand interaction, and targeted to a cell-type through 
biomaterial optimization 24. Once DNA delivered, it can then be transcriptionally targeted 
to the cell type of interest and the gene product itself could also be specific to the cell 
type of interest. Thus many layers of targeting can be enabled in a non-viral gene delivery 
system and particles that use multiple methods of targeting will likely become more 
widespread in the future. The directions sketched above and other innovations in biology, 
bioengineering, materials science, and nanotechnology will continue to guide the field of 
non-viral gene delivery.     
 
8.3 Future Directions 





The method developed in this thesis for assessing uptake rates is a more high 
throughput method than purely qPCR methods that have been used. This new method 
developed can be used to compare multiple cell lines and multiple biomaterial structures 
to elucidate how biomaterial structure affects gene delivery function. One can compare 
healthy versus cancerous cell lines to elucidate cell specific differences in gene delivery.  
For a future direction, it would be interesting to compare cells from different tissues as 
well as primary normal and cancerous cells from the same tissue to investigate how these 
differences change DNA cellular uptake and nuclear uptake rates. 
 
8.3.2 Poly(β-amino ester) Monomer and Polymer Structure Function 
Relationships Elucidated Via Principal Component Analysis 
 
Now that a PCA approach for how biomaterial structure affects gene delivery 
function has been demonstrated, it would be intriguing to further grow the library of 
materials used as well as increase the variable parameters considered.  For example, 
incorporating polymer-DNA binding constant data for the principal component analysis 
would be interesting.  Since for PCA analysis, data sets are normalized and high-
throughput data acquisition preferable, rather than utilizing the time-correlated single 
photon counting method, a semi-quantitative binding assay, such as YO-PRO®-1 total 
fluorescence may be a preferable alternative.  
Also, developing a principal component method which is able to assess data library 
sets with missing data for certain variables would be great because one could include far 
more data, including partial data sets found in the literature. Currently, the method 
requires all data for all variables to be present. With further data, it is believed that this 
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Table 1. Literature summary. 
Application Biomaterial / Vector Biomolecule Cell Type Animal Model References 
Biomolecule Delivery of Soluble Signals 
Bone 
PLGA microspheres in 
poly(propylene fumarate) 
scaffold surrounded by gelatin 
hydrogel 
BMP-2 and VEGF  
ectopic / orthotopic 






















alginate hydrogel with PLG 
microspheres 
PDGF and VEGF  
ischemic limb i.m. 






FGF-2  mutant diabetic mouse 
16 
Insoluble Biomolecule Delivery Affecting Cell-Cell and Cell-ECM Interactions 
Bone PLGA porous scaffold GRGDS peptide sequence 




Bone PEG hydrogel nanospacing of RGD peptide rat MSCs  
47 
Neural 
self-assembling nanofiber from 
peptide amphiphile 


















hESCs and iPSCs  
48 
Viral Vectors for Ex Vivo Cell Engineering 
Bone Adenovirus hBMP-2 
rat marrow stromal 
cells 
Orthotopic 
implantation into rat 
59 




rat myocardial infarct 
model 
58 
Cardiac Adenovirus hVEGF 
human skeletal 
myoblasts 
porcine heart model of 
chronic infarction 
57 
Neural herpes simplex virus type-1 rat HGF 




rat’s ischemic brain 
61 
Viral Vectors for In Vivo Regeneration 
Bone adenovirus coated on allograft BMP-2 
C3H10T1/2 cells for 
in vitro 
femoral allograft 
surgery on female 
mouse 
62 
Eye recombinant adenovirus 2/2 RPE-specific 65-kDa protein  
subretinal injections 
into young adult 
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Non-viral Vectors for Ex Vivo Cell Engineering 
Bone nucleofection with plasmid recombinant hBMP-6 
primary porcine 
adipose tissue-
derived stem cells 
injection into lumbar 
paravertebral muscle in 
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66 
Cardiac PEI nanoparticle hypoxia-regulated VEGF 
rabbit skeletal 
myoblasts 




Non-viral Vectors for In Vivo Regeneration 
Bone liposomal vector BMP-2  
transplantation into 
peri-implant bone 
defects on pig calvariae 
69 
wound healing 
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